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i. CHOOSING A RESEARCH PROJECT/MENTOR
ichael E. Mendelsohn, MD, FACC (Molecular
Cardiology Research Institute, New England Medical
Center, and Molecular Cardiology and Medicine, Tufts
University School of Medicine, Boston, Massachusetts)
ow can you find someone who will help you achieve your
esearch goals? The first priority is to know yourself and
our area of research interest. There is no correct timetable
or this; it really has to do with where you are in your own
nternal sorting-out process and career development. Once
t is time to choose a mentor to help you explore your
nterests or to make a transition into a new research area,
here are key questions to address.
hoosing a mentor. The process of selecting a mentor is a
everse interview process. After a lifetime of being inter-
iewed for jobs or academic programs, the tables are turned
nd now you orchestrate the interview. Remember that
oung investigators usually end up doing work in their
entor’s area of expertise first. Therefore, make sure you
ave real interest in the research being done by your
rospective mentor’s laboratories or research program be-
ause you will be focusing on these.
What is a mentor? Mentor was a friend of Ulysses in
he Odyssey. In fact, in the story the goddess Minerva
ssumes the form of Mentor when she accompanies
elemachos to search for his father because Mentor was
o respected as a wise, faithful, and trustworthy counselor
o Ulysses. This is a good starting list of important traits
o look for in a mentor. When starting the process of
hoosing a mentor, I recommend that cardiology fellows
eet with at least two and preferably three potential
entors. Do not make a snap decision. Begin to meet
otential mentors no later than the first four months of
our second year of fellowship if you are on the tradi-
ional fellowship trajectory. Set up meetings with poten-
ial mentors and sit down with them to talk about what
hey do in their research programs. Above all else, pay
ttention to the personal interaction as you begin to know
otential mentors. Is this a person you can feel good
bout working with for an extended period of time? Does
he “chemistry” between you feel right?
Go ahead and talk about the specific research question
ou are especially interested in, but remember: because of
he way science is done today, it is often a team effort. As
result of the enormous sophistication being brought to
ear on research questions in all areas, the mentors you
nterview are going to have established research efforts
hat are intricate and well developed. So, be sure you likepotential mentor’s area of interest as much as you like
he person.
Obtain copies of papers that are representative of the
entor’s work. If a paper has been submitted and is under
eview, ask if you can have a copy of it to get a sense of
hat is currently happening in their program. Keep it
onfidential, but take it home, read it, and think about it.
s it boring? Is it the best thing you have read since The
odfather? Try to understand whether there is some
ntrinsic appeal to you in the scientific area being inves-
igated by a potential mentor. Whether it is a study of
rachial vasomotion and endothelial function in outpa-
ients, culling an existing dataset using outcomes research
ethods, or cloning a protein and understanding how it
orks to regulate blood vessel cell function—does it
atch your interests? No matter how much you like a
erson, if they have nothing going on in your true field
f interest, reconsider that person’s value to you as a
entor.
Ask potential mentors how often they meet with trainees.
ow often are their laboratory meetings? Ask how often
ou will personally meet with your mentor. I have a
aboratory meeting once a week on Thursday mornings and
pend the rest of Thursday meeting individually with
rainees, and this schedule is something I try very hard to
rotect.
Have potential members describe the structure in their
aboratory environment. Whether it is an outpatient clinical
aboratory or a bench laboratory does not matter. Are you
oing to work side by side with the mentor? That is unusual
nless it is someone who is more junior, but it may be
referable to you. Will you be assigned to someone who is
everal years more advanced than you who is spearheading a
roject, and will that person become your day-to-day
entor? If that is the case, you need to also meet that
ndividual.
What is the lab like? Is it a big lab? Are there other
ellows in the lab? Are there other fellows expected to
oin the lab soon or perhaps at the same time you will be
oining? If there are people who have been through the
ab, try to speak with them and ask them what the
xperience was like. Is it mostly a postdoctoral labora-
ory? Is it filled with international fellows or fellows from
ithin the U.S.? Is it mostly undergraduate and graduate
tudents? What is the mix? Where is the lab located? Is
t in proximity to the clinical division, where you want to
e able to attend seminars and conferences that are
ffered? Is it in proximity to where you will see patients
n an outpatient clinic setting?
What is going to be expected of you by your prospec-
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October 4, 2005:5A–72Aive mentor? What will they want from you? That is often
very revealing question. If the answer to that question
s, “I need you to be sure my coffee is here every morning
nd then we will talk,” . . . well, enough said! If you know
our prospective mentor is interested in you having an
ntense educational experience that will be fun, that is a
ood start. Be very frank about your own stage and
nterests by stating clearly, “I am not sure I want to do
esearch,” or “I am passionate about research.” Bring into
he mix what you are really thinking. This is about what
ou want, not what you think other people want from and
or you.
In our research center, there is a mentoring or teaching
elationship at every step, and they differ. The center
irector and co-director have a different form of mentor-
ng relationship than the one that postdoctoral fellows
ave with individual principal investigators; the pre-
octoral students and college and high-school students
eceive an enormous amount of mentoring and teaching
rom everyone in the laboratory. So, the opportunity
or you to practice being a mentor is also part of the
rocess.
An important part of your experience should include
raining in the legal and ethical aspects of conducting
esearch, including data management, as well as publication
ractices, and authorship, including the world of peer review
nd privileged information. You should learn about collab-
rations, human subjects’ research, and conflicts of interests.
entors should review with you the handling of research
ata, including the collection and recording of primary data
s well as what is required in terms of annotating and
ndexing laboratory data. Today, a lot of this may be
omputerized. Research data are legal documents. It is
mportant to learn about these issues and their implications.
lso, ask about the retention of your data and where it is
tored when you are done working on the project. Can you
ave copies to take with you? If you spend three years of
our life doing something and then join the faculty some-
here else, this will likely be important to you. Data
anagement is important. It can be laborious, but investi-
ators have to know how to take, record, and keep data.
hat includes an understanding of whom the data belong
o, where data will be stored, how data will be processed,
nd what are considered good data-keeping practices. A
entor-to-be should be able to explain how these important
atters will be learned.
ther mentoring issues. Accessibility to your mentor is a
ritical issue. If a mentor says, like the old New Yorker
artoon, “No, Thursday is out. How about never? Is never
ood for you?” this is not the person you want for a mentor.
ou want to be able to call and say, “I just wrote my first
rant and have incorporated your comments—could you
ook at it again?” The response should be: “Sure.”
Is the potential mentor someone who will listen atten-
ively? Is the person interested in your self-sufficiency? I like
ery much this quote from a professor of mine in under- eraduate school. I went to Amherst College and my political
cience professor, George Kateb, who is quite a brilliant
eacher and is now a professor at Princeton, said something
will never forget it. He paused one day in the middle of a
ecture while talking about the process of teaching. He
ooked up at us and said, “You know, it’s the purpose of a
ood teacher to make himself obsolete.” I have never
orgotten that comment; it is a great definition to bear in
ind when choosing a mentor.
Does the potential mentor have good interpersonal
kills? This is key. Is the mentor unlikely to be ruffled by
our success and become competitive with you? That is
ot an inconsequential issue; it is a sad issue, frankly, but
t needs to be brought up because there are insecure
eople everywhere and they do not make good mentors
ery often. The last thing you want is to develop an area
f expertise and then to have your mentor’s name
ppearing on your paper for the next decade when you
nish training. Likewise, you do not want to be working
n an area and have a mentor who continues publishing
apers that are competing directly with what you want to
o. That is a sensitive issue and conversation, but it is one
ou ought to have early on. Carve out an area of research
s you mature and define your research and career goals.
good mentor, in the process of making him or herself
obsolete,” ought to be able to look you in the eye and
ay, “I’m going to stay out of that area. In fact, when it
omes to that one paper that’s really transitional, my bias
s going to be to take my name off.” That is the goal and
he hope: a mentor who really helps launch your inde-
endent career.
Another good quote is from Bishop Stephen Neill (1):
The bad teacher imposes his ideas and his methods on
is pupils and such originality as they may have is lost in
he second-rate art of imitation.” You have to be encour-
ged and emboldened to be creative. Granted, sometimes
ou are going to have research ideas that are a bit
whacky.” In the beginning, such ideas are part of
earning and being creative. A mentor’s job is to gently
ay, “That’s kind of peripheral. Let’s bring it closer to
ome of the issues you were talking to me about earlier.”
aving said that, do not be pigeonholed or discouraged
rom exploring that which excites you. You are certainly
ot there to become the mouthpiece of someone whose
ork is already well established; you are there to benefit
rom the process and environment. Of course, you will
ecome a representative of the work you do together with
our mentor, at least in regards to those issues that are
ermane to the science you are doing together, but that is
ery different. You need to be allowed to be original and
reative and to differentiate.
When choosing a mentor, consideration also must be
iven to the financial support you will be provided. If you
re learning at the bench, you need to know that at least two
ears of work will be supported if you are already experi-
nced and three years of work will be supported if you are
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October 4, 2005:5A–72Aot already experienced. In other words, ideally support
hould be provided to you without your having to write a
rant. You may want to write a grant, but you should not
ave to obtain a grant in order to receive a full training
xperience.
If you are learning clinical research, I strongly urge you
o consider a didactic training course in statistics, epide-
iology, outcomes, trial methods, and so forth. Summer
ourses in these areas are often offered by some of the
etter programs; if this is not available at your institution,
ill the prospective mentor support your going some-
here to take such a course? It is a wonderful investment
n your future.
onclusions. There are many research training websites
nd I encourage you to peruse them (Table 1). There are
lso a number of National Heart, Lung, and Blood Institute
NHLBI) research training programs for postdoctoral indi-
iduals, including programs for minorities and disabled
esearchers (Table 2).
Educator Amos Bronson Alcott (1799–1888) said: “The
rue teacher defends his pupils against his own personal
nfluence. He inspires self-distrust. He guides their eyes
rom himself to the spirit that quickens him. He will have
o disciple.” In other words, you should not become a clone
f your mentor (2).
But, perhaps Albert Einstein (1879–1955) said it best: “It
s the supreme art of the teacher to awaken joy and creative
xpression and knowledge” (3).
uestion and Answer
uestion: For fellows who are considering working with a
receptor who has a private interest or a financial interest in
he work, what are some of the questions or concerns to be
ddressed before getting involved in a project?
r. Mendelsohn: That is a complicated question. I would
egin by asking a trainee why he or she would want to get
nvolved in something like that at this point in their
raining. Unless the trainee is seeking training in the
usiness/industry side of research, I would caution against
hat. On the other hand, for example, if the trainee is one of
he MD/MBA students we have at our institution, then this
s exactly what they might want to pursue. In that case, there
able 1. Research Training Websites
http://www.nih.gov/NIH homepage
http://www.training.nih.gov/handbook/
http://www2.nas.edu/cosepup
The Committee on Science, Engineering, and Public Policy’s
(COSEPUP) homepage
http://www.nextwave.org
American Association for the Advancement of Science (AAAS)
Science’s NextWave
http://www2.nas.edu/cpc
National Research Council’s Career Planning Center for Beginning
Scientists and Engineers (CPC)
rom www.nhlbi.nih.gov/funding/training/redbook/trainslides.ppt.re specific questions relating to who owns the technology. ohat will happen if new technologies are discovered along
he way? What rights, if any, will evolve for the mentor, the
chool/university, and so on?
uestion: Should a mentor be someone involved in the
eld in which you want to do research? Sometimes you
an not find such a person in your own university,
specially in translational science research. Do you rec-
mmend we look all over the country and find somebody
utside the institution you are working in and try making
hem a mentor? Or are we pretty much restricted to our
wn university?
r. Mendelsohn: That depends on the stage you are at
n training. To make the analogy to graduate students,
efore doing a thesis, a graduate student often does
otations in different laboratories before selecting a men-
or. So, there are two separate approaches to your
uestion. One would be to visit a number of different
enters for a short time and at least get a sense of what is
oing on. But if, as I think your question implies, you are
eady and the best person in your mind to work with you
s not at your campus, then what do you do? I feel very
trongly that you should go to the best laboratory you can
nd work there. Many training programs support that: go
able 2. NHLBI Postdoctoral Programs
Postdoctoral programs for all individuals:
● NIH Summer Employment Program
● Individual Postdoctoral National Research Service Award (F32)
● Institutional National Research Service Award (T32)
● Intramural Research Training Award
● Staff Fellowship Program*
● Institutional National Research Service Award in Sleep Research
(T32)
Postdoctoral programs for underrepresented individuals:
Minority scientists
●Minority Institutional Research Training Program (T32)
●Minority Access to Research Careers (F34)
● Research Supplements for Underrepresented Minority Individuals in
Postdoctoral Training
Scientists with disabilities
● Research Supplements for Individuals with Disabilities in
Postdoctoral Training
Awards for new researchers:
●Mentored Clinical Scientist Development Award (K08)
● Independent Scientist Award (K02)
● Career Transition Award (K22)
●Mentored Patient-Oriented Research Career Development Award
(K23)
●Mentored Quantitative Research Career Development Award (K25)
Awards for minority scientists and researchers with disabilities:
Minority researchers
● NHLBI Minority Institution Research Scientest Development
Award (K01)
● NHLBI Mentored Minority Faculty Development Award (K01)
● Research Supplements for Underrepresented Minority Investigators
Researchers with disabilities
● Research Supplements for Investigators with Disabilities Developing
Independent Research Careers
Performed at the NIH.ff site as needed.
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October 4, 2005:5A–72Auestion: What is more important when choosing a
entor: the mentor’s area of research or the tools that the
entor is going to provide? Sometimes a mentor is doing
ork in an area that may not be your first choice, but you
now that this mentor will provide you the greatest number
f tools you will need to succeed. Because we may change
irections later in terms of our specific research interests,
hat is more important in the training period, the topic or
he tools?
r. Mendelsohn: I do not think it is the tools. It is the
nvironment. You have to be drawn to the area you are
oing to work in. You would not want to go study clinical
eart failure if really deep down what you want to do is
utcomes research in electrophysiology. Certainly, once you
ave chosen an area, many state-of-the art tools are going to
e available to you if it is a good laboratory or a good
esearch program. Most young people who come to the
aboratory can learn almost any methodology in a week.
hat is not the issue. The issue is asking the right research
uestions, and learning to do this comes with the right
nvironment.
r. Fuster: It is very common to think that mentors come
rom the skies to you and, if they do not, you think there are
o mentors. What Dr. Mendelsohn said is extremely
mportant; you really have to go after mentors yourself. You
nterview them. If you do not, there are no mentors, because
ll of us are very busy and we are not likely to turn to you
nd say, “You look good to me. Let me mentor you.” It is
nfortunate because many people think there are no men-
ors in their institution. But did you ask? Did you go after
hem and read their papers? This is what Dr. Mendelsohn
s talking about, and this is very important.
There is also the concept of the person who really
dvises you in your career, in general, not in specific
rojects. Such a general mentor is absolutely critical.
gain, it is based on experience. One of the great
roblems is getting a mentor for specific research, but
here is nobody around you who really guides your career
n a more general sense. Maybe you do not belong there,
ou are really not in the right place, and you need
omeone who can look at your situation and help you see
hat. So, I am emphasizing the general individual who
eally knows you, whether that is someone in your own
nstitute or somebody you had some attachment to
efore. It is very important that you have an individual or
ndividuals who really guide your careers. They must be
rustworthy. These are people who really would do
nything for you.
r. Mendelsohn: I could not agree more. If you are
oing to be a cardiologist, there are leaders in cardiology
t your institutions who are not involved in the specific
rea you are seeking to work in, but they still may be
onderful mentors in the general sense that Dr. Fuster is
escribing. These are the people you can bounce ideas off
f and say, “You know, I have narrowed my mentor
earch down to Person X and Person Y. Can you help me ihink about it?” To have someone who you trust to be
vailable to have that conversation with you is very
mportant.
r. Fuster: Here is another issue: what happens after six
onths when you find that your mentor is not the person
ou wanted? That is a tough issue, but we see it
ommonly. In my experience, the first person you choose
s a mentor fails 50% of the time. Then what do you do?
irst, go to the head of the department or division and
resent the situation. The department or division head
hould understand the situation, know the involved
arties well, and know best how to approach it. Never try
o take care of this yourself. Out of the blue, you may say
few words that can be damaging to you in the future. So
ou have to be very cautious, and this is why you need the
dvice of people who will give you an overall view of how
o proceed. Again, this is a very common problem, and
ou should be at least ready with some idea of how to
pproach it.
r. Mendelsohn: It is another good reason to have a more
eneral mentor helping “shepherd” you through the process.
r. Fuster: In regard to mentoring, classically, you look for
entors who are savvy, often 60 years of age or older, great
rofessors, and people with a lot of experience. Dr. Mendel-
ohn, do you think these people are practical as mentors in the
orld we live in today? In general, are the younger generations
f researchers, who are much more into what is happening
ight now in research, better able to be a mentor, although not
he general mentor who assists you with the practical issues of
career?
r. Mendelsohn: I think that while it may be the
urpose of mentors to make themselves obsolete, you do
ot want them to be already obsolete! Most of the time,
he really good senior mentors of the type that you are
escribing as the “classic” image of a mentor have a cadre
f superb, “fire in their belly,” next-level investigators
ho are between the ages of 35 and 50 years, who run
ubstantial programs with their own R01s, and who really
re absolutely in the “sweet spot” to be superb mentors for
ersons at the start of their careers. You are absolutely
ight; those are the people you want to work for because
hey are at the center of the most current issues in the
eld.
I. FUNDING OPPORTUNITIES
OR INVESTIGATORS IN THE EARLY
TAGES OF THEIR CAREER DEVELOPMENT
. William Balke, MD (Office of the Dean, University of
Kentucky College of Medicine, Lexington, Kentucky)
he metrics for academic success are salary support from
eer-reviewed grants and authorship in publications. Other
actors come into play, such as teaching abilities and
nterpersonal skills, but the bottom line is that those two
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October 4, 2005:5A–72Aetrics are what matter. There are many opportunities to
ain credentials in both of these metrics.
There are a number of sources of support (Table 3). One
requently known but underutilized area of support is going
irectly to the National Heart, Lung, and Blood Institute
NHLBI) or the National Institutes of Health (NIH). The
IH website has a link called the “K Kiosk,” which is
pecifically for training information and awards. The web-
ites for both the American College of Cardiology and the
merican Heart Association are very user-friendly and
ontain information for young investigators.
There is additional help available from other underuti-
ized resources (Table 4). Many institutions have institu-
ional NIH K30 or K12 awards, which are designed for
linical research curriculum development and the develop-
ent of independent clinical scientists. Seek out faculty who
ave an award that might be suitable for you and then ask
hem about it. Also, the people at specific institutes at the
IH are very friendly and cooperative. Their goal is to help
et the best applications to fund the best science, so the
nformation they have is timely and pertinent.
oan repayment program. The NIH Loan Repayment
rogram (Table 4) is an opportunity to get some relief for
he loans that have been incurred, both through undergrad-
ate and graduate medical education. The program supports
eople who are in training for clinical research or basic and
linical pediatric research programs. It is not required that
ou have your own grant; if you are part of a training
rogram at a university and have a doctoral-level degree, you
ualify as a government research-funded individual. This is
or individuals with student loan debt equal to 20% or more
f your annual salary.
Up until fiscal year 2003, there was approximately a 58%
uccess rate in terms of approved applications for clinical
esearch and 49% for pediatric research.
Training grants are available for individuals with or
able 3. Sources of Support Information
ational Institutes of Health; National Heart, Lung, and Blood
Institute (NIH/NHLBI)
ttp://www.nih.gov
ttp://www.nhlbi.nih.gov
Award Program Announcements — “K Kiosk”
ttp://grants2.nih.gov/training/careerdevelopmentawards.htm
merican Heart Association
ttp://www.americanheart.org
merican College of Cardiology
ttp://www.acc.org
he Original How to Write a Research Grant Application
ttp://www.niaid.nih.gov/ncn/grants/write/index.htm
dviser, Teacher, Role Model, Friend: On Being a Mentor to Students
in Science and Engineering
ational Academy Press
ead online at http://www.nap.edu/readingroom/books/mentor/
r purchase at http://books.nap.edu/catalog/5789.htmlarning a health-professional doctorate (Fig. 1). Residentsften are supported by institutional training grants (T32).
ome individuals in the first couple of years of fellowship
ave the opportunity to be in a fellowship T32 training
rant, which is quite an honor because these positions are
imited and highly competitive.
ational Research Service Award (NRSA) (F32). The
RSA, otherwise known as the F32, is for post-doctoral
raining within the broad scope of biomedical, behavioral, or
linical research (Table 5). The F32 is an individual version
f the T32 that funds you; it is something you apply for as
principal investigator with a mentor’s support. It will fund
our time during the research activities of your fellowships.
ndividuals in a four-year cardiology fellowship, with the
rst two years for clinical work and the last two years
evoted to research, be it clinical, basic, or translational,
hould be applying for these grants in the middle to end of
he second year of fellowship, as they will fund you for the
ast two years. Traditionally, most of these awards go to
hDs. This is not because MDs are not competitive, but
ather MDs do not think about them; MDs actually have a
ompetitive advantage to the extent that MDs are under-
epresented and they work very hard to review favorably.
If you have finished college and medical school, did your
ouse staff training, and been exposed to other people doing
esearch but you have not done any yourself, that is fine.
ou can still apply because the experience you are going to
et once you receive the award is going to give you that
xperience. You want to describe the new training experi-
nces that you are going to get and how those experiences
re going to broaden your scientific background. In other
ords, describe your potential to become an important
ontributor to biomedical, behavioral, or clinical science.
Some of the most important aspects of applying for the
able 4. Help Along the Way
entor(s)
nstitutional K30 and/or K12 Award faculty
urrent awardees
IH Program Officer and Study Section Scientific Review
Administrator (SRA)
IH Loan Repayment Programs
ttp://www.lrp.nih.gov
5 programs including clinical research and basic/clinical pediatric
research programs
Eligibility requirements
● Doctoral-level degree
● Government research funding (federal, state, or local) or domestic
nonprofit research
● Student loan debt 20% annual salary
● U.S. citizenship or permanent residency
● Non-federal government job
NIH pays income tax liability
2-year award with ability to renew for an additional 2-year period
Maximum payment  $35,000/year
NIH “Service Obligation”: conduct qualifying research supported by a
domestic nonprofit or U.S. government (federal, state, or local)
entity for 50% of time (at least 20 h per week based on a 40-h
week) for 2 years. NIH makes quarterly loan repayments concurrent
with the participants’ satisfaction of their service obligation.
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October 4, 2005:5A–72A32 award are the sponsor and training environment. Your
ponsor or mentor is probably the single greatest determi-
ant of your long-term success as an academic physician.
hoosing a mentor wisely is probably the single most
mportant thing you will do as a young investigator, and you
hould judge your sponsor on specific criteria. When you
pply, your mentor will write a statement outlining his or
er experience in training researchers. You need to know
his information to see if it is worth spending your time with
hat individual. Clearly, anyone worthy of being your
entor has to be productive in terms of research grant
upport and publications. Also, you must be in an environ-
ent that has the staff, research support, and facilities for
igh quality research training.
The actual research proposal for the F32 award must be
ypothesis-driven and include specific aims, which are
estable predictions of your hypothesis. The research pro-
osal should contain preliminary data, if available, although
t this stage, most investigators will not have much prelim-
nary data. If you are proposing a clinical project and you are
aired with a mentor, you can use preliminary data from his
r her studies, noting that this is what the group has done
nd that you will be adding your own work. The proposal
hould have a research design, and it should describe how
he design relates to your career development plans.
The last element of the F32 application process is
raining potential: what is the value of this experience over
he time period being requested? How will it help you
repare for a career as an independent investigator? It may
ive you skills. It may give you exposure. It may give you a
umber of things that will enable you to take the next step.
t does not have to be long, but you need to think about the
raining potential of what you are proposing to do.
awards. Let us assume you are at the end of your
ellowship and you have determined you do not want to go
nto clinical practice; instead you want to do research. What
o you need to make that career goal happen? First, you
eed the tools and education for clinical or basic science
esearch and you may need some sophisticated training
epending on your area of interest. You can use a K award
o assist you in designing a program with didactic studies to
elp you with the clinical or basic science research aspects of
ants (F & T awards) for individuals with or earning a health professionaligure 1. National Research Service Award (NRSA) fellowships and training grable 5. Ruth L. Kirschstein National Research Service Awards
NRSA also known as an F32)
ligibility requirements
Citizens or non-citizen nationals of the U.S.
Permanent residents (Alien Registration Receipt Card I-551)
Individuals on temporary or student visas are not eligible
Doctoral level degree: PhD, MD, DO, and so on
andidate
Previous academic performance
Previous research experience (if any) and performance
New training experiences designed to broaden the candidate’s
scientific background
Potential to become an important contributor to biomedical,
behavioral, or clinical science
ponsor (mentor) and training environment
Research qualifications in the area of the project
Extent and quality of his/her proposed role in guiding and advising
the applicant
Previous experience in training researchers
History of research productivity and support
Availability of staff, research support, and facilities for high-quality
research training
esearch proposal
Hypothesis driven
Specific aims: testable predictions of the hypothesis
Preliminary data (if any)
Research design
● Scientific soundness
● Feasibility
Relationship to the candidate’s career development plans
raining potential
An assessment of the value of the proposed fellowship experience as it
relates to the candidate’s needs in preparation for a career as an
independent researcher
pplication receipt dates
April 5th; August 5th; December 5th
tipend (2005 schedule)
$35,568 (0 years since earning degree) to $51,036 (7 or more years of
postdoctoral experience) up to 3 years’ support
llowable costs
Tuition and fees: 100% of 1st $3,000 and 60% of $3,000
Institutional allowance: up to $4,400/year
Other training costs (e.g., travel to remote field sites): up to $3,850
ayback
One month of payback for each month of training, up to a maximum
of 12 months. This requirement can be fulfilled by teaching or
research (a minimum of 20 h per week) on a continuous basis,our study and then have a mentored clinical research
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October 4, 2005:5A–72Arogram with your mentor. The NIH offers a variety of K
wards that are institute-specific (Table 6, Fig. 2).
The K awards (K08, K23) (Table 7) bridge the transition
or those in the specialty/subspecialty period of training.
hese awards can be applied for in the last year of
ellowship, and they take affect when you get your early
aculty position.
From 1999 through 2002, almost 50% of K08 and K23
pplications received funding at the NHLBI. Although award
ates have fallen with the recent tightening of the NIH budget,
he success rate of K-award applications remains significantly
etter than the traditional NIH investigator-initiated awards
e.g., R01). For fiscal year 2004, the funding success rates for
HLBI K08 and K23 applications were 27% and 28%,
espectively. Eligibility requirements are the same as the other
wards discussed (Table 7). The candidate’s statement needs to
nclude information about qualifications, commitment to an
cademic career, an actual need for further training, how the
ward will contribute to short- and long-term career goals, and
clear commitment of a minimum of 75% of time to the
roposed research. The application also must include a detailed
areer development plan that takes you from the end of your
linical training to emerging as an independent investigator at
he end of five years. The research plan is a formulaic one that
ll good science follows and the NIH asks for in their
pplications forms—specifically the hypothesis, specific aims,
ackground, significance, preliminary studies, and the research
esign. Clearly, the research plan has to be appropriate for you
nd the stage of your career.
Again, picking a mentor is very important. The K08 and
23 applications are judged on all the aforementioned
riteria, but the mentor may be the most important. The
entor has to state his or her willingness to protect your
ommitment of 75% of your time to your research program.
The K23 is identical to the K08, except that the K23 is
or doctorate-prepared individuals who are going to do
atient-oriented research. This is the kind of research that
equires you as the principal investigator to interact with
iving, breathing, conscious patients. What kind of research
ould this entail? If you are interested in outcomes research
rofessional doctorate. Note: Individuals with clinical doctorates may also
owing awards are not shown: Academic Career Award (K07); Mentoredigure 2. Career development awards (K awards) for individuals with a health p
e eligibl e for awards shown for individuals with research doctorates. The follable 6. K Awards Available From the National Institutes of Health
01 Mentored Research Scientist Development Award
areer development in a new area of research. 3 to 5 yrs; salary
determined by sponsoring institution.
02 Independent Scientist Award*
evelop the career of the funded scientist. 5 yrs; 75% effort.
05 Senior Scientist Award
or outstanding scientists with a sustained level of high productivity.
5 yrs; 75% effort; funding determined by the sponsoring institution
07 Academic Career Award
evelopmental/leadership in academic instruction, research,
administration. 2 to 5 yrs; 25%–75% effort; requires institutional
sponsorship.
08 Mentored Clinical Scientist Development Award*
evelopment of the independent clinical research scientist. 3 to 5 yrs;
75% effort.
18 Career Enhancement Award for Stem Cell Research*
upports full- or part-time training in use of human or animal
embryonic, adult, or cord blood stem cells. 6 mos to 1 yr.
22 Career Transition Award*
upport to an individual postdoctoral fellow in transition to a faculty position.
23 Mentored Patient-Oriented Research Career Development Award*
evelopment of the independent research scientist in the clinical arena.
3 to 5 yrs; 75% commitment.
24 Midcareer Investigator Award in Patient-Oriented Research*
evelopment of clinical mentors conducting funded research. 3 to 5 yrs;
25% to 50% effort.
25 Mentored Quantitative Research Career Development Award*
o foster interdisciplinary collaboration in biomedical research by
supporting career development experiences for scientists with
quantitative and engineering backgrounds. 3 to 5 yrs; 75% effort.
26 Midcareer Investigator Award in Mouse Pathobiology Research
rovides support for established pathobiologists who wish to devote up
to 50% of their effort to research and mentoring in the field of mouse
pathobiology. 3 to 5 yrs; renewable; 25% to 50% effort.
30 Clinical Research Curriculum Development
nstitutional award for development of a clinical research curriculum.
12 Mentored Clinical Scientist Development Program Award
upport to an institution for the development of independent clinical
scientists.estigator Award in Mouse Pathobiology Research (K26). Source: NIH
o
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October 4, 2005:5A–72An heart failure patients and you will be interacting with
atients in your heart failure clinic, this is for you. If you are
ining an existing database for new and unique markers for
Table 7. Mentored Clinical Scientist Developm
Oriented Research Career Development Award
Eligibility requirements
● Citizens or non-citizen nationals of the U.S.
● Permanent residents (Alien Registration Receipt C
● Individuals on temporary or student visas are not e
● Clinical doctoral level degree: MD, DO, some Ph
psychology, and so on)
● Completion of clinical training (both specialty and
● Ineligible: current and former PIs on NIH R01, F
awards (K01, K07, K23, and so on), sub-projects
Candidate: candidate’s statement
● Qualifications (background)
● K08: commitment to a career in biomedical resear
K23: commitment to a career in patient-oriented
● Need for further training
● How the award will contribute to the immediate a
● Clear commitment of 75% of time to proposed re
Career development plan
● Likelihood that it will contribute substantially to t
● Appropriateness of the content and duration of th
● Consistency with the candidate’s career goals and
● Quality of the proposed training in the responsibl
● For individuals with limited or no prior research e
first year or two, must be fully integrated into the
● Interactions with an internal/external advisory com
Research plan
● Specific aims
● Background and significance
● Preliminary studies
● Research design
● Scientific soundness
● Feasibility
● Potential to achieve the goal of the award
● Appropriateness of the project for the candidate a
acquire research skills necessary for independence
● Inclusion of plans for the protection of animal and
Mentor
● Research qualifications in the area of the project
● Extent and quality of his/her proposed role in gui
● Previous experience in training researchers
● History of research productivity and support
● Provisions for internal/external advisory committe
● Protection of at least 75% of candidate’s time to p
(For more than one mentor, the qualifications, role,
Environment and institutional commitment
● Specifics of the types of facilities, resources, and t
● A minimum of 75% of full-time effort will be pro
Letters of reference (3)
Application receipt dates
● February 1st, June 1st, October 1st
Salary
● Institute specific
● Generally  $75,000 (legislated maximum salar
Research development support
● Institute specific
● K08: up to $25,000/year; K23: up to $50,000/year
Facilities and administrative costs
● 8%ardiovascular disease, then a K23 award is not appropriate. tmisconception is that the K23 award cannot have
ardcore basic science components. If you have three or four
ims, one of which has to be achieved working with patients,
Award (K08) and Mentored Patient-
3)
-551)
e
.g., nursing, rehabilitation, audiology, clinical
pecialty) at time of award activation
awards (R29), comparable career development
G or SCOR grants
areer goals and objectives)
ch (career goals and objectives)
ng-term career objectives
ientific development of the candidate
posed didactic and research phases of the award
research experience
duct of research
ence, the didactic component, proposed during the
ng program and justified based on their needs
e
her stage of development and as a vehicle to
uman subjects.
nd advising the applicant
ed research
ommitment of each must be discussed)
g opportunities available to the candidate
for the program
5  $180,100)ent
(K2
ard I
ligibl
Ds (e
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October 4, 2005:5A–72Aour first three aims on mice or zebra fish; it qualifies for a K23
s long as there is a human study component.
The success rate on K23 award application acceptance is
ery close to the K08 awards at the NHLBI and several
ther institutes. Once again, the application requires exactly
he same information as the K08. And remember, if you are
ot successful the first time, the success rate on resubmis-
ions for many of these is even better.
uestion and Answer
uestion: How mobile are awards like a K08 or K23? If
hey are mentor-dependent, how do you travel with them?
r. Balke: These awards are very mobile. All you have to do
s demonstrate to the National Institutes of Health (NIH)
dministrative staff that you’re going to a mentor and an
nvironment at least as good as you were in your original
nstitution. This happens all the time. It does not have to
et re-reviewed or go back to a study section. Obviously you
an’t move one of these awards into a private practice
ituation and have it continue to support your salary, but
therwise they are very mobile awards.
uestion: Many of the awards you mentioned are more to
ive you support for your salary. Are there other grants or
wards that pay for your research, for example, to enroll
atients or to do a statistical analysis or other direct research
urposes?
r. Balke: Let me explain how the actual dollar amount
orks. You are absolutely correct that the majority of the
onies are for salary protection. Depending on the institute
nd the award, you may request as much as $50,000 per year
or supplies and research support. Because these are men-
ored awards, the NIH expects, actually demands, that the
entor have enough resources to help you get your work
one. If you have a clinical trial as part of your project,
bviously $50,000 is not going to fund a clinical trial of any
orthiness. But it is your mentor’s resources and the
nstitutional resources that will provide that. That is why the
entor is so important and the criteria of having a mentor
eing funded in a peer-reviewed setting and being produc-
ive is so essential. If you have a mentor who does not have
grant, you will not get a K23 or a K08.
uestion: Can the NIH loan repayment program be
ombined with some of these other grants, or are they
utually exclusive?
r. Balke: They are absolutely independent of one another
nd you can have both, so you should apply for both. Also,
ou can qualify for the loan repayment program without any
f these other awards, too.
uestion: What do they mean when the requirements talk
bout covering 75% of your time? Is that based on a 40-h
ork week, or does it mean three-quarters of the time that
ou spend working in research?
r. Balke: The answer from the NIH is a little murky on
hat, but generally, when institutions with K awards have
een investigated by the Office of the Inspector General, the jnterpretation of that rule is based on 75% of your total
ffort. So, if you are working 80 h a week, it is 75% of 80 h.
f you are working 40 h a week, it is 75% of 40 h. The NIH
s not going to play games with these time percentages. For
xample, you cannot claim 75% of a 40-h work week for
esearch and then have your department chairman make you
ork every weekend in the clinic to make up for this
rotected time. It does not work that way, which is a good
hing for you as you are trying to establish your career.
uestion: If you are in the second half of your training,
oing research, and thinking about applying for an award,
ould you recommend going for the National Research
ervice Award (NRSA) or for a K08 or K23?
r. Balke: I would apply for an NRSA, even if it is only for
year. You are a principal investigator on an NRSA. Then
hen you go in for your K23 or K08 you have already
tarted to develop a reputation and a track record for being
funded investigator, and that looks great on your applica-
ion. You will use a lot of the things that you learn in the
RSA for the K08 and the K23. I would suggest you not
aste an opportunity to get a score on the board, even if it
s only a field goal, which the NRSA might be.
uestion: Some mentors say just go directly for the K08 or
23; do not waste time with an NRSA.
r. Balke: It depends on your institute and what your
iscipline is, but you cannot have a K08 or K23 activated
nless you are a junior faculty member. So, if you are in your
hird of four years of fellowship, I would apply for an NRSA
or my fourth year of fellowship. This time next year I would
e preparing my K08 or K23.
r. Fuster: Say I am finishing the training program and I
eard all this talk about productivity, productivity, produc-
ivity, and I have two choices. One is to write the proposal
or an NIH grant; the other option is to begin working on
research project because I am convinced I can write a paper
aster than going through all that. I think getting funded at
hat stage is the most important goal. Would you interpret
hat productivity means at different stages of careers?
r. Balke: For an example, let us assume you are in your
hird year of fellowship and you have got only X amount of
ours in the day. Do you apply for an NRSA or do you
nish a paper? I do not see them as mutually exclusive. An
RSA is not that difficult of a grant. It is shorter, and much
f what you do to produce a paper will go into your NRSA
nyway. If you are doing a paper, those are your preliminary
ata. When you write a paper, if you do it well, the paper is
ddressing a hypothesis; that hypothesis is going to be part
f your grant. I do not necessarily see it as an either/or
ituation.
When applying for the K08s, K23s, or the R01 awards,
our ability to compete increases with manuscript produc-
ivity. That is when you really want to start getting some
raction with those applications. However, you can get a
08 and a K23 without a lot of publications. If you finish
our fellowship with one really solid publication in a good
ournal, you have more than enough to launch a K08 or a
K
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October 4, 2005:5A–72A23. I am chairman of the National Heart, Lung, and
lood Institute K23 study section. I have seen applications
ome in with one or two papers that are superb, from JAMA,
ew England Journal of Medicine, Nature, Science, Journal of
linical Investigation, Cell, and so forth. One or two papers,
our years worth of work, two years in the lab, and two years
n the clinic, that is great. You see applications come in with
4 papers in cardiovascular niche journals, and they do not
ucceed. You have to try to strike the right balance.
r. Fuster: When you are ready for publication, before you
o anything else, should you discuss with your mentor about
he order of authorship?
r. Balke: Absolutely. This is hard for all of us. One of the
ort of silent genes that select us for being in medicine is the
act that we do not really address issues, we kind of settle
hem as we go along. This is your career. This is your life.
rab it by the horns and do not be passive about it. Be
olite, but do not be passive. Sit down with your mentor and
ay, “I really am interested in this project you are doing with
-wave alternans, for example. I know this is your project,
ut I am going to meet these patients, I am going to analyze
he wave forms, I am going to do the statistics. Where is my
ame going to be listed on this paper?” And if you agree
ith wherever he or she puts you, that is great, but it is also
ll right if you want to be in a different position. Recognize
hat your mentor may say, “I started this project, there is this
ther more senior fellow who has been doing a lot of the
ork, so he or she will be first author, you will be second,
nd I will be last. But let us see how the project concludes.
f, for some reason, the percent contribution changes, then
e can always revisit this.”
I have accepted and actually administered that kind of a
osition a number of times. It often ends up exactly the way
t was originally described, but it can change later. The last
hing you want to do is set up a situation where you put a
ery acrimonious wedge between you and your mentor
ecause you had one idea in your mind, he or she had
nother, you did not talk about it, and then when the paper
oes out the door, you have big disagreements. Life is too
hort and you do not need that kind of aggravation. So ask
p front. Nobody is going to be offended if you do. Just be
olite about it.
r. Fuster: Can you give a sense as to whether authorship
rder is important, or is it more important that you can
ransmit how you contributed to a paper?
r. Balke: At this stage in your career, it is paramount to
ontribute at a level that gets you author attribution any-
here in the author list. Once you are on the author list,
hen order has some importance. First author is the best,
nd if you can get that position, please try. Being first author
eans you are the person who really made the project
appen. It is not necessarily your idea but you understood the
dea, you did a lot of the work, you contributed intellectually
nd substantially to the completion of a project, and you are
ort of the fulcrum that all the different pieces went through.
he last author is usually the person whose laboratory or kesearch program conceived the whole direction. If you
annot be first, be second. If you cannot be second, be third.
et as close as you can to the front of the line.
If you are a second- or third-year fellow and you are in
he middle of a pack of 20 authors, it is still okay. It is a
ublication. But no matter where you are on the list, when
ou go for an interview or when you write your description of
our grants, talk about it like it is your project. You have got to
now it. You just cannot be along for the ride. If I am
nterviewing someone for a junior faculty position and I have a
ourth-year fellow who has got a couple publications, maybe
rst author in a small journal article but fifth author in
ournal of Clinical Investigation, if he can tell me the
ypothesis and he gets excited about the work and tell me
hat he and the team did, I do not care if he is fifth or first
uthor; at that point, it is all the same. He contributed; it is
is or her work.
r. Fuster: Do you think it is right or wrong for a senior
esearch member, the one who runs the area and has a lot of
xperience, to give someone else the opportunity to be last
uthor?
r. Balke: I do not know that I would say it is right or
rong. It is a matter of personal style. At this stage in my
areer—I finished my training in 1991—I do what I can
ithin the honest scope of the work to give the last spot and
orresponding spot to junior faculty when I can. Here is a
ery specific example. We have a program looking at some
f the molecular determinates of contractile dysfunction in
eart failure and we are doing a number of animal models.
his has been a long-standing research program that I
eveloped when I was a post-doc and have continued ever
ince. But for the latest paper, the clinical fellow is actually
he first author, the new junior faculty member is the last
uthor, and I am the next to last as corresponding author.
he next paper that we put out on this model in this group,
ew junior faculty members will be the last end-
orresponding author, and I will be buried somewhere in the
iddle. It is fine by me. And it is not dishonest. One thing
ou cannot do is put people on the list or in positions if they
ave not contributed to the work. That dilutes the quality of
he science and the whole process that we are all so
ompletely vested in.
r. Fuster: I agree every contributor should be there and
omeone who is not a contributor should not be. I feel very
ositive about giving people the opportunity to be the last
uthor. When we talk about the importance of altruism, this
s how it makes things go. It is to create incentive, and I feel
ery strongly about what you said.
r. Balke: Let me add that if you can find mentors who say
hey will use their seniority and clout to help get the first
everal papers that result from the work you do together into
he best journals and then will voluntarily remove their
ames from later publications to help you develop your own
eputation as an emerging independent scientist, that is the
ind of mentor you want to wrap your arms around and
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October 4, 2005:5A–72Aever let go. That is a generosity you rarely see, but it is
hat you need.
In our study section, I occasionally see situations where
entors are secure enough that they actually make explicit
n their support statements for the candidate these kinds of
enerous offers. If you can pair yourself with someone like
hat, it will be one of the best opportunities in your entire
areer. Even if you do not find a mentor like this, put this in
he back of your mind and when you mentor, which will not be
any years from now, you should do the same thing. It is not
question of whether you have 2 or 300 publications in your
urriculum vitae, it is a question of the quality of the work.
II. BRIDGING FUNDING
PPORTUNITIES FOR YOUNG INVESTIGATORS
obert O. Bonow, MD, FACC (Northwestern University
Feinberg School of Medicine, Division of Cardiology,
Northwestern Memorial Hospital, Chicago, Illinois)
he number of young investigators under the age 35 getting
heir first National Institutes of Health (NIH) grants has
eclined from 23% in 1980 to about 4% in 2001 (4). The
ifference is not made up by the next level faculty, those age
6 to 45 years, where there has been no growth in numbers.
e have lost a generation of investigators; the same
nvestigators who could now be serving as mentors for the
ext generation. This is making it tough for young investi-
ators to find good mentors, although it certainly can be
one. This drop-off in young NIH grantees explains why
any of us consider MD investigators an “endangered
pecies.”
This is especially a concern, given that during the period
rom 1990 to 2000 many more PhDs than MDs applied for
IH grant funding, although the overall level of funding
tayed somewhat the same during this period (Fig. 3).
mportantly, MDs and PhDs have a similar chance of
uccessfully getting funded. We need to get young MDs
nthused about getting funded and see to it that they get the
ob done.
Also of concern are a number of other issues that impact
n MD’s life in academia. For instance, how does thism
igure 3. NIH funding: first-time applicants and awards 1990 to 2000.
rom Nathan DG, Wilson JD. N Engl J Med 2003;349:1860–5.iscrepancy between PhD and MD researchers translate
nto whether they get the next grant? In terms of
nvestigator-initiated individual grants (R01s), nearly three
imes as many PhDs than MDs are first-time awardees.
hen the award comes up for renewal, more than two-
hirds of PhDs try to get their grant renewed, but only about
7% of MDs seek renewal. As for the percentage who are
uccessful getting their award renewed, only 17% of first-
ime awards for MDs get renewed, which accounts for only
0 of 405 first-time awards granted in 1996. That compares
o a 33% renewal success rate for PhD applicants. So, we are
ot only losing MDs who might become grant recipients
he first time around, but then they are dropping out after
he initial award for a lot of competitive reasons.
Part of this is related to the fact that the transition from
ellow to faculty is one of the most difficult hurdles on the
ath to a career as a clinical investigator. What can be done
o make this transition a little easier? At the NIH, there are
mportant transition awards for junior faculty members as
ell as those in the last stages of fellowship, as discussed by
r. Balke.
There are other institutions offering support as well,
ncluding the American College of Cardiology (ACC), the
merican Heart Association (AHA), and the Department
f Veterans Affairs (VA). Take these opportunities seri-
usly. If you go to the AHA Scientific Sessions, for
xample, there is a Saturday afternoon session in which you
an get survival skills necessary for early career development.
ou can have one-on-one discussions with successful scien-
ists as well.
ransition awards—AHA. While funding from the AHA
s only about 5% of the total funding of the NHLBI, the
HA focuses most of its research funding on young
nvestigators. The AHA strategic goal for research is to
dentify opportunities and implement programs to increase
he number of beginning investigators; specifically, those
ith no more than four years since their first full-time
aculty or staff appointment.
There is a portfolio of possible grants from the AHA that
iffer among the AHA affiliates and the organization’s
ational level of programs. This discussion will focus on the
cientist Development Grant and the Fellow-to-Faculty
ransition Award. The Scientist Development Grant sup-
orts highly promising beginning scientists in their progress
owards independence (Table 8). For this grant, applicants
hould be a faculty/staff member or a fellow who is about to
ecome a faculty member. Applicants must be initiating
ndependent research careers at the early faculty level,
sually at the rank of instructor or assistant professor (or
quivalents). Applicants can be writing this grant and
etting the award while making the transition.
The Scientist Development Grant applies up to $30,000
er year towards salary plus 10% for indirect costs, as well as
35,000 per year for project support. If grant recipients have
ther means of funding their salary, much more of the grant
oney may be applied to project support. For example, if a
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October 4, 2005:5A–72Arant recipient is joining a faculty and will be doing
chocardiograms one day a week, that may generate enough
o cover the recipient’s salary, leaving more of the grant
oney for project support.
The intent of the AHA Fellow-to-Faculty Transition
ward is to provide a supportive mentored experience
uring this transition period (Table 9). This is not funded
eavily at the local affiliate level, but has a high success rate
f you apply for this at the national level. Applications can be
ade to either the affiliate or national grant sections, and
ometimes it may be appropriate to apply to both. With this
ward, one may obtain research support during one’s fel-
owship and carry the remainder into the early faculty years.
It is important to indicate participation in a strongly
entored research program, which is very similar to the
IH K award application process. Therefore, applicants
ill be judged strongly not only by their own interests and
cience, but also by the scientific track record of their
entors.
Fellows can receive the award for work at one institution
nd then carry it to another institution where they join the
aculty.
Other AHA programs for beginning investigators include
he Beginning Grant-in-Aid and the Established Investi-
ator Grant. The Beginning Grant-in-Aid program is
esigned to promote independent status to promising be-
inning scientists up to and including the faculty level of
ssistant professor or equivalent. This award is less fre-
uently funded within the AHA portfolio because there is
ore support going to the Scientist Development Grant.
owever, in some of the AHA affiliates there may still be
vailable funding for Grant-in-Aid. When looking for the
able 8. AHA National Scientist Development Grant
bjective
To encourage and adequately fund research projects that bridge the
gap between completion of research training and readiness for
successful competition as an independent investigator.
ligibility
MD, PhD, DO, DVM, or equivalent doctoral degree who is a faculty/
staff member initiating independent research careers, usually at the
rank of instructor or assistant professor (or equivalent).
itizenship
U.S. citizen
● Permanent resident
● Foreign national holding HI, HIB, TC, TN, or O1 status
udget/annual award amount
Principal investigator salary/fringe: up to $24,091/yr
● Project support: at least $35,000 per year (all of award may be
budgeted for project support and 10% indirect costs if PI salary/
fringe are not requested)
● Indirect costs: not to exceed 10% ($5,909)
●Maximum annual amount: $65,000
nline
http://www.americanheart.org/presenter.jhtml?identifier3004142
ource: additional details provided from http://www.americanheart.org/presenter.
html?identifier3004142.rograms offered by AHA affiliates, see what is being
S
junded in any given cycle or in previous cycles to determine
hose awards that may be applicable to your situation, but
nderstand that the Scientist Development Grants are
oing to be much more attractive, and that is where the
HA wants to put the money.
The Established Investigator Grant is for someone at the
ext career level beyond fellowships. This award is for
ndividuals who have already established themselves as
ndependent investigators and is meant to support the career
evelopment by funding innovative projects not funded
lsewhere. The grants usually are given to investigators four
o nine years after their first faculty or staff appointment.
his is the kind of prestigious grant that should be a goal for
erious young investigators.
Beginning investigators should be applying for grants at
he NIH K award level as well as for the Scientist Devel-
pment Grants. It is not possible to get funded from both
rms, but it’s wise to apply for both; if an applicant gets
ejected by one program, they may get accepted for the
ther. The same thing is true for the Established Investi-
ator Grant, as investigators move up the NHLBI grant
rogram ladder as their career advances.
For the year 2004, exactly 60% of AHA research funding
ent to applicants at the level of assistant professors, fellows,
nd instructors. Other career guidance information is available
rom the AHA, including mentoring information and the
HAMentoringHandbook (5), at the organization’s web site,
ww.americanheart.org/research. Becoming a member of the
HA gives you access to myamericanheart.org, which provides
able 9. AHA Fellow-to-Faculty Transition Award
bjective
To provide funding to physician scientists during critical period of
career development spanning completion of research training through
early years of first faculty/staff position.
To provide a supportive mentored experience during this transition
period.
ligibility
MD, MD/PhD, DO, or equivalent doctoral degree who needs
additional research training under sponsor/mentor supervision before
independent research.
itizenship
U.S. citizen
● Permanent resident
● Foreign national holding HI, HIB, TC, TN, or O1 status
ward amount
Training portion
Up to $65,000/yr
Provides for no indirect costs
First faculty/staff appointment
Up to $132,000/yr
Includes 10% indirect costs
otal amount
5-year maximum @ $593,000
Duration, 5 years, with annual review
nline
http://www.americanheart.org/presenter.jhtml?identifier2230ource: additional details provided from http://www.americanheart.org/presenter.
html?identifier2230.
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October 4, 2005:5A–72Aven more specific career information as well as more specific
ays to obtain grant support from the AHA.
ransition awards—ACCF. The American College of
ardiology Foundation (ACCF) is a very attractive source
f information and funding for fellows. There are fewer
rants available, but they are quite prestigious. The ACCF/
erck Research Fellowship awards are for one-year re-
earch fellowships with preference given to individuals with
o more than two years of full-time research experience
Table 10). The new focus of this award this year is
ardiovascular disease and the metabolic syndrome.
The ACCF Career Development Awards (Table 11) are
or junior faculty. There are separate awards for investiga-
ors involved in research related to heart disease prevention
nd hypertension/peripheral vascular disease. Applications
ay be made by fellows as long as they have a faculty
ppointment for the next year.
For those with imaging interests, there is a new award
vailable: the ACCF/General Electric Healthcare Award
or Cardiovascular Imaging (Table 12). The intent of this
ward is to support investigators looking for innovative new
trategies for imaging and/or new imaging agents.
The ACC also offers the ACCF/Pfizer Career Develop-
able 10. ACCF/Merck Research Fellowships in Cardiovascular
isease and the Metabolic Syndrome
bjective
To support research addressing diabetes or the metabolic syndrome as
they pertain to cardiovascular disease
ligibility
Anyone currently in a recognized, accredited adult cardiology
fellowship training program
● Preference given to individuals with no more than 2 years of prior
full-time research experience.
● Preference given to clinical research training and experience directly
involving patients or human subjects.
ward amount
$60,000
● 1-year research fellowship (four awarded annually)
● Full-time research commitment
nline
http://www.acc.org/about/award/awardopps.htm#metabolic
able 11. ACCF Career Development Awards
CCF/Harry B. Graf Award for Heart Disease Prevention
CCF/William F. Keating Award for Hypertension and Peripheral
Vascular Disease
bjective
To foster the early research career development of junior
cardiovascular faculty in research areas specific to each award
ligibility
No more than 5 years out of training
● Academic rank of instructor or assistant professor
● ACC member
ward amount
$65,000, solely for salary support
● 1-year research award
● Full-time research commitment
nline
http://www.acc.org/about/award/awardopps.htm# ●ent Award in Clinical or Preventive Cardiovascular Med-
cine (Table 13), which is a clinical research award. Each
edical school can recommend only one candidate. New in
005 is the ACCF/Guidant Foundation Fellowship and
areer Development Award in Women’s Cardiovascular
ealth (Table 14) to encourage research in cardiovascular
isease in women. More information about various awards
s available at the ACC website, specifically at
ww.acc.org/about/award/awardopps.htm.
ransition awards—NIH, VA, and Foundations. In ad-
ition to the many extramural K awards discussed by Dr.
alke, investigators who are early in their training might
onsider going to the NIH, working in a laboratory with
orld-class people. The NIH K22 Career Transition Award
s an important research fellowship within the NIH in the
ntramural branch, which is an intensive research environ-
ent—effectively a huge clinical research center with 100%
esearch time. As a research fellow, you can take this K22
ransition grant with you when you transition out of the
IH.
This K22 award requires an intramural phase at the NIH,
hich includes direct costs of up to $150,000 per year
ncluding salary, followed by an extramural phase during
hich the award continues, provided there is an extramural
aculty appointment that is on a tenure track. The extramu-
al phase requires at least 75% research time for two years
able 12. ACCF/GE Healthcare Cardiovascular Career
evelopment Awards in Cardiovascular Imaging
bjective
To foster the early research career development of junior
cardiovascular faculty in the area of imaging technologies and targeted
imaging agents.
ligibility
No more than 5 years out of training
● Academic rank of instructor or assistant professor
● ACC member
ward amount
$65,000/year per award, solely for salary support
● 2 two-year research awards
● Full-time research commitment
nline
http://www.acc.org/about/award/awardopps.htm#ge
able 13. ACCF/Pfizer Career Development Award in Clinical
r Preventive Cardiovascular Medicine
bjective
To provide training opportunities for physician-scientists to pursue
cardiovascular research in an academic setting.
ligibility
MD or DO degree
● Instructor or assistant professor not more than five years out of
training
● ACC member
ward amount
$65,000/year
● 3-year research award (up to two awarded annually)
nline
http://www.acc.org/about/award/awardopps.htm#pfizer
a
i
A
i
s
w
i
i
D
i
T
s
t
e
i
f
D
t
f
a
i
h
a
m
t
l
t
r
r
p
e
g
i
I
O
V
R
A
D
N
l
o
O
b
s
w
D
a
M
y
b
3
e
s
t
d
I
b
s
t
a
c
n
p
t
p
o
d
I
c
f
m
d
h
T
D
O
●
O
●
●
A
●
●
O
●
18A Symposium Presentations JACC Vol. 46, No. 7 Suppl A
October 4, 2005:5A–72And provides up to $150,000 per year in direct costs
ncluding salary plus fringe benefits.
The VA also has Clinical Research Career Development
wards (www.va.gov/resdev), but they are only applicable for
nvestigators on staff with salary support at a VA hospital on
ite. The intent is to foster research careers of clinical scientists
ho are not yet fully independent but will soon become
ndependent clinical investigators. The VA awards share sim-
larities with the NIH K awards and the AHA Scientist
evelopment Grants; specifically, applicants are not yet fully
ndependent, and they must have a strong mentor relationship.
he VA awards provide three years of support, including
alary and supplemental research support for a fully
rained clinician scientist who is entering or has recently
ntered a career in clinical research.
Finally, there are many foundations interested in support-
ng young careers. These foundation transition awards come
rom foundations such as the Schweppe Foundation, Doris
uke Foundation, Robert Wood Johnson Foundation, and
he GlaxoSmithKline Research and Education Foundation
or Cardiovascular Disease. There are many additional local
wards, and they can be found in the cities where your
nstitutions reside. This is where a mentor can be quite
elpful, because many mentors know about these awards
nd have used them successfully.
A successful transition requires dedication, focus, and
entorship. Importantly, you should have fun and enjoy
his part of your career. Many of us are overachievers—we
ike instant gratification and do not take bad news easily. On
he other hand, a successful research career is like a
ollercoaster ride. Every young investigator will face times of
ejection. You have to have a thick skin. You have to have
ersistence. Yet, it is a very invigorating career, and it can be
njoyable. You get to meet interesting people, and you are
iven the opportunity to teach the next generation of
able 14. ACCF/Guidant Foundation Fellowship and Career
evelopment Award in Women’s Cardiovascular Health
bjective
To encourage clinical research that will broaden scientific knowledge
related to the mechanisms or treatment of cardiovascular disease in
women
ne Fellowship and One Career Development Award
Fellowship
● Current fellow or within one year of training
●Mentor with recognized experience in treatment or research in
cardiovascular disease in women
Career Development
● Instructor or assistant professor with no more than five years out of
training
ward amount
Each amount: $65,000/year
Two-year research award
nline
http://www.acc.org/about/award/awardopps.htm#guidantnteresting people. It is a very rewarding experience. tV. PANEL DISCUSSION:
PPORTUNITIES FOR YOUNG INVESTIGATORS
alentin Fuster, MD, PHD, FACC (Zena and Michael A.
Wiener Cardiovascular Institute and the Marie-Josée
and Henry R. Kravis Center for Cardiovascular
Health, Mount Sinai Medical Center, New York,
New York)
obert O. Bonow, MD, FACC (Northwestern University
Feinberg-School of Medicine, Division of Cardiology,
Northwestern Memorial Hospital, Chicago, Illinois)
ugustus O. Grant, MB, CHB, PHD, FACC (Department
of Medicine, Division of Cardiology, Duke University
Medical Center, Durham, North Carolina)
r. Fuster: About 4% of young investigators are funded by
IH grants today in comparison with 28% in 1980. I would
ike to ask, why is this happening? Is it because cardiology
ffers other funding opportunities? Or is it getting tougher?
ne would think that it should not be getting tougher
ecause all of us have been presenting information here
uggesting that there are more opportunities than ever. So,
hat is actually going on here, Bob?
r. Bonow: I am not sure I have the answer. You could
rgue that the 4% figure for funding is a little misleading.
aybe the grant is going to an older investigator, and
ounger people are being supported through that grant.
However, I do not completely buy that explanation
ecause if you look at that intermediate group of researchers
5 to 45 years of age, that group’s funding is not expanding
ither. I am concerned that we are kind of an endangered
pecies with fewer and fewer people going into research. By
he way, that graph I showed was not just cardiovascular
isease research funding; that was funding across the board.
t may be worse in cardiovascular disease research, possibly
ecause clinical cardiology is so exciting. When you start
aving lives at 3:00 in the morning with a balloon catheter,
hat can be habit-forming; who has time for research?
Training programs are supposed to be training clinicians
s well as scientists and future academic leaders. In any
ardiology training program, we accept the fact that a
umber of participants will ultimately go into clinical
ractice. As a profession, however, we must provide not only
he tools but also an environment that encourages young
eople and attracts them to research.
The reason we have this meeting is to give you the
pportunity to discuss with all of us your aspirations and the
ifficulties or hurdles you face. I do not have the answer. All
know is that the data tend to speak for themselves and, of
ourse, many others have been raising alarms regarding
unding for a number of years. As a result of those alarms,
any of the National Institutes of Health (NIH) career
evelopment awards came to fruition, and the K awards
ave been very successful. So, we may see a turnaround in
his as we update that graph over the next 10 years.
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October 4, 2005:5A–72ARight now, the K award applicants get funded at a very
igh level. If you apply for a K award with a good mentor
nd a good project, you have got almost a 40% chance of
etting funded, which is great. From my perspective, the
roblem is going to come in the success of moving K award
ecipients into R01 grants, which is the original and
istorically oldest grant mechanism used by NIH. Going
rom a K to an R01 grant moves you from the mentored
xperience to the independent experience. That is an im-
ortant step because they are not funded at the same level.
Also, there is the NIH budget itself, which is going up
ach year, but the budget has gone from increasing 15% per
ear in the last five years to just 3% this year, with a lot of
hat increase going to bioterrorism, not cardiovascular
isease. So, the ability to take all those K award recipients
nd advance them into R01s is going to be tricky.
I have a question for Dr. Fuster: While the team
pproach is a great concept, how do you reward the team
layer in the current academic environment? The person
ith a grant tends to get all the credit at the university, in
erms of promotion and so forth, so how does the dean
ecognize a good team player? Certainly you contributed to
his grant, but you are not the recipient or principal
nvestigator (PI) on it. A lot of medical institutions are
truggling with that issue. We all agree there is a need for
eam-based research and building new research teams.
r. Fuster: In my view, the NIH is stuck in the PI concept,
nd this is a mistake. As we move towards the future, we
ust identify young people and provide the resources and
ncentives necessary for these people to be recognized.
nless this is done, it is going to be a huge problem.
uestion: My question relates to clinical work versus
esearch. Many of us love clinical work but are also drawn by
esearch. As fellows, we are trying to find a way to combine
hem and be happy with both worlds. Is that truly possible?
r. Grant: I would say, it is. If I have conveyed the idea of
dichotomy, I would like to correct that. On the one side,
here is someone like Dr. Vatner who spoke with you earlier
bout dedicating yourself to basic cardiovascular research.
s for myself, I have been on the Duke faculty for 25 years,
nd I continue to see patients while I run an NIH
01-funded laboratory. So it is possible to do both.
The question is: how do you divide your time? I commit
majority of my time to basic research, but it is certainly
ossible to still maintain my clinical contact. After all, that
s why we became physicians in the first place. If you are
rying to decide your commitment in terms of effort and
ime, then my message is this: if your maximum commit-
ent is to basic research or to clinical patient care, there are
ifferences in lifestyle involved. But both are rewarding.
r. Bonow:Also, it depends on the kind of research you are
alking about pursuing. If it is a highly competitive area of
asic investigation, that can be difficult, which is why we
alked about focus. That scenario would require an 80%
inimum commitment by you in order to be competitive
ith the PhDs who do this 100% of the time. dYet even if you are doing basic investigation, it is great to
ave a clinical presence. It makes you more aware of where
our research should be going, the real world it is going to
e applied in, and why the research is important. Also,
aving that clinical presence helps you keep from getting off
rack into some irrelevant area, and it allows younger
rainees to see you as a real doctor, and perhaps it will help
ou draw them into your laboratory. And there is another
onus, too: reserving some time for clinical work maintains
he reason why you went to medical school in the first place,
nd that is the patient experience.
All of that applies to basic laboratory research. If your
esearch is more clinically based, it may be quite easy for you
o be in a cath lab involved in research of vascular function,
or example, or myocardial infarction or medical devices. In
he cath lab, you are dealing with those cases every day, and
alf of what you do clinically may be adding to your research
atabase.
So, I agree with Augustus: certainly you can combine
oth clinical and research work, but when you do that your
ocus becomes really critical, and you have to watch your
ime on the clinical side.
r. Fuster: I would like to add to what Bob said. I have
ombined clinical research and clinical practice all my life. It
s hard, although it can be very enjoyable. What you must
emember is that you are competing when you apply for
rants. It is impossible to do basic science today and be a
reat clinician because the competition is so much greater.
ut it is possible to take the clinical investigation track and
e a translational researcher working with basic investigators
nd enjoying what you are doing while still getting grants.
owever, to make it work you have to be methodical with
n organized pattern in your life; it has to be very strict.
r. Grant: This comes back to the issue of focus again. If
ou are interested in vascular biology or some other partic-
lar area, an ideal research career would be to select a group
f patients who have a related problem and then work
owards gaining focused clinical experience directly related
o your research. With a career built around that sort of
aradigm, you can be extraordinarily successful.
uestion: Dr. Bonow, you were speaking of the American
eart Association (AHA) Fellow-to-Faculty Transition
ward, and there are the K08 and the K23 Transition
wards as well. It seems as though it would be difficult to be
art of a mentored program if you are going to leave the
nstitution where you are doing fellowship and go to another
nstitution. To me—unless I am not understanding the
ward—that seems like a limitation. How do you identify a
entor at an institution where you have not been hired yet
n order to obtain one of these awards?
r. Bonow: It is tricky, but it is possible. It requires
omework and long-distance mentoring, just like we talked
efore about the ability to reach out and identify potential
entors. As part of the recruitment process, you could be
oing that. As you are selecting one place over another, due
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October 4, 2005:5A–72Ailigence is your responsibility to identify those individuals
ho will mentor you.
I should add that, compared to the NIH awards you
entioned, the AHA award is a little easier to transfer. You
an pick that up and move with it if you need to. In doing
o, however, you have got to be certain that there is a
entor on the other end of your move because there will be
equired review of your progress. If your progress was great
s a fellow but it starts to slip as a faculty member because
ou moved, that is not good. So, if you are considering a
ove, you have got to look very carefully at the mentorship
n the other side.
uestion: I hear that sometimes, even though you are
orking with a good mentor, it is better to move to a
ifferent institution as faculty to get a better opportunity and
ore experience. Can you keep the same mentor and do this
ong distance, or is it better to just stay in the institution
here you are a fellow, finish your work, and then move?
r. Bonow: It depends on your work. It may work if you
re dealing with a database and outcomes research. If it is
ench research, it will be virtually impossible unless you are
ust finishing up some data analysis and writing it up in the
ransition period.
There is no problem in staying. This comes up all the
ime as we are talking with fellows about getting faculty
ositions: is it better to go someplace else where you might
et a better deal? Also, if you move, you are coming in to
our new position as an accepted senior person as opposed
o somebody who has been a fellow and is now just moving
nto faculty. It is very individual and based upon you, the
nstitution, and your track record there. Independent of that
ersonal feeling of whether you should stay or go, the key
ssue is what will a move do to your research career? Is it
oing to suffer because you are moving?
The question often comes up: when is the right time to
eave and move? Frankly, it comes up not only as a fellow
ut throughout the rest of your life. All of us have had
pportunities almost every year to change our stripes and go
omeplace else. I bet Augustus has had offers this year and
alentin has, and I have too. At some stage, you decide this
ight be the right thing to do. But if you are productive and
uccessful, the offers only get better. Therefore, if you are
oing well where you are, you might join the faculty at that
nstitution for a couple more years, get a few more grants,
ecome independent, and then when you have the R01 you
ight want to leave.
r. Grant: In a lot of ways, this is truly a personal decision.
nd the decision should turn around specific arguments, for
xample: am I really at the stage of my career where I can
ruly be independent? Do I have the skills that I need to
tand on my own feet? Am I prepared to write—or better
till, have been successful at writing—my first grant? Can I
omfortably sit down with my data and prepare a completed
anuscript? If you feel that all the pieces are in place and
ou are truly comfortable with where you are in your career,
hen I say the decision can go either way. lIf you can identify deficiencies in your skills at any level,
nd you are in an environment in which those deficiencies
an be corrected, then surely the answer is to stay longer and
ot move. It is a very personal decision, and you must
eevaluate it from time to time. There is no timetable or any
ules to tell you exactly when that transition is appropriate.
uestion: I have a question about the Fellow-to-Faculty
ransition Award. Do you have to be actively engaged as a
ellow at the time of the award?
r. Bonow: Yes, and because of the award you may decide
o extend your fellowship. There is nothing wrong with
etting a couple of extra years of fellowship training if you
re in an environment where you are really protected. As
oon as you join the faculty, your protection becomes a real
ssue; even when you have 75% protected time, you will have
eople biting at your heels to spend a little more time seeing
atients, doing other things. That is where you need a
entor to protect your time and stand behind your grant. If
our fellowship is ending, then you would be eligible for the
areer Development Awards, which are specifically for
unior faculty.
uestion: Do you think medical schools or universities
ould do more to assist in this transition into research,
hich seems to be the hard part? I am talking about making
t easier in terms of support, because a lot of grants require
he institution to make a commitment that could cost them
40,000 a year. That might be a problem in some institu-
ions that do not have a lot of resources.
r. Bonow: It is true for NIH K awards, too, because they
o not really support your salary. From the institution’s
oint of view, K awards are great and yet every time we get
ne, we swallow hard because now we have got to find a way
o support this person when 80% of their time is protected
or research. Some medical schools are stepping up to do
his better than others, and this is an important consider-
tion as you are looking for faculty positions. What is the
chool’s climate right now in terms of the environment and
upport for young people? If you get a K award, will you be
rotected? Will you be supported? Those are important
uestions to be asking.
uestion: This question is about doing basic research and
rying to learn some clinical research skills at the same time.
t is hard to get protected time, but if you are doing some
ulture studies you may need three to six months of
rotected time. My concern is if a patient comes in maybe
nly once a year, will I be permitted to go and enroll that
atient for my clinical research? That is part of the problem
hen you are a fellow.
r. Grant: That is a very good question, but you really need
o decide your top priority. You cannot develop a meaning-
ul career in biomedical research without a strong and
lmost total commitment to it. In our institution’s fellow-
hip program, if you choose either basic or clinical research,
n the clinical side it requires a minimum commitment of
ne year. On the basic research side, most people who do
aboratory research in our institution are going to ask you to
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October 4, 2005:5A–72Apend two years. Why the difference in the time you are
eing asked to commit? The complexities of basic biomed-
cal research now are such that if you have never done it
efore, you cannot walk away with a meaningful experience
ithout dedicating at least two years to it.
The idea that when there is a week or two available you
hould just go into the laboratory and get something done is
ot a serious proposition at all. I have had people in my lab
ho have not been totally committed in terms of their
esearch time. They have got an experiment set up, but this
erson is really a pediatric cardiologist and not a researcher;
omeone comes into the clinic with an interesting congen-
tal abnormality, they drop the test tubes, and run to do the
atheterization. In my opinion, you cannot double up like
hat on a repeated basis and obtain a meaningful research
xperience. Like with many things in life, you have got to
ake a choice.
r. Bonow: Mike Mendelsohn showed a slide that said if
ou are learning bench research, you need at least two years
n the laboratory if you are already experienced or three years
f you have never really done it before to get up to speed. For
ou, it may be that you need to get the clinical training
ecause you still want to be a card-carrying pediatric
ardiologist, which is good. Then the issue becomes: what is
he support system in your institution to give you an extra
ear or two of training?
Dr. Grant has noted that Duke University has such a
ystem. We have kind of a system in place, too at North-
estern—anybody who wants a fourth year gets a fourth
ear. We hope they will get a grant for that fourth year, but
f they do not, we will find a way to support them, whether
hey are doing basic or clinical research. Beyond that, if they
re really committed, they will find a way to do the fifth year.
This is a discussion you have to have with your program
irector. If you cannot do it at your institution, perhaps you
eed to go get the clinical training you need and start
ooking now for that mentoring experience someplace else
here you could be supported if you move. Obviously, if you
an get a grant, that is great, but it would be good during
our training period to have some protected time as well.
r. Fuster: This question is very important because it
rings into discussion the issue of your own commitment.
s you start seeing all the barriers and difficulties you face,
ou have to ask yourself if you are really committed to an
nvestigational career or not. Most of us were not genetically
ade to do investigational work. I was at the Mayo Clinic,
fellow like many of you. I earned my degrees in cardiology
n England, and when I came to the Mayo Clinic I started
rom zero. It was only after six or seven months that I found
y way as a researcher, and it was only by working at night.
ou must commit to the fact that you want to be an
nvestigator and then find a way to become an investiga-
or—maybe by finding extra time to do research or whatever
lse it takes—but you need to have this commitment,
therwise it is going to be very difficult. Yes, the training
rogram itself does not give you much time to do many wther things, but if you are really passionate about research,
hen the time gets carved out for it somehow.
I am sure many of you are thinking that “What these guys
re talking about is not for me.” Yet, we are making a very
ttractive proposition to you today, as long as you are
ommitted. You might say, “Well, I enjoy research in
chocardiography. Forget about grants. I would just like to
nderstand some basic issue in hypertrophic cardiomyopa-
hy.” Even with training programs being so tight today, you
ill find a way to do some work in hypertrophic cardiomy-
pathy and maybe write a paper or two with your colleagues.
o, I do not think there are barriers if you really are
ommitted and excited about something, and this is what
e are trying to convey to you today. If you are not very
xcited, you probably should follow a different path.
uestion: I have a very practical question regarding choos-
ng a mentor in basic science research. Please comment
bout choosing somebody outside of cardiovascular re-
earch, maybe even in hematology, who is interested in
iological questions with potential relevance to cardiology.
pecifically, could you comment about institutional support,
ecessary grant applications, and ultimately finding jobs?
r. Bonow: This is one of the reasons why I believe
ivisions of cardiology should not be independent of de-
artments of medicine because there are so many things in
ardiology that interrelate, including immunology or hema-
ology and inflammation, for example. Right now, we have
junior faculty member whose mentor is a bone physiologist
ecause she is studying why valves calcify. It is all ossifica-
ion and bone signaling, so non-cardiology collaboration
hould be allowed and fully supported. How are we going to
ucceed at team-based research unless we are reaching out to
ring in different kinds of team members? Interdisciplinary
r multidisciplinary research is encouraged in many places.
would like to think you would find within your department
f medicine the support mechanisms necessary for this.
r. Grant: It is a good idea to think about skill set you want
o acquire and then make your decisions independent of
epartmental barriers. I will cite a personal example for you:
any years ago, I decided that I needed to learn more about
olecular biology. I sat down and spoke with my depart-
ent chair as to what laboratory I should go to, and we
ecided that the hematology lab was a great place.
That is because if you look in all systems, hematologists
re one of the few groups of biomedical investigators who
ave ready access to the material being studied, namely
lood. Some of the earliest and most fundamental work
elated to genetics and molecular biology was done in
ematology laboratories. The heme-carrying proteins
urned out to be very simple molecules, so this was a great
lace to go and acquire the initial skills I needed. Then I
ould return to my cardiology lab with the skills I learned in
ematology. So, absolutely decide on what skills you need,
nd do not let departmental barriers stand in your way. Go
herever you need to learn those skills.
D
m
m
o
c
o
b
d
d
b
g
f
b
v
a
Q
t
m
fi
w
d
t
D
r
d
y
t
T
f
l
e
y
t
y
s
O
a
a
f
s
t
i
t
D
t
e
s
p
s
d
y
t
D
t
a
y
a
t
D
D
w
Q
t
D
a
r
u
a
o
a
o
i
m
p
f
F
t
g
y
D
h
c
h
q
F
g
a
t
p
d
w
e
D
p
t
g
t
n
F
p
D
t
t
D
h
F
k
h
22A Symposium Presentations JACC Vol. 46, No. 7 Suppl A
October 4, 2005:5A–72Ar. Fuster: This is critical. Forget about divisions, depart-
ents, or anything. We are in research, and today there are
erging technologies across the board. So as to the question
f who is your mentor, it does not necessarily have to be a
ardiologist. You may require a mentor who is a hematol-
gist, but I caution you that it is important that your mentor
e in touch with the appropriate people in the cardiovascular
ivision. It is critical that there is always a link between the
ivisions rather than a separation. That is important advice
ecause I can give you examples of people who I suggested
o to other divisions, but then the mentor absorbs that
ellow. The fellow may be doing really well, but is somewhat
eing held hostage. When something like this happens, it is
ery important that there be communication with the
ppropriate people in your own fellowship program.
uestion: My question is for those of us who short-
racked. Is there a feasible way to do preliminary experi-
ents and generate data to satisfy early career grants while
nishing clinical training but not having protected time
hen you have already done your three years in the lab? Or
o you recommend applying for transitional funding, then
rying to stay on as a fellow?
r. Bonow: It is always a question: how do you do the
esearch versus the clinical training? So, you have already
one your three years of research; now you are doing two
ears of clinical training. It would be great if you could have
ime to write the grant now for the work you want to do.
he question is: what grant are you going to be applying
or? Is this for a faculty Career Development Award as you
ook to transition into faculty, or are you going to try to
xtend your research training fellowship for a couple of
ears?
You may be able to get a couple more years of research
raining through a transitional grant. Based upon your three
ears of research, you should have the experience, mentor-
hip, and preliminary data to write a very successful grant.
f course, you have to find time to do that in the middle of
clinical training period. We have also been wondering
bout this issue with the career development types of
ellowships and the best approach for someone who is
hort-tracked. Perhaps we should schedule some research
ime into that last year, permitting somebody to get back
nto the laboratory again where they can have a little buffer
ime and be writing grants.
r. Grant: If you had a very successful three years and got
wo or more papers published, then I would strongly
ncourage you towards the end of your clinical rotation to
tart putting your ideas together into a grant proposal. The
eople who review grants, particularly at the AHA, under-
tand the transitional situation, and the expectations are
ifferent. If, on the other hand, you feel you did OK during
our three years but have a lot to learn, then you may want
o get back to the lab first before writing that grant.
r. Bonow: But, Augustus, what would you recommend
he target be in terms of the grant she is applying for? We
re going to assume you are a very successful investigator: gou have a successful three years, wrote a bunch of papers,
nd now what kind of grant should she be looking to move
oward next?
r. Grant: Maybe the Scientist Development Grant.
r. Bonow: One of the Career Development Awards also
ould be good.
uestion: When you are looking for a grant, how impor-
ant are your preliminary data?
r. Grant: It depends on the nature of the grant that you
re writing, but good preliminary data always help. It is
eassuring to the people reviewing the grant that you
nderstand the implications of what you are proposing
nd that you have some skills in problem-solving. On the
ther hand, there are grants for which preliminary data
re not that crucial. To a certain extent, the grant depends
n other variables too, such as the mentor you have
dentified, and the commitment of the institution and your
entor to you.
If you are going for a national award at the NIH level,
reliminary data are definitely significant. However, in
oundation grants, such as the Robert Wood Johnson
oundation or certain AHA grants, preliminary data are not
hat critical. It depends more on the environment you are
oing to work in and the commitment of the people around
ou to your success.
r. Fuster: I want to ask three young investigators if they
ave any questions or comments for us? Do you have any
omments or anything you disagree with in terms of what
as been said? Or is there something important, or any
uestion that is left unanswered, from your own perspective?
ellow 1: My experience with the postdoctoral fellowship
rant is in an institution where a number of people write
pplications every year. Those who have preliminary data
end to get higher scores than the ones who do not, so
reliminary data makes a difference. It probably makes a
ifference in your ability to write a good grant. If you
orked in this field and have a little experience, it makes it
asier to write.
r. Bonow: That is what Dr. Grant was saying: if you have
reliminary data, it is always better than not having it. But
he question is: should you even bother applying for this
rant if you have no preliminary data? The answer is that
here are some grants where the preliminary data really are
ot that important.
ellow 1: But your score is going to be better if you do have
reliminary data, so you are more likely to get funding.
r. Bonow: If you are competing against somebody down
he street who has got preliminary data, then yes, it is going
o be a tough competition for you.
r. Fuster: Veronica? Do you disagree with anything that
as been said?
ellow 2: I have not applied yet for a grant, so I do not
now much about it. But I know that the more data you
ave, the better score you get, and the easier it is to get the
rant. I have one question, though. Sometimes we get the
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October 4, 2005:5A–72Apportunity, as fellows, to mentor high school students. Is
hat good to do or not? How would you approach that?
r. Fuster: It is absolutely critical. We have a program—
nd I am sure the others can speak to similar programs—in
hich very young people at different stages have opportu-
ities during the summer to come in to the medical school
nd you can tutor them. Some of the best experiences I ever
ad were to guide students before medical school into areas
f research or interest or methodology and see their excite-
ent. If you follow-up on these individuals, you tend to find
hat they go for academic careers. That is why I feel effort
hould be focused on that group of people very early because
hat is where the excitement really is, and sometimes they do
ot face some of the obstacles and problems you see later on.
r. Bonow: I agree; in fact, I wish we had more opportu-
ities to expose young people to young investigators like
ou. That is because I am an old person, I am irrelevant to
high school student. But all of you are much closer to the
ction, and you can be the stimulus for the generation after
ou.
r. Grant: Every summer at our institution, we have high
chool students who spend four to six weeks on campus
here they will be exposed to fellows in different areas.
ome will get a chance to go up to the coronary care unit in
he evenings and spend a few hours, just to see what you
o—no hands-on experience, of course, but just to see what
our life is like as a clinician. We will have perhaps 150
tudents on our campus during the summer.
If you run across any of them in similar situations, it is
reat to interact with them, and let them see the fun you are
aving. And I stress that point about having fun. About five
ears ago at Duke University, we did a survey to find out
hat had the greatest influence on fellows like you in
egards to choosing a career in academic medicine. And this
s perhaps a word of caution to the three of us sitting up
ere; the fellows decided that the most important thing was
he happiness of the faculty around them. If it was not
pparent that the faculty was really having fun and enjoying
hat they were doing, then the fellows decided that this
areer really was not for them. The lesson is that, if we do
ot reflect the fun that academic medicine really can be,
hen surely you look in from the outside and consider it
nattractive. And let me reassure you: this can indeed be a
un thing to do.
r. Fuster: Augustus, this leads to a very important
uestion about competitiveness. In general, one of the
ilemmas for young faculty members is that they are
truggling because there are so many demands clinically,
nd, at the same time, they are working in the research
rena, and they have to survive. Then you find a young
erson who comes into the system and begins to notice the
ension and stress. Please comment about how you view
his.
r. Grant: It is a very important issue, and this issue of
tress and tension is, in part, the reason I mentioned it. We
o not convey nearly as often as we should the fact that what le do is fun. Yes, it is reasonable to be competitive, but you
an be competitive in a very honest way and in a way that is
eant to be a search for truth, but the goal is not to be
etter than anyone else. The more we all stress the positive
n terms of those interactions, the better off both sides will be.
r. Bonow: For the three of us here and those like us who
re out there doing what we do, we need to expose fellows
o the research successes of our faculty. Fellows are caught
p in the day-to-day clinical arena. They see negative
hings; they know all the dirty laundry long before I know
bout it. We need to expose them to the excitement that
ome of the faculty is having with other fellows, and the fact
hat other fellows are getting their papers in really good
ournals. At the same time, we need to expose fellows not
nly to the successes of their peers but also to the fun and
xcitement that can go with it. We have research confer-
nces, and those are helpful, but getting fellows to come to
ur meetings is hard sometimes, so we try to mandate that
ellows attend those meetings.
ellow 3: I fully agree with the idea of getting people
xposed early to research. My own exposure to the field of
esearch occurred when I was a junior in high school.
hrough a program at Washington University in St. Louis
was exposed to a top-notch electrophysiology laboratory,
nd I made a decision at that time to be a researcher.
r. Fuster: We could summarize by saying that the
pportunities are great in the research arena and certainly in
linical research, which we have not touched upon much in
his conversation. You have to find out for yourself whether
r not you really enjoy this kind of work. How will you
now? Maybe you will wake up in the middle of the night,
s Mike said, thinking about the questions you are investi-
ating. Importantly, you have to engineer your own oppor-
unities, become exposed earlier to the possibilities of
esearch work, and be around smiling people. Thank you
ery much.
. CAREERS IN CLINICAL RESEARCH
aniel B. Mark, MD, MPH (Outcomes Research Group,
Duke Clinical Research Institute, Department of
Medicine, Division of Cardiology, Duke Heart Center,
Durham, North Carolina)
ric D. Peterson, MD, MPH (Outcomes Research Group,
Duke Clinical Research Institute, Department of
Medicine, Division of Cardiology, Duke Heart Center,
Durham, North Carolina)
ach year, basic scientists make significant discoveries about
he mechanisms and processes of disease. These discoveries
ust be evaluated and used, where appropriate, to develop
ew methods to diagnose and treat human illness. The
bservations made in clinical medicine, in turn, need to be
ed back to the basic scientists to stimulate and refine further
esearch. Over the last 30 years, while the demand for
igh-quality, quantitative research evaluating the techno-
ogical and biological advances in clinical medicine has
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October 4, 2005:5A–72Ancreased, the number of qualified, adequately prepared
hysician-scientists entering careers in clinical investigation
as dropped sharply. This is unfortunate in as much as it
reates a bottleneck in the process of translating research
ndings into improvements in public health. Although a
areer in clinical research has many challenges and involves
ccepting certain tradeoffs, it offers a unique opportunity to
mpact the health and well-being of large numbers of
ndividuals.
Clinical research or investigation can be defined as
atient-oriented research that involves the whole patient,
ot just parts of patients or specimens from patients.
igh-quality clinical investigation uses many different types
f tools and is distinguished by a reasonable expectation that
ne is going to materially improve our understanding of
ome disease process and its diagnosis, treatment, or pre-
ention. In addition to performing clinical trials, clinical
esearch often employs the methods of outcomes research
uch as epidemiological studies, cost-effectiveness analyses,
nd quality-of-life outcomes to reach beyond answering the
asic questions of efficacy, effectiveness, and safety in an
ffort to help further guide clinical decision making at
arious levels.
We will provide some thoughts about the personal
lements necessary for success in a clinical research career, a
ramework for developing your career, and some consider-
tion of the challenges that a clinical researcher encounters.
e also will highlight some of the myths we believe have
urfaced around clinical research training and offer our own
iews of the realities of contemporary career development in
linical research (Table 15).
ersonal elements for a successful career. Many of the
easons that people choose medicine as a profession are also
nherent in careers in clinical research, and there are general
uestions that everyone should consider and answer for them-
elves before embarking on a career. First, is the work going to
e worthwhile? Certainly, clinical investigation can offer im-
ortant, meaningful work that provides the opportunity to
ake a substantial difference in the lives of patients and in our
able 15. Myths and Modern Advice
Traditional Advice Modern Advice
ake the single, well-traveled path
to success.
There are many different types of
successful research careers and
many paths to choose from.
linical researchers need to be the
expert clinician, and statisticians
will run the numbers.
Get formal training in research
methods, operations, and
quantitative methods.
orking on large, multicenter
projects is a bad career move.
Future impact projects will be
large, collaborative endeavors,
not single-investigator
initiatives.
nce you have a successful
project, publish as many papers
as possible.
Medicine is moving fast, and life
is short. One impact paper is
worth 100 “variations” on the
theme.cientific understanding of an illness. Second, will the com- iensation be fair? As with any career choice for each individual,
he compromises or trade-offs one makes to realize his or her
ltimate goals are all part of the compensation formula.
pportunities to work with smart people, flexibility to pursue
ersonal research interests, international travel, or the chance
o be on CNN discussing breakthrough research are of signif-
cant value to some people. Others prefer more time with
amily and patients, or pursuing interests outside their primary
areer. You have to decide what balance meets your goals best.
third question that often arises is will there be appropriate
ecognition for the work? This, too, is an individual preference,
ut one that should fit into the context of one’s overall goals in
ife. A principal investigator of a large, multicenter clinical trial
f a potential blockbuster drug will necessarily be someone
omfortable in the spotlight and who can speak to large public
udiences, and this serves as a measure of recognition and
ccomplishment. Others may desire advancement opportuni-
ies at their company or institution where they can broadly
nfluence research emphasis in a particular area. A fourth
uestion is what kind of atmosphere do you desire to work in?
linical investigation is now rarely an individual endeavor. It is
mportant at the outset to consider what kind of people you
nvision working with: will you have common motivations,
imilar goals, and reasonably comparable means of achieving
hem? For this question, it is also important to give much
onsideration to what position you want to play on the team.
re you drawnmore to generalizations or details? Do you want
o lead or follow?
Although there is no single prototype that exemplifies the
uccessful clinical researcher, there are some key personal
lements that are generally present. A passion for the work and
ubstantial resilience to failure are core characteristics com-
only found in people who are highly successful in their
hosen profession, and clinical investigators are no different.
owever, successful clinical researchers also must be able to
ormulate good questions. The ability to obtain research
unding will largely depend on developing research questions
ith the potential for substantial impact. Another common
haracteristic of successful clinical researchers is that they are at
east somewhat unreasonable. To make a significant contribu-
ion, one often has to be willing to go against the flow, look
eyond what is popular or current, and explore what others
ay consider to be foolish or eccentric ideas. You must also
ossess the confidence to challenge your own ideas and take a
keptical look at what you have produced. Finally, clinical
esearch is not an endeavor for dilettantes. There is an
mportant body of technical information that one needs to
aster and a variety of skills that must be developed in order to
e a successful, high-quality clinical researcher; these will be
iscussed in later text.
eveloping your clinical research career. Once one has
hosen to pursue a career in clinical research, six major steps
hould be undertaken as part of the preparation process. The
rst is to define your career specifications.
How much time do you want to spend doing clinicalnvestigation versus practicing or engaging in some other
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October 4, 2005:5A–72Arofessional activity? There is a variety of different models at
ifferent institutions, and some institutions will not guar-
ntee protected time to do your research.
How do you want to fund your research? If you choose to
ork in industry or in government, you will have less
ressure there. If you choose to work in academic medicine,
lthough you might have more leeway in pursuing your
articular research interests, you will have a much harder
ime getting money to do it. In academic medicine, there are
hree primary sources of funding: federal grants, industry
rants, and foundation grants. Academic institutions rarely
ave money available to support clinical research. Each
unding source comes with its own pros and cons.
What role do you want to take in research? Do you want
o be the thought leader, the principal investigator, the
erson who sits at the head table with people looking to you
or the next step in a big clinical trial or project? Do you
ant to be a clinical site principal investigator, which allows
ou a seat at the head table, but not necessarily having to
ead the way?
What is going to be your research focus? It could be on a
isease or condition such as acute coronary syndromes, or it
ould be on a technology such as echocardiography or
nterventional cardiology. Do you want to deal primarily
ith gathering novel patient data or alternatively focus on
stablished datasets?
Lastly, what career path will you choose? Traditionally,
he single path to success was to get an early career
evelopment award, then an R01, move to lab director, and
hen on to chief of some department and so on. Today,
any paths exist to a successful career in clinical research,
ven outside academic institutions. Excellent opportunities
an be found at federal regulatory agencies such as the Food
nd Drug Administration, at funding agencies such as the
ational Institutes of Health or Agency for Health Care
esearch and Quality (AHRQ ), in health care management
rganizations like Centers for Medicare and Medicaid
ervices (CMS) or managed care, and in industry.
While it is instructive to outline your career specifica-
ions, it also should be with the understanding that it is not
o be used as a fixed blueprint of the future. You will likely
hange course many times throughout your research career,
s medicine changes and as you change, and you must
ossess the flexibility to adapt to the inevitable detours. It is
seful, however, to have a guide to look back on after a time
nd reassess where you are and whether you are still going
n the direction you intended.
A second major element in preparing for a career in
linical research is to identify mentoring relationships. You
hould identify a role model or two who will help guide and
dvise you on your overall career progression. This person or
hese people should have a good track record of not only
ndividual research productivity, but also of helping to create
uccessful independent investigators. Your principal mentor
lso should be senior enough to step aside and let others be
he first author on publications. In addition to the principalentor, it is also necessary to have other people serving in
econdary mentoring roles to make sure everything is
overed. No one person will be an expert in every skill
eeded to be successful in clinical research, and you will
eed to align yourself with people who have essential
ontent or methodological expertise in your field. It is
mportant to recognize this early and form relationships and
etworks that will help you to grow and that can help guide
nd support you when you need to cross a bridge.
A third major element is to undertake didactic training in
linical research conduct and methodology. Early training is
eneficial, but you may want to consider getting some
esearch exposure first so you get a sense of which electives
o pursue. A degree, such as a masters in clinical research or
masters in public health, can be helpful but it should not
e considered essential. A fellowship such as the Robert
ood Johnson Clinical Scholars Program also can provide
he training, education, and skill development necessary to
ecoming a successful, high-quality clinical researcher.
Short courses” or conferences alone are not sufficient for
evelopment. The core essentials of didactic training to
ursue should include biostatistics, principles of clinical
esearch, clinical trial methodology, ethical issues, and
esearch management. Elective elements may include ad-
anced statistical topics, molecular genetics of disease,
ealth services research, or health economics.
Another major element in launching a successful clinical
esearch career is to apprentice on a successful research
eam. Consider your career specifications and seek out
pportunities to work with like-minded people on projects
nderway. There will be plenty of opportunity to get
nvaluable hands-on experience if you use your mentoring
etwork and are willing to ask for what you want and then
ollow through on your commitments. It is no longer
onsidered a bad career move to work on large, multicenter
rojects as a young investigator. Future impact projects will
e large, collaborative endeavors, not single investigator
nitiatives. In the past, it was believed that the formula to
uccess was to focus on one small area and become the
xpert in this area. That is no longer the case. There are now
pportunities to work in multiple areas and be the bridge
etween the more narrowly focused experts.
A fifth element in preparing for your clinical research
areer is to conduct your own research projects. You should
ocus your efforts on addressing interesting questions that
dd something new to the literature or knowledge base and
re not just replication or “me too” research. The results of
our research should have the potential for future clinical
mpact, although this is often delayed. It is important to
ave several projects to take ownership of so that you will be
riting manuscripts for publication as first author.
Once you have a successful project, you should not feel
bliged to publish as many papers as possible on those results
the tonnage approach to clinical research). One impact pub-
ication is worth 100 “variations” on a particular theme.
Finally, immerse yourself in the culture of research.
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October 4, 2005:5A–72Attend national and international meetings, keep current
n the literature in your field, seek new networks and
esearch relationships, and pursue new funding sources
nd opportunities.
etting the most out of your clinical research career. If
ou are already in a training program, you might wonder if
ou are currently in the right place to continue your career.
here are some clues that can help you determine whether
r not you are getting the most out of your clinical research
raining experience. First, is there divisional and departmen-
al support for clinical research training? Without firm
nstitutional commitment and support for the development
f high-quality clinical investigators, the push toward per-
orming largely clinical duties may impede your ability to
uccessfully develop your clinical research career. Part of this
nstitutional support should include protected time to learn
nd perform research. Another indication of whether you
re in the right place is if there are appropriate role models
nd mentors available to you. Are they helping you network,
hallenging you, advancing your skills, and being generally
upportive? Lastly, an institution that has a good record of
linical research trainees going on to have successful clinical
esearch careers is also a good indicator of the quality of its
linical research training program.
What can you do if your institution is not supportive of
linical research training? There is no reason to forego your
oal of becoming a clinical investigator if this is the case.
ne avenue to pursue is to arrange for a two-year clinical
esearch fellowship somewhere else. Contact the National
nstitutes of Health about clinical research training pro-
rams that you can apply for and search the Web for other
ellowship opportunities. Consider combining resources.
or example, didactic training could be obtained at a public
ealth school or a graduate school. Separate from this, you
ay become associated with a research group that is willing
o take you on as a junior member of the team to work on
n interesting problem. Start networking with people who
o what you want to do; you can often help create your own
pportunities just through being interested and involved.
unding will be the biggest stumbling block. Institutional or
ndividual National Research Service Award (NRSA) train-
ng grants may be helpful in providing support for a training
ellowship.
Once you have gotten past the preliminary training phase
f your career and are ready to look for a faculty position as
clinical researcher, there are several things to take into
onsideration. A big issue here, as with clinical research
raining, is to make certain there is divisional and depart-
ental commitment to protected research time. The insti-
ution should have enough clinicians to do the clinical work
ithout having to press clinician-researchers into giving up
heir research time to clinical endeavors. Look for an
nstitution that is willing to support your salary for two or
hree years while you get your research going and can submit
or funding. It is also important to assess whether the
nstitutional leadership (deans and chairs) has a modern tnderstanding of clinical research and supports the multi-
isciplinary culture necessary for your success.
There are a number of things you can do if you find that
ou cannot get a job at a clinical research powerhouse. With
he ease and accessibility of the Internet, you could consider
reating a virtual clinical research enterprise. Ask yourself
hat strengths you bring to the clinical research table (e.g.,
atients for randomized clinical trials, technical procedural
xpertise) and use your network to find a research team
ooking for your particular ability. You can also network
ithin your own institution to form a mini-team of experts
hat can partner with outside groups.
dditional challenges to consider. While clinical research
s ultimately a highly rewarding enterprise, no review of careers
n clinical research would be complete without exploring some
f the, perhaps, less desirable aspects of the profession. Perhaps
he biggest hurdle in clinical investigation is getting funded for
our time and research, and it is a continuous challenge. You
ill always be working toward getting your next research
roject funded if you are at an academic institution, which can
e a pleasant motivator for successful researchers but often
ecomes a source of frustration for others. Another problem-
tic issue in clinical investigation is all the paperwork. You
opefully will be successful enough to hire people to help you
ith that aspect, but you will be ultimately responsible for what
ets submitted to your institution and to outside agencies.
uch like a tax lawyer, you may have to keep aware of
hanging government regulations and requirements, and many
nstitutions now require annual certifications for performing
linical research. Finally, you will fail and you have to be okay
ith that. If you are tempted to use failure as an excuse to
etreat to private practice, you may as well go into private
ractice now.
There are certainly more lucrative pursuits in the medical
rofession than a career in clinical investigation. There are
ess frustrating paths to a successful career for a physician. It
ould take the span of an entire career before one can see the
rogress that one has contributed to improving medical
are. However, if you have the passion and the curiosity for
t, and if you want to take part in the evolution of clinical
ractice, no career is more rewarding than clinical research.
I. CAREERS IN CLINICAL TRIALS
ND EPIDEMIOLOGY: TOOLKIT
OR THE CLINICAL INVESTIGATOR
lliott M. Antman, MD, FACC (Samuel A. Levine
Cardiac Unit of the Cardiovascular Unit, Brigham and
Women’s Hospital, and Harvard Medical School,
Boston, Massachusetts)
here is a basic “toolkit” for those who wish to become a
uccessful clinical investigator. This toolkit includes “fire in
he belly,” credible clinical skills, certain computer-related
kills, and a mentoring environment. You must have each of
hese four domains because if you miss any of them, it is not
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October 4, 2005:5A–72Aoing to work out all that well for you. Let us take each of
hese separately.
First, as part of your own genetic makeup, you have to
ave fire in the belly. As Eugene Braunwald, MD, FACC,
aid at an American College of Cardiology meeting in 2003,
Enter a career in clinical research only if you are truly
urious and feel the thrill of the chase.” In other words,
esearch is not something you do because somebody told
ou it should be done. You must decide that clinical research
oves and inspires you. Also, Dr. Braunwald went on,
Research (that is, answering the question) should be an end
n itself, not a means to an end (promotion, recognition).”
Second, you cannot be a good clinical investigator unless
ou have credible clinical skills. No one will listen to you in
erms of the preparation and design of clinical trials if you
o not know how to take care of patients and understand
linical problems. This is not difficult because you are all in
raining situations where you will acquire those clinical
kills, but you must maintain these skills if you desire a
areer in clinical investigation.
Moreover, as Dr. Braunwald points out, you must guard
our time available for research jealously. He said, “Clinical
xcellence is essential for a clinical investigator, but excess
linical duties during your fellowship can prevent you from
cquiring the substantial skills required of a clinical inves-
igator.” Similarly, if you are constantly in the lab without
he protected time to do clinical research, it will detract
rom your development as a clinical investigator.
The third element in the toolkit of a successful clinical
nvestigator features skills pertaining to computers and the
igital world. You must be able to do literature searches,
hich are getting easier given the advances in computer
echnology, electronic publishing, and grasp digital library
echniques. At the outset, make sure you abide by all human
esearch regulations, which are readily available on the
nternet (Table 16). There are also minimum requirements
elating to biostatistical skills, including concepts of trial
esign, basic techniques of data analysis, and familiarity
ith meta-analysis, decision analysis, and cost-effectiveness
nalysis. However, do not make the mistake of relying on
able 16. Human Research Resources on the Internet
National Institutes of Health
Office of Human Subjects Research (OHSR)
http://ohsr.od.nih.gov/
United States Department of Health & Human Services
Office for Human Research Protections (OHRP)
http://www.hhs.gov/ohrp/
U.S. Food and Drug Administration
Guidance for Institutional Review Boards and Clinical Investigators
1998 Update
http://www.fda.gov/oc/ohrt/irbs/
Bioethics Resources on the Web
National Institutes of Health
http://www.nih.gov/sigs/bioethics/index.htmlnalysis when there are weaknesses in your research design. is biostatistician David DeMets, PhD, said, “No clever
nalysis can rescue a bad or flawed design.” You must have
foundation in biostatistics or you risk making critical
rrors in the interpretation of data. Finally, once you have
nished your research, you must be skilled in writing it up
nd presenting your observations.
The fourth and final component in the clinical investi-
ator’s toolkit is the mentoring environment. None of this
ill work and flow easily for you unless you live and work in
n environment where there is a strong mentoring, nurtur-
ng philosophy.
rial design. If you hope to be a credible clinical investi-
ator or epidemiologic researcher, your basic core curricu-
um must include concepts of trial design. Most of what we
o in clinical trials is to compare treatment groups; often we
ount the number of patients in treatment group A versus
hose in treatment group B who experienced an event or who
eached a primary end point that allows us to compare the
roups. At times our analysis is based on time to events
sing life-table methods or the Kaplan-Meier methodology.
It takes time to develop a clinical trial; it requires thinking
hrough all the implications of a particular analysis. Those
f us involved in the Thrombolysis In Myocardial Infarction
TIMI) study group, for example, have started a major
linical trial that is scheduled to enroll 13,000 patients. This
s a trial comparing clopidogrel, the most commonly used
hienopyridine following percutaneous coronary interven-
ion, with a novel thienopyridine that may offer advantages
ver clopidogrel. It took us 1.5 years to design this clinical
rial.
When defining a question to study, it should be clinically
elevant as well as sensitive to the treatment effect you are
nvestigating. Complete ascertainment of patients who are
nrolled in the trial is very important. If you have missing
ata, you detract from your power to make an observation
bout any differences that might or might not exist between
reatments. If it is a regulatory trial, agencies such as the
ood and Drug Administration (FDA) are going to do a
orst-case-scenario analysis; if you fail to ascertain all data
nvolving patients, the FDA reviewers will assume the worst
ase scenario and conclude that all your dead patients were
n your investigational arm so that they do not end up
pproving something unsafe. Also, the information you
cquire must be resistant to biased assessment. This is why
e often use clinical events committees, for example, who
re blinded to treatment assignment to make official deter-
inations about whether events occurred. Then, based
pon their assessment, the primary end point is analyzed.
linical events committees are very important forums,
hich are pivotal to clinical trials.
Meta-analyses provide the kind of information we use
hen we are working on guidelines. Understanding how the
ata have been pooled is very helpful as a clinical investi-
ator. For example, you can conclude that there is a
reatment effect, but you never know exactly what the effect
s; you are always estimating it, and any estimate of
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October 4, 2005:5A–72Areatment effect must recognize that not every patient
ithin a given trial responds the same way, so there is
ithin-trial variability. The Oxford group has popularized
his, and it is referred to as the fixed effects model. At the
arvard School of Public Health, it was suggested that not
very trial gives you the same information, because there
ay be subtle differences in patient populations or protocol,
eading to between-trial variability, which is the random
ffects model. If the trials are homogenous, it collapses back
own to the fixed effects model.
equired reading. There are three resources that I con-
ider required reading for the clinical investigator. These
ooks explain much of what I have reviewed here. They
nclude the classic Stanton Glantz book, Primer of Biosta-
istics (6), which now includes a CD-ROM that allows you
o actually run all those statistical routines I have mentioned
ere in passing. Fundamentals of Clinical Trials is an
xcellent book by Lawrence Friedman, Curt Furberg, and
avid DeMets (7) that discusses the fundamentals of
linical trials and power calculations. Diana Petitti’s Meta-
nalysis, Decision Analysis, and Cost Effectiveness Analysis (8)
s very readable. Its subtitle is Methods for Quantitative
ynthesis in Medicine, and it explains the equations of
esearch and how to calculate data using worked examples.
You do not have to worry about buying a complete
tatistical package to actually perform some of these runs.
here are free public access domain websites, for example,
ttp://home.clara.net/sisa/index.htm, where you can do sta-
istical analysis directly on the Internet.
Also, it is important to be aware of the regulations
overning human research and particularly the attention
aid to patient safety (Fig. 4). You have to know whether or
ot you are doing research that involves treatments gov-
rned by FDA guidelines. The code of regulations and
uidance provided by the FDA to investigators and to
igure 4. Regulations governing human research. With permission from
irculation 2004;109:2672–9. FDA  Food and Drug Administration;
CP good clinical practice; HIPAAHealth Insurance Portability and
ccountability Act of 1996; IRB  Institutional Review Board; NIH 
ational Institutes of Health.ponsors of trials can be accessed at http://www.fda.gov/ npacom/morechoices/industry/guidedc.htm, and these are
lso available on public domain access websites as well. I
entioned other internet sites featuring guidelines for doing
uman research (Table 16). I recommend you review these
f you are seriously considering a trial in clinical investiga-
ion. There are excellent commentaries and guidance pro-
uced by the FDA, the National Institutes of Health
NIH), and others that will help you design a clinical trial
hat meets regulatory requirements.
Presentation skills are important, of course, and one good
ook to consider when working on your writing is Ed
uth’s Writing and Publishing in Medicine (9). He does a
errific job of outlining the structure of a scientific paper. Be
ware that all the major cardiology journals now require
lectronic submissions, and you have to know all the
pecifics of what the individual journal expects. For exam-
le, you cannot just keep writing endlessly; there are word
ount limits on papers submitted to the journals, as well as
imits on the number of figures, tables, and references. You
lso must declare your relationship with industry or any
onflicts of interest. You must be prepared to go through
ultiple drafts. Personally, I am not really comfortable with
manuscript until I have been through three to five drafts,
nd Dr. Braunwald has said that 7 to 10 may be necessary
ecause you have to keep writing until you really have it
own correctly. Of course, once you have submitted the
aper, you have to be able to respond to reviewers, a very
mportant skill.
Besides print skills, you need to consider your oral
resentation skills. Before you make your presentation, you
ust be thoroughly familiar with the topic. Always adhere
o rules for slide preparation; for example, limit the number
f lines of text on the slide. Make sure you rehearse—with
nd without slides, with and without a pointer. If you take
he time to rehearse and you consider what can go wrong,
ou probably will not panic if something does indeed go
rong during your presentation. Always start your talk by
ooking in the center of the back row. By gazing out that
ay, you engage the whole audience; then you can start
isually “walking” around the audience in quadrants, allow-
ng your eyes to move from one quadrant to another.
areer goals. Finally, I want to discuss career goals. I agree
ith Dr. Braunwald who advises that you choose your
aboratory, research group, or mentor carefully. A “big
ame” is not necessarily a great mentor. There are resources
n mentoring in cardiovascular science, including a men-
oring handbook available through the American Heart
ssociation (http://www.americanheart.org/presenter.
html?identifier3016094).
Also, according to Dr. Braunwald, accept your first
aculty position only if it will allow you to devote at least
wo-thirds of your professional effort to clinical research;
nything less is likely to stunt your growth as a clinical
nvestigator. Furthermore, align your research and clinical
ctivities. For example, cloning of gene-encoding ion chan-
els, research in clinical electrophysiology, and care of
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October 4, 2005:5A–72Aatients with arrhythmias is a good alignment of goals. If
ou clone genes encoding ion channels and then conduct
opulation research that has nothing to with that, you are
ot synthesizing your efforts into a meaningful, cohesive
irection.
The focus of your investigative efforts should be to devote
ourself to the study of a clinical problem or disease and stay
ith it. Do not become a slave to a single technique, but
aster whatever techniques are necessary to address the
roblem. I knew nothing about various biostatistical tech-
iques when I started my career in clinical investigation; I
eveloped them one by one, taking courses, reading books,
nd working my way through it.
onclusions. There are important differences in the types
f research done in cardiovascular medicine. In basic re-
earch, mechanisms are valued the most; in clinical investi-
ation, it is the outcome. For an epidemiologic investigator,
revention from a public health perspective is the most
alued part of research. The research strategy for the basic
cientist is to control all the variables so that you can actually
est the one thing you are interested in and eliminate the
umber of degrees of freedom. We cannot control all the
ariables when we are doing clinical investigation, so we
andomize one variable and enroll enough patients so that
opefully matching occurs in the groups enrolled in the
tudy. Public health epidemiological investigation matches
verything except for one variable to see if that one variable
s truly impacting on the health of the particular point of
nterest. All of this requires very few events if you are a basic
cientist; maybe all you need is 20 events, so the sample size
s a lot smaller. But for clinical trial research, we may need
,000 to 20,000 patients to get the necessary power to
ctually observe whether there is a statistically different
ignificance. From the public health perspective, if you are
n investigator you will likely need far more than 20,000
atients; more likely, you will need a study group along the
rder of magnitude found in the Framingham Heart study
o make reliable public health observations.
Please, do not get discouraged if you do not knock the
all out of the park the first time at bat. However, you
hould question whether clinical research is the best career
or you if you have nothing substantive to show two or three
ears after you have completed your research scholarship
raining. Remember that even if you do not continue as a
linical investigator, your experience in clinical research will
reatly enhance your abilities both as a teacher and a
linician. Even if it does not work out, it will be very
aluable time that you have spent.
uestion and Answer
uestion: I am an interventional fellow at Seton Hall
niversity and a foreign medical graduate. Coming here, I
ave an ambition to achieve the best I can in this country.
already am an internal medicine doctor, and I am trying
o pursue a career in cardiology. I finished my residency rnd am looking for a fellowship. This has turned out to be
ery difficult because I am a foreign graduate. I was told by
ne university that they would not even consider my
pplication. So I looked for ways to advance my career,
ound a research fellowship, and discovered that I loved it!
ow I am a U.S. citizen and am looking for a job. That too
as turned out to be difficult. I cannot navigate around to
nd how I get connected with academia. So I am still
ooking for my academic career, but it is not as easy as I
hought it would be.
r. Fuster: If you want to pursue such a career, you really
ave to focus a lot. In other words, I would not just say, “I
eed an academic job at an academic institution.” If you go
here with a specific goal, a specific project, specific focus,
ou have a much higher chance.
r. Antman: I agree. You clearly demonstrated the first
art of the toolkit, which is the fire in the belly. Without
hat, the rest of this conversation would not be taking place.
ocus is extraordinarily important. If you go in with a very
iffuse concept, it will be highly unlikely that you will have
uch success getting an academic position. Identifying a
iche where you can provide some experience, some exper-
ise, some resources that are missing in a particular academic
nvironment will be much easier. Think about what excited
ou most in the work you have done up to this point.
uestion: Realistically, for those of us who are one or two
ears out of graduation from our fellowship, it is hard to say
e have an area of focus. Also, your focus in research
hanges by your mentor and by what institution you go to,
o there is a fusion we have to go through. But let us say I
ave a focus. It is still premature, and I take my first job as
unior faculty. Then pharmaceuticals knock on my door
elling me to enroll patients in all these protocols, saying
hat could be a way to get into clinical research. Another
ay to possibly get my turn would be to say I want to
nalyze the data from different perspectives. So, you have
ot some competing ways as a junior person trying to find a
ocus. Where can you go?
r. Antman: These are very perceptive points. It is per-
ectly acceptable to take stock of where you are at a given
oment in time and say, “Have I actually got the right focus
ere, or should I be making a 30-degree change in where I
m going to be spending my energies and efforts?” I did that
yself; I had spent quite a bit of time involved in clinical
rials on antiarrhythmic therapies to suppress recurrences of
trial fibrillation. I became very convinced that I was
nterested in clinical investigation and clinical trial work, but
evolved more and more toward investigation in acute
oronary syndromes. So I redirected my original focus when
ther opportunities became available, and I realized that this
xcited me even more.
I do want to caution you about the barrage of pharma-
eutical and device manufacturer trials. That is because we
ive and work in an environment where there is conflict of
nterest with those sponsors in terms of their product with
espect to clinical investigation. If, however, what you are
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October 4, 2005:5A–72Aalking about is getting involved in a clinical investigation
hat may be industry-sponsored, that is perfectly fine as long
s it is through an environment where you have the
cademic links. I am specifically cautioning against just
igning on to be an investigator for a clinical trial that is
ndustry-sponsored for which there is straight reimburse-
ent for recruiting patients, but there really is no return in
erms of your career development for that effort.
II. CAREERS IN OUTCOMES RESEARCH
arlan M. Krumholz, MD, SM, FACC (Departments of
Medicine [Section of Cardiovascular Medicine, and the
Robert Wood Johnson Clinical Scholars Program], and
Epidemiology and Public Health, Yale University School
of Medicine, and the Yale-New Haven Hospital Center
for Outcomes Research and Evaluation, New Haven,
Connecticut)
utcomes research is the study of the end results of health
are. All studies have outcomes, but what distinguishes this
eld of research is that it aims to describe and improve the
nal result of clinical decision-making and health care
elivery, with particular emphasis on the patient’s perspec-
ive. Outcomes research focuses on what is ultimately
chieved by our efforts in health care. This applied research
eeks to align the needs of patients with the performance of
linicians and the health care system to produce optimal
utcomes with the available resources.
Interest in outcomes research is growing, as practitioners
nd policymakers increasingly appreciate the importance of
igorously examining how health care is delivered in order to
chieve the best results. We are in the midst of a rapid
xpansion in diagnostic and therapeutic options for our
atients. At the same time, health care costs continue to
ise, placing great stress on those who are paying for care
nd affecting the national economy. We need research that
efines the best patient-centered, clinical strategies and
rovides insight about how to move established knowledge
nto routine clinical practice.
Outcomes research is not based on a particular method-
logy, but rather is defined by the type of questions it
ddresses. The questions focus on measuring and improving
he effectiveness, efficiency, equity, safety, timeliness, and
atient-centeredness of health care. As such, the methods
re often at the interface of social sciences and medical
cience, drawing on the methods of clinical epidemiology,
iostatistics, health policy, economics, sociology, psychol-
gy, business, and anthropology. The perspective spans
ecision-making at the individual level through policy at the
opulation level. The findings have implications for indi-
idual choices about clinical strategies and for broad-
anging health policy. The research has many facets, but is
lso always oriented toward improving practice and policy.
Outcomes research is the ultimate translational research.
esearchers have demonstrated that scientific break-
hroughs in the laboratory or even in clinical trials do not hecessarily have a favorable impact on population health.
he dissemination of the information, the adoption into
ractice, the effect in real-world populations, the application
y real-world clinicians, and the acceptance by typical
atients may be variable and lead to results that are different
rom what was anticipated by the initial reports.
The basic science of outcomes research addresses the
eed for improved methods of collecting and analyzing data
bout clinical practice, patient health status, and population
ealth. This basic science also needs to provide new orga-
izational interventions that can promote a more effective
nd efficient approach to health care delivery. In this
ontext, the advent of electronic health records in particular
s an opportunity and challenge as it heralds an era of
nprecedented accessibility to detailed information about
atients and providers.
The field tends to attract individuals who embrace the
hallenge of producing knowledge and insights that can be
ranslated into action to benefit patients and populations.
he end product is not only a publication, but fundamental
mprovements in care and health care delivery. Outcomes
esearchers contribute to the development of decision-
aking and practice that is firmly embedded in science.
riority areas. The National Heart, Lung, and Blood
nstitute Working Group on Outcomes Research in Car-
iovascular Disease identified a set of top priority areas for
he field (10). This list was not intended to be all-inclusive,
ut rather to highlight where there is a great need for
nvestment. The top-tier priorities included:
Development of surveillance systems for cardiovascular care
and outcomes, referring to the need for continued moni-
toring of the national patterns of care and outcomes.
Promotion of “patient-centered” care, highlighting the need
for studies that would identify the determinants of
patient-centered outcomes in people with cardiovascular
disease, evaluate interventions designed to enhance
health status and quality of life, and incorporate health
status into all appropriate clinical trials.
Development and translation of “best practices” in clinical
practice, which addresses the need to determine and
enhance how well clinical strategies perform in the real
world.
The Working Group also identified the following areas
hat are important to the field: 1) promotion of the use of
xisting data; 2) facilitation of collaborations with other
ederal agencies; 3) investment in the basic science of
utcomes research, with an emphasis on methodological
dvances; 4) strengthening of appropriate National Insti-
utes of Health funding agency study sections with individ-
als who have expertise in outcomes research; and 5)
xpansion of opportunities to train new outcomes research
nvestigators.
raining. To have the opportunity to make consistent,
igh-level contributions that can positively influence health
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October 4, 2005:5A–72Aare requires a commitment to gain the necessary skills.
here is no single path to attain these skills and true
ompetency will require lifelong dedication to learning, but
he effort must be made in a serious and sustained manner.
ome people will find the best approach through degree
rograms while others will find different opportunities.
hat is important is an eagerness to learn and a willingness
o commit the necessary time and energy.
The basic content of training for a career in outcomes
esearch includes: 1) biostatistics; 2) clinical epidemiology
nd health service research methods; and 3) principles of
ealth policy and management. In addition, knowledge of
nformatics and economics is becoming increasingly impor-
ant. Trainees may specialize in specific areas but basic
ompetency in all of the areas is necessary.
Another important skill that does not appear in any
ormal curriculum is how to ask good questions. Instructors
eed to foster curiosity in their students and nurture their
bility to ask important questions. Students should be
ncouraged to question conventional wisdom and not
eadily accept dogmatic statements without understanding
he basis for the knowledge. They need to take advantage of
heir clinical experience in conceptualizing questions that
ill have meaning for patients.
There is no single best time to start acquiring these skills.
or some people the opportunities to commit time to this
ndeavor occur in medical school, while others will recog-
ize their interest later and pursue it as part of a fellowship
r even afterwards. The amount of time that it will take to
stablish a firm foundation of knowledge in research meth-
ds will vary by individual and may be influenced by
ersonal circumstances. What is clear is that the foundation
s a critical component to long-term success.
Perhaps the most important component of training is
entoring. Mentors are needed throughout a person’s
areer, but the best training programs will encourage stu-
ents to develop a network of mentors who can provide
uidance about learning strategies, project selection, and
areer guidance. Programs should encourage the develop-
ent of local and distant mentors. Having mentors outside
he trainee’s institution can be very valuable, and certainly
o one mentor can accomodate all of one person’s needs.
he presence of a mentor network allows for broad coverage
or the support that is essential to a new investigator.
areers. Careers in outcomes research range from research
o application and service. Within academic institutions,
ndividuals with this expertise can lead efforts to generate
nowledge that can evaluate and guide current practice and
olicy. In addition to research, these individuals often are
lso involved in local, state, and/or national initiatives to
mprove health care. The distribution of time may vary, as
ome individuals may devote relatively more time to service
nd others more to research. Funding for research is
vailable from many sources, including the National Insti-
utes of Health, the Agency for Healthcare Research and
uality, the Centers for Disease Control and Prevention, rhe American Heart Association, industry, and various
oundations.
This training is also ideal for other venues. People with an
nterest in service may eventually be strong candidates for
eadership positions in academic departments, hospitals, and
ealth care systems. Outcomes researchers also are well
ositioned to contribute to positions in health policy,
ncluding those with local, state, and federal agencies.
ndustry and consulting agencies have a great need for
eople who think critically about health care delivery and
an interpret and understand the clinical research literature.
oundations and other philanthropic institutions can ben-
fit from people with clinical experience and skills in
enerating knowledge about practice patterns and popula-
ion health.
onclusions. Societal forces are raising the awareness of
he importance of elevating clinical practice and health care
olicy. Outcomes research holds abundant opportunities to
valuate, guide, and improve practice and prepare investi-
ators who are capable of leading positive change. Medicine
as remarkable opportunities and challenges in the years
head. Ultimately its success will be measured in lives that
re bettered, an accomplishment that will require a keen
ocus on improving what we do and ensuring that each
atient has access to the very best care. Outcomes research
s well positioned to contribute directly to that goal.
III. CAREERS IN IMAGING RESEARCH
obert S. Balaban, PHD (Laboratory of Cardiac
Energetics, National Heart, Lung, and Blood Institute,
National Institutes of Health, Bethesda, Maryland)
maging is a remarkably broad field today, ranging from the
tudy of a single molecule, to a cell, to whole tissues—all the
ay up the scale to the intact human where clinical studies
re conducted. In our quest of understanding the interpre-
ation and control of genetic information to generate a given
henotype, imaging provides key information in space and
ime of many of the key elements of this process. One of the
ost important advances of the past five years is the ability
o extract information at the cellular level within intact
issues or subjects. These advances in molecular imaging are
etting very close to melding structural biology, cell biology,
nd physiology to greatly improve our understanding of
asic physiological processes, as well as genetic regulation of
hese processes.
evelopmental biology. If you follow developmental bi-
logy, for example, trying to understand how a blood vessel
s created or destroyed, you quickly realize that the interac-
ions of cells in space and time are critically important in
his and most differentiation processes. So, in order to
ransfer a stem cell into the heart and get it to replace a
amaged region of the heart through regenerative processes
equires a better understanding of how these cell-cell
nteractions occur. Obviously, imaging is going to play a key
ole in the understanding of this process.
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October 4, 2005:5A–72AMapping the human genome has been very important in
eginning to understand these developmental processes, but
he genome itself isn’t the end of the discovery process. This
asic network of genetic expression control is what we are
oing to be working on for the next several decades in
iology and medicine. What are the rules guiding develop-
ent? What controls the distribution of blood cells, or
ssociated nerves?
One great example is a high resolution X-ray computed
omography (CT) scan of the vasculature geometry of
enetically identical mice. The question to ask is when do
hese vasculatures deviate from fixed rules of the genome
nd are identical to when more “random” distributions of
essels are found obeying more general rules outlined by the
enome. In many studies it is becoming clear that only the
ery initial stages of the vasculature are “hard wired” while
he rest relies on more general rules. These general rules
ould be to obtain a mean oxygen tension in the tissue, or
emove a particular metabolite where there are almost an
nfinite number of solutions to satisfy these rules with how
he vessels are placed in the tissue. This leads to what
ppears to be almost random distribution of vessels since we
o not yet understand the general rules applied. Imaging
ill help us learn what those rules might be and tells us
here the more specific genome pattern rules are replaced
y more general rules where physiology, environment, and
iming start playing a more important role in the process.
his type of study, deciding when the genome’s influence
nds and when the general rules apply and become domi-
ant, is one of the areas where the role of imaging is going
o be very prominent.
Imaging is also one of the major readouts in any genomic
creen (11). One program is conducting a genomic screen of
he mouse, looking for early embryological deficits in
tructure and function of the heart using a mutagenesis
pproach. These studies have discovered genetic models for
ost of the early cardiovascular and in utero diseases in
an, and now we’re starting to map out which genes may be
esponsible for those particular events (12).
Stem cells are a hot topic today, and imaging will play a
ey role in understanding how to place stem cells in the
yocardium using an interventional approach. We are using
agnetic resonance imaging (MRI) to guide the injection of
tem cells into the region of interest within the myocardium
13). Later on we will be able to see labeled stem cells and
ollow them for weeks to understand how they are differ-
ntiating and see that they eventually do contribute to the
ontractile process. Imaging will play a key role in tracking
hese cells, monitoring differentiation, and helping us un-
erstand what is going on in the myocardium as we try to
ontrol cellular differentiation.
mage-guided therapy. We are moving beyond using im-
ging to deliver therapy. Interventionalists have been using
-ray–based imaging methods to guide the therapy for
any years. However, this approach has been generallyimited to a view of the vascular space due to the dependence gn contrast agents. Thus, the types of procedures that can be
ttempted are limited by what you can see and potentially
ven the radiation dose required. With modern imaging
ools like real-time MRI to guide procedures, we can now
ot only get a better view of the tissues that are being
orked on but also get immediate feedback on the function
nd viability of the tissue under repair without any radiation
ose. This type of dynamic soft tissue imaging, together
ith appropriately modified robotics, will allow us to tackle
roblems we never thought we could in the past.
maging: what is the right modality and right spatial
cale? A clinical or basic science investigation requires a
ound and important biological question to be addressed.
o answer this question you must choose the modality that
an, or that you foresee will, provide you the appropriate
nformation in the right spatial scale to resolve the key
ssues. The most successful long-term research programs are
riven by the biological or clinical question, not a particular
echnology or imaging modality. This permits one to adapt
r adopt technology as you move forward on your problem
ather than search for applications to point a given technol-
gy at.
One example of the importance of scale and technology is
he study of regional blood flow in the heart. The MRI
echniques are now permitting physicians to see small
ubendocardial perfusion defects in the heart and the
uestion arising is: “how small of a perfusion defect is
ignificant?” Our previous experience in determining the
ormal distribution of flow in the heart was obtained by
hopping it up into little blocks and counting the density of
icrospheres we had previously injected into the vascula-
ure. These data suggested a wide variation in blood flow of
lmost two- and sometimes three-fold under a variety of
onditions suggesting that flow heterogeneity was normal
nd not indicative of any vascular pathology. However, we
nd others noticed early on with high-resolution MR
erfusion images that have much higher spatial resolution
han the tissue-blocking approach that we observed very
ittle flow heterogeneity in control patients and animal
odels. This observation was followed by a systematic
maging study of microsphere distribution within the heart
t several different spatial scales that revealed the micro-
pheres were not very reliable beyond a cm3 or so of heart
issue (14).
Another very important development has been the use of
ulti-photon excitation schemes to observe subcellular
vents in vivo (15,16). This form of microscopy allows us to
o deep into tissues while maintaining the resolution we
eed to examine a single cell with a microscope; this gives us
1- to 2-m spatial resolution deep (300 m) in the
ntact animal. Functional imaging with subcellular resolu-
ion using this type of approach is going to become an
ncredible basic science tool. If you have to get down to the
ellular origins of a physiological event, this technology is
oing to play a major role. For example, the myosin head
roup angle, sarcomere length, and overall fiber orientation
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October 4, 2005:5A–72Af muscle cells in vivo can be determined using this
pproach. In vascular biology, endothelial cells can be
bserved in vivo along with physiological information in-
luding their intracellular Ca2 levels, membrane potential,
eceptor-binding or protein expression, and a great deal
ore. This can be directly coupled to measures of the
iameter and flow within the vessel containing the
ndothelial cell attempting to evaluate the functional
mportance of intracellular events on a given vascular
rocess in vivo. This remarkable imaging approach truly
rings cell biology, molecular biology, and physiology
ogether, making it a huge area of research for the next
everal decades as we start putting the cells and tissues
ack together into functional and clinically relevant
tructures.
X. CAREERS IN ELECTROPHYSIOLOGY RESEARCH
ric N. Prystowsky, MD, FACC (Clinical
Electrophysiology Lab, The Care Group, LLC,
Indianapolis, Indiana)
n electrophysiology, there are three broad areas to consider
n terms of choosing a research career: clinical electrophys-
ology, clinical trials, and basic research. Whatever area you
elect, there are general principles for a successful research
areer. First, select an area that excites you and is consistent
ith your skills. Do not select an area of research because
our mentor likes it or because someone tells you it is what
ou should do. The fact is that if you do not like an area of
esearch, you will eventually get bored, lose productivity,
top writing papers, and go into something else. Likewise, if
ou are not good at what you do, even if you like it, you are
oing to get very frustrated and quit.
Initially, it is important to stay focused. If you publish five
r six papers in an area, people get to know you and accept
ou as an expert in a specific area. Once you have that kind
f reputation, then you can branch out into other areas.
owever, I disagree with the concept that you should do
esearch in six different areas. Pick something you are good
t, something you like, stay focused, and write your papers.
It also is important to ask relevant questions about
elevant problems that can be answered in your lifetime.
eople who say, “I am going to change the world,” are very
rustrated because the odds are that they are not going to
hange the world. Focus yourself on what is useful, impor-
ant, and doable; then you will not get frustrated.
If you want to be a researcher in private practice, you need
skills set. I did not just start in private practice doing
esearch; I had a very detailed nine-year university career
efore I ever transitioned into practice. If you are really
erious about research and it is something that is important
o you, you clearly have to start in an academic environment.
You must set your research priorities. If you want a 50-50
plit between research and clinical practice, that is a good
odel. It is also a very popular model. Although universities
un the clinical trials, the greatest number of patients is ssually enrolled from private practices. Typically, private
ractices have a huge volume of patients and at least one
erson who enjoys doing research, going to medical meet-
ngs, and developing a reputation as a successful private
ractice researcher.
Finally, if you do not want to split your time evenly
etween research and clinical practice, it is perfectly accept-
ble to set research as a minor priority. With whatever level
f research you choose as your priority, remember the skill
ets you need. In my opinion these are in descending order
f importance. As clinical researcher, you will need to learn
anuscript development, abstract development, lecture
kills, and grant writing. As a basic researcher, you will need
kills in grant writing, manuscript writing, abstract devel-
pment, and lecture skills. Lecture skills are important
ecause commonly an investigator who has written a couple
f influential papers gets invited to your institution, and
nly then do you realize he or she cannot put six sentences
ogether. As a clinical researcher, your job is to go out and
et people know what you are doing.
Why did I put grant writing so low on the list of clinical
esearch skills? Considering the current climate, grant writ-
ng for clinical researchers is not high on the skills set list
ecause it is unlikely you are going to have a lot of success
btaining grants. From talking to my colleagues, it is the
pposite situation in basic research. Grant writing is prob-
bly at the top of the needed skills set for a basic researcher.
ndeed, if you cannot get grants, you are probably not going
o do basic research. In addition, manuscript writing and
ecture skills are important for basic researchers.
areers in electrophysiology research. If you are looking
o participate in clinical electrophysiology research, there are
any areas you might want to consider and many questions
ou should ask.
ATHETER ABLATION. In January 2004 I became the
ditor-in-chief of the Journal of Cardiovascular Electrophys-
ology. We ask all of our reviewers to consider three
uestions. The key question is not “Is it true?” but rather,
Does it matter?” It is particularly important to consider
who cares” when considering catheter ablation research.
e do not have a good handle on just where ablation fits
nto a number of medical conditions; thus everyone is going
o be interested in research. However, the project has to be
n an area where we are going to care about and value the
esearch.
What are the hot topics in ablation research? There is the
eed to integrate new energy sources and three-dimensional
apping systems into clinical practice. We need more data
n computed tomography and how it relates to electrical
apping. Finally, another area in need of further research is
ew catheter delivery systems.
ISK STRATIFICATION FOR SUDDEN DEATH. This is an area
n clinical electrophysiology research that needs more atten-
ion. Which test offers high predictability? Most noninva-
ive tests we have suggest who does not need a defibrillator.
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October 4, 2005:5A–72Ahe question is who does need a defibrillator? The problem
s all the false positives that current tests are prone to. This
s a major problem, and there needs to be research that will
elp us hone in on the patients who are most likely to
enefit from an implantable defibrillator.
Another important research question is which patients
ith genetic syndromes require treatment? Which patients
ith long-QT syndrome, Brugada syndrome, or hypertro-
hic cardiomyopathy need to be treated? The list of genetic
yndromes is long, and the question of which patients
equire treatment is a hot area of research.
UTONOMIC NERVOUS SYSTEM. Although there is signifi-
ant autonomic input to arrhythmias, this is an area that is
een sorely neglected by most electrophysiologists.
One of the biggest problems in cardiac electrophysiology
elates questions of why certain problems occur. For example:
) What causes inappropriate sinus tachycardia? It is a fairly
common but vexing problem. Patients cannot stand it.
It occurs in young people. It remains a terribly frustrat-
ing problem because nobody has a good handle on it.
) Why are there diurnal variations in the onset of
arrhythmias?
) Why does someone have atrial fibrillation one day but
none for the rest of the year when the patient has the
same substrate and same potential triggers every day?
) Why is it that someone born with long-QT syndrome and
a potassium channel ionic defect lives a completely normal
life for 18.5 years and then suddenly goes into cardiac
arrest? What happened that day? Why did it occur?
) Why do people develop neurally-mediated syncope, and
how do we treat it?
ome of the questions are very simple, but the answers
ave evaded us. Unless you are an electrophysiologist, you
ay not even know this, but patients often tell us that
ending over initiates an arrhythmia. Interestingly, in my
xperience, this occurs mostly in atrioventricular (AV)
ode re-entrant tachycardia or AV re-entry associated
ith Wolff-Parkinson-White syndrome. What is it about
hose arrhythmias that make people susceptible when all
hey do is bend over? We have no idea, although there are
robably clues here that would help us understand why
rrhythmias occur. The problem is that nobody has tried to
nvestigate these topics.
MPLANTABLE DEVICES. Everybody is excited about cardiac
esynchronization therapy (CRT) for heart failure. How-
ver, there are a number of important questions to be
nswered regarding the utility of CRT.
) Which patients derive the most benefit from CRT
devices?
) How do you optimally pace these patients?
) What is the optimal pacing site or sites with CRT?
) What is the optimal pacing mode with CRT?f you like device research, I would focus on CRT becausee are just starting to explore this area and because it is
oing to consume investigators for several years.
TRIAL FIBRILLATION. There is an endless list of questions
n the area of atrial fibrillation (AF).
) Why does AF occur?
) What is the link between increased vagal tone and AF
onset?
) Which patients with heart disease are suitable for
catheter ablation?
) What is the optimal catheter ablation method to cure AF?
) Which patients do better with rhythm control?
here are countless questions that need to be answered with
F, and I suggest you go after them.
ENTRICULAR TACHYCARDIA. Ventricular tachycardia
VT) is not quite as popular a research topic today because
T is easily treatable. You put a defibrillator in and that
olves much of that problem, but there are many questions
egarding VT that are still unanswered and are means for
lenty of research opportunities.
) What is the mechanism of VT in structurally normal
hearts?
) What is the triggering mechanism for VT in stable
ischemic scars?
) What is the triggering mechanism for sustained VT in
ischemic cardiomyopathy?
) What is the best method to cure unstable VT using
catheter ablation?
here is a lot of interest in using catheter ablation to treat
he particular VT-causing substrate. This topic is just
tarting to be investigated and could be a really burgeoning
rea for research.
etting research experience. If you are in clinical practice,
ou can get involved in research through nonindustry-
ponsored multicenter randomized trials. Even if you do not
ave a lot of research experience, you can become involved
ith clinical trials because many studies need to enroll a
arge number of patients. In addition to enrolling patients
or a specific trial, you can become involved in writing the
aper from the study.
Industry-sponsored clinical trials are other opportunities
o gain research experience. Often the questions generated
or these trials are usually straightforward and focused.
Industry-sponsored clinical trials can be enjoyable. You
re offering your patients new therapies in which you are
mong the first to discover new information and potential
enefits from the studied therapy. Additionally, industry-
ponsored trials provide an opportunity to network with
xperts in your particular field of interest.
The field of molecular biology is where the most innovative
nd impactful research is being performed today and will be for
he foreseeable future. It is critically important to gain a better
nderstanding of how certain arrhythmias start.
Because I am not a basic researcher, I would not be the
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October 4, 2005:5A–72Aerson to give you advice on what areas of basic research you
hould be considering. However, if you want to do basic
esearch, the best advice I can give you is to find a mentor
ou trust who does basic research in the area you want to
ecome involved in. Sit down with your mentor and ask for
dvice regarding which areas of research have the greatest
erit for future research.
Never allow your own lack of understanding regarding a
pecific technique to hurt your research. Instead, bring in an
xpert who could help you find the missing pieces to the
uzzle. Do not think you have to do it all by yourself.
ollaboration is often key to answering the most important
uestions.
. CAREERS IN TRANSLATIONAL
NVASIVE RESEARCH: CONFUCIUS,
RACTALS, AND RELATIVITY
ames J. Ferguson, MD, FACC (St. Luke’s Episcopal
Hospital, Texas Heart Institute, Baylor College of
Medicine, and the University of Texas Health Science
Center at Houston, Houston, Texas)
“The essence of knowledge is: having it—to apply it; not having it
—to confess your ignorance.”
Confucius
“The hardest thing of all is to find a black cat in a dark room,
especially if there’s no cat.”
Confucius
hat is translational invasive research? The traditional
esponse has been that “translational research” involves
aking new understanding from the basic science laboratory
nd bringing it forward into the world of clinical practice,
he proverbial “bench-to-bedside” process. In reality, trans-
ational research can involve taking problems that arise at
he bedside, bringing them to the bench to tease out some
ew mechanistic understanding, and then coming back to
he bedside to apply this knowledge to the original clinical
roblem.
The logical inference is that to perform meaningful
ranslational research, you have to truly understand the
igure 5. Overlapping disciplines. Translational invasive research involves
ot just cardiology but also overlapping disciplines and cross-talk between
isciplines that may impact clinical applications.otential clinical utility of your subject matter. That means
a
tn intimate acquaintance with real-world clinical care. This
s not bench research for bench research sake—this is bench
esearch that has tangible ties to the bedside. True transla-
ional research requires the application of some aspect of
ench research, some new mechanistic understanding, for
xample, that can be applied clinically. While you may not
ave to be the world’s foremost bench researcher, you do
ave to understand the underlying physiology and how it
ay relate to and overlap with underlying clinical
pplications.
reas of overlap. There are many scientific areas that may
ave specific invasive applications (Fig. 5). Translational
nvasive research involves reaching out and overlapping with
variety of disciplines.
This requires forging new conceptual linkages that par-
llel the complexities of the overlapping biological processes
nd pathways. My own career is a case in point. I did not
tart out my academic career in the field of coagulation; I
tarted out researching complex hemodynamics. However,
fter coming to the Texas Heart Institute and seeing the
pplication and relevance of coagulation to interventional
ardiology, I asked some very simple questions relating to
he coagulation status of patients coming in for coronary
ntervention. Simple, mundane questions like, “How should
e be utilizing a bedside marker like the activated clotting
ime to guide coronary intervention?” From this simple
pplication of a bedside coagulation monitoring device,
hole new areas of application and understanding began to
pen up, and the world of coagulation became linked to the
orld of platelets and inflammation, endothelial function
nd homeostasis, and lipids and atherosclerosis (Fig. 6).
It is like a vast intellectual fractal network: the closer you
ook, the more detail (and interactions) you begin to see.
nd as we consider something as seemingly mundane as
ntithrombotic therapy, we discover that it has the potential
o interact with numerous biologic processes, and vice versa.
omething simple—coagulation in the cath lab—now pro-
igure 6. Translational invasive research relies on overlapping disciplines
nd the forging of new linkages. In this case, various influences affect and
re affected by coagulation; therapies that affect one of these factors (such
s antithrombotic therapy) may have consequences that extend beyond
heir primary actions.
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October 4, 2005:5A–72Aides us an entry into the whole complex world of vascular
iology.
A recent series of articles in Circulation (17,18) summa-
ize the complexities of coagulation, inflammation, endo-
helial function, atherosclerosis, and vascular biology. This
s exactly the kind of overlapping fractal complexity inves-
igators have to have their intellectual arms around as they
nter into translational invasive research. No, it does not
ave to be just inflammation or lipids or platelets or
oagulation. Rather, it helps to begin to have a grasp of how
hey all fit together, recognizing that while there may be no
bsolute unifying theories, there are a number of intriguing
lternative hypotheses.
The world of peripheral interventions continues to grow.
he atherosclerotic solar system does not just revolve
round the coronary circulation, there is the entire vascular
ree, not just on the arterial side, but the venous side as well,
n area long neglected by vascular biologists. Some very
xciting work is being done with bone marrow stem cells
nd autologous stem cell injections, both for acute myocar-
ial infarction and for heart failure. Valve repair and even
alve replacement are being undertaken percutaneously. A
ariety of novel therapies to reduce the injury associated
ith myocardial infarction are now in clinical application.
nd while cooling and distal protection did not work all
hat well, this work has provided very exciting new insights
nto the biology of the vessel wall that will set the stage for
number of potentially fruitful future studies. New diag-
ostic technologies are emerging, expanding on intravascu-
ar ultrasound (IVUS) and optical coherence tomography,
ncluding new image processing algorithms, “virtual histol-
gy” IVUS techniques. And last but not least, exciting new
nterventional applications such as left atrial appendage
losure devices are finding wider acceptance. Each one of
hese “hot” topics involves some sort of invasive translational
esearch, taking new advances into the catheterization
aboratory.
Next year, the list will no doubt change. When consid-
ring an academic career in translational invasive research,
aybe today’s “hot” areas do not really matter all that much,
ecause the field is moving forward so rapidly. But I would
ubmit that you still have to look at the here-and-now to
gure out where the there-and-tomorrow is going to be.
Advances will be made, and these advances will lead to
dditional questions, particularly through translational re-
able 17. Do’s and Don’ts for Clinical Investigators
Do Don’t
eep reading; keep learning Assume anything
each—expand your horizons Lose credibility
ind a mentor Be afraid to be wrong
ork collaboratively Get lost in the politics
rite down new ideas Get lost in the cath lab
et good clinical training Get too narrowly focused
ollow through Just depend on the NIHearch, which is not just providing the answer to a question,ut rather it is the process of answering the question that
aises more questions which, in turn, raise still more
uestions. The clinician-scientist is integral to this process
ecause we must take bits of information and integrate them
ogether, to hang them on an underlying conceptual phys-
ologic framework. It is not just collecting the facts—it is
ranslational research that is putting them together.
o’s and don’ts. There are practical “do’s” and “don’ts” for
he budding investigator (Table 17). These recommenda-
ions consider what we should be doing or not doing if we
re going to be successful. From my own about-as-far-from-
mniscient-as-you-can-get perspective, the things young
nvestigators should be doing would be as follows: first,
eep reading, keep learning. If you stagnate, if you ossify
ntellectually, you will be a dinosaur in about two years.
ake the time to teach, and not just always the same old
hings. Extend yourself; learn and teach about new
hysiologic pathways and mechanisms. You will never
earn anything quite as well as when you have to stand up
nd lecture about it.
Find a mentor and work collaboratively. Productive
esearch depends on teamwork. Write down new ideas—
ne thing that I have done over the years is to keep a folder
f ideas that pop up from time to time (some good, some
ad, but all new), and then review them from time to time
o see if they are any better or worse or any more or less
elevant. As I mentioned before, if you want to do mean-
ngful translational research that carries to the bedside, you
ave to have a solid foundation of clinical training, so get
he good clinical skills you need. Finally, to be successful,
ollow through; carry your projects (and papers and grants)
ll the way through to completion.
Now, the don’ts: what should you not be doing? First, do
ot assume anything—things are not true just because
verybody says they are true. Do not lose your credibility—it
s probably the single most important academic asset you
ave. Do not say things because people expect you to say
hem—say things because you believe them. Your audience
an tell the difference. Do not be afraid to be wrong. I have
able 18. Key Skills for Clinical Investigators
Interventional skills ()
Clinical skills
Academic skills
Reading (cross-discipline literature)
Riting (manuscripts, grants, presentations)
Rithmetic (statistics, trial design)
Intellectual skills
Curiosity
Synthesis
Discipline
Integration
Interpersonal skills
Collaboration/individuality
Leadership
Patience
Sensitivity
Integrity
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October 4, 2005:5A–72Aeen wrong many more times than I have been right, and I
lways learn more from being wrong and recognizing it than
rom being right. It is good to remember that while Babe
uth once held baseball’s home run record, he also holds the
ajor league record for strikeouts.
Do not get lost in the politics of your day-to-day work.
lso, do not get lost in the cath lab just doing lots of
rocedures, while that may be rewarding and fun, transla-
ional research looks beyond what you are doing at the
oment to think more broadly about what you are doing.
rom a translational standpoint, there is a risk in getting too
arrowly focused because one also may have to reach out to
ther scientific perspectives as well. Paradigms change and
athways expand, converge, and diverge—you need to be
ore than a “one-trick pony.” And, ultimately, do not just
epend on the National Institutes of Health or the Amer-
can Heart Association or the American College of Cardi-
logy for funding; there are other funding opportunities,
ncluding industry, that need to be considered.
arketable skills. What about the skills that you need as
clinical researcher? Obviously, for invasive translational
esearch, great interventional skills are a plus, but they are
ot a sine qua non. You do not have to be a superb
nterventionalist, but you do have to have clinical skills and
solid clinical perspective (Table 18).
Required academic skills include the three R’s of academ-
cs. However, in our case reading, ’riting, and ’rithmetic
ecome the reading of cross-discipline literature; the writing
f manuscripts, grants, and presentations; plus the arith-
etic of statistics and clinical trial design. Other skills
equired in this field are a number of intellectual skills:
uriosity, synthesis, discipline, and integration. Importantly,
o not forget the oft-neglected interpersonal skills, includ-
ng your ability to collaborate, your work ethic, your
eadership skills, your ability to teach and be a mentor
ourself, and, most importantly, your integrity.
onclusions. As we look at the evolution of interventional
herapy—from the old days of balloon angioplasty, to
irectional atherectomy, to lasers, to rotational atherectomy,
o stents, to distal protection, to drug-eluting stents—we
egin to appreciate the bigger-picture perspective. With
ime, our adjunctive therapies have come to include glyco-
rotein IIb/IIIa antagonists, the thienopyridines, low-
olecular-weight heparins, and direct thrombin inhibitors.
s we look at our ever-evolving “standard” of care, we have
ome to recognize that there is always room for improve-
ent; we do not have all the answers, and there is always
ore to learn.
As clinician investigators we hopefully will continue to
sk those questions. From a scientific perspective, we only
ee half of the picture; the other half of the picture is the
linical application. The essence of translational research is
o put the two of them together to form a whole, and to
ppreciate that even the whole picture is not the final word,
ut is really just a complex fractal array that can be put
ogether—and taken apart—in a number of different ways. rI. PANEL DISCUSSION: MOVING
EYOND THE CLINICAL EXPERIENCE—
PECIALIZED RESEARCH OPPORTUNITIES: PART 1
habet O. Al-Sheikh, MD, FACC (Cardilogy Consultants,
PA, Pensacola, Florida)
obert S. Balaban, PHD (Laboratory of Cardiac
Energetics, National Heart, Lung, and Blood Institute,
National Institutes of Health, Bethesda, Maryland)
. Willaim Balke, MD (Division of Cardiology,
University of Maryland School of Medicine, Balitimore,
Maryland)
obert O. Bonow, MD, FACC (Northwestern University
Feinberg School of Medicine, Division of Cardiology,
Northwestern Memorial Hospital, Chicago, Illinois)
ames J. Ferguson, MD, FACC (St. Luke’s Episcopal
Hospital, Texas Heart Institute, Baylor College of
Medicine, and the University of Texas Health Science
Center at Houston, Houston, Texas)
alentin Fuster, MD, PHD, FACC (Zena and Michael A
Wiener Cardiovascular Institute and the Marie-Josée
and Henry R. Kravis Center for Cardiovascular
Health, Mount Sinai Medical Center, New York,
New York)
ric N. Prystowsky, MD, FACC (Clinical
Electrophysiology Lab, The Care Group, LLC,
Indianapolis, Indiana)
r. Bonow: Bill, what is your take on whether we should be
ecommending that fellows participate in multicenter clin-
cal trials for their research experience?
r. Balke: That question comes up every year, and there is
o absolute right or wrong answer. The positives for
orking on a clinical trial while a fellow relate to the
xposure and experience of getting involved in the wave of
he future—and that is team research. The disadvantages
ostly relate to the fact that you are not going to get
dentified with the project to the same extent if it was your
wn single-center study at your own institution. The short
nswer is: the most important thing is to learn research
kills. If you have the opportunity to get involved in a really
nteresting multicenter trial, where you are going to be
ontributing at an intellectual and substantive level, then
hat is reasonable.
r. Bonow: Terry, do you want to add to that?
r. Ferguson: You should look at doing research as the
pportunity to acquire a skill set. Of course, you do not
ecessarily need a skill set of taking histories, doing physi-
als, and filling out case report forms. But you do need an
ntellectual skill set and an opportunity to pose questions,
ormulate hypotheses, write abstracts, prepare manuscripts,
nd present findings. So, I view it as an opportunity to get
our feet wet. We all know that there is no shortage of
nstitutions out there that use fellows as a cheap source of
abor to generate case report forms. That is not a particularly
ewarding activity; however, if there is a legitimate chance to
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October 4, 2005:5A–72Aarticipate in clinical trials and do more of this intellectual
ork, then participating in a multicenter clinical trial
rovides real opportunities. It also gives you a chance to
egin to network with the players, to “sit at the table” and
egin to get involved with this process of making yourself
nown and developing your skill set.
r. Bonow: Your take-home message seems to be to
xplore ahead-of-time exactly what your role is going to be
nd be sure that you are going to be gaining from the
xperience either a skill set or a networking opportunity or
oth, not just the opportunity to do grunt work. Eric, did
ou want to add to that?
r. Prystowsky: I take a slightly contrary view. If you want
o be a clinical trialist: fine . . . but not if you are trying to
evelop a research career. As I said in my talk, you are far
etter-off finding something you like to do, defining the
rea, and doing projects; otherwise, you will not get known.
n the other hand, investigators have come out of Duke
hat you all know because they did research in an area. If you
re not sure what you want to do, and there is a way to get
our feet wet working on a multicenter trial, fine. But, if you
ore-or-less know your field and it is not clinical trials, my
dvice would be stick to your field and do not get roped into
hat. You are not going to be a player in those trials, quite
onestly, unless you grow up in the field.
uestion: Do you think there is enough advocacy within
he cardiology community for international medical gradu-
tes (IMGs) who are here on visas and who all have to leave
he U.S.?
r. Al-Sheikh: No, I do not think there is enough
dvocacy. We have to realize the importance of IMGs, who
eceive their medical degrees outside the U.S. or Canada
nd come to North America for advanced training. We need
o do more. The primary obstacle—and I think you all agree
ith me—is the immigration law. We need the IMGs. In a
ew York survey, if you look at the percentage of IMGs
ho want to go back to their country of origin, they found
obody wanted to go back.
Unfortunately, since September 11, 2001, IMGs hoping
o continue their careers in the U.S. have faced more
estrictive immigration policies. The law makes it difficult
or them to come here and stay permanently, because it
ants them to go back to their countries of origin, but we
eed them. If we believe there is a real shortage in the
orkforce in cardiology, wait and see: it is going to get
orse. And if we do not solve this problem—IMGs
omprise 30% to 40% of all cardiology trainees (19)—it is
oing to be a major problem in the future.
r. Bonow: I would emphasize that you should get
nvolved with the American College of Cardiology, because
hat is where the whole workforce issue is front and center.
t is addressed in the new Bethesda Conference report on
ardiology’s workforce crisis (http://www.acc.org/clinical/
ethesda/beth35/index.pdf).
uestion: I have a couple questions for Dr. Balke about the
08 award. You noted that the award rate level is somewhat pifferent per the National Institutes of Health (NIH)
nstitute that is granting the K08 award. Sometimes grant
pplications can apply to various institutes. Does the appli-
ant decide which study group is going to review the
pplication, or is that determined at NIH? And secondly, if
ou are a faculty member who is getting salary support as
art of your clinical activity and you receive a K08 award,
hat influence do you have on how the money is spent? Do
ou have to take any of that as salary, or can it all be used for
quipment or salary support for a laboratory technician?
r. Balke: The K08 is institute-specific, and that affects the
cceptance rates as well as the actual awards. Some institutes
ward more project support than others. You can send in a
over letter with your application and it can be routed to a
pecific institute or a combination of institutes. It is easy to
ee how some cardiology research, both clinical and basic,
ould cover the National Heart, Lung, and Blood Institute
NHLBI) and the Institute of Aging, so you can specify
oth.
If you know enough about the study sections, you can
equest your application go to a study section. In general,
ost of the institutes have their own K08 study sections, so
ou cannot subdivide it more than that.
To answer your second question: the K08 and the K23
re salary-support awards. You need to have a minimum of
5% protected time for the research effort, and your salary
ill be 75% of what your institutional salary is, up to the
nstitute-specific limit. In the NHLBI right now, that is
bout 75K. You cannot redirect that money into something
lse; however, your home institution can augment that. So,
or clinical activity, you can get money for that work.
r. Bonow: I would like to ask Bob Balaban a question.
etsy Nabel was here, and I think she encouraged many
able 19. NHLBI: Divisions of Intramural Research
aboratory research program
Biochemistry and Biophysics Center
Laboratory of Biochemistry (LB)
Laboratory of Biophysical Chemistry (LBC)
Laboratory of Cell Signaling (LCS)
Cell Biology and Physiology Center
Laboratory of Cardiac Energetics (LCE)
Laboratory of Cell Biology (LCB)
Laboratory of Kidney and Electrolyte Metabolism (LKEM)
Laboratory of Molecular Cardiology (LMC)
Genetics and Development Center
Laboratory of Biochemical Genetics (LBG)
Laboratory of Developmental Biology (LDB)
Immunology Center
Laboratory of Molecular Immunology (LMI)
linical research program
Branches
Cardiovascular Branch (CVB)
Cardiothoracic Surgery Branch (CSB)
Hematology Branch (HB)
Laboratory of Animal Medicine and Surgery (LAMS)
Molecular Disease Branch (MDB)
Pulmonary-Critical Care Medicine Branch (PCCMB)eople to wonder about intramural opportunities. I ex-
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October 4, 2005:5A–72Alained how intramural experience at NHLBI was very
eneficial to my career. What are the opportunities for
eople now who are already in a cardiology training pro-
ram to do something intramurally with NHLBI for a year
r more and then go back out into the university experience?
r. Balaban: There are training programs in the basic and
linical cardiovascular research as well as special programs in
maging sciences, genomics, and bioinformatics at the NIH
ntramural laboratories in Bethesda, Maryland. If you come
o an NHLBI intramural training program you will be
etting an experience from all of the institutes at the NIH,
ot just the NHLBI. This change in the intramural pro-
ram has occurred over the last few years as it has become
vident that multidisciplinary experiences are required to
repare fellows for the next wave of clinical research areas.
The training programs are an intensive hands-on research
xperience, perhaps without the same degree of clinical
esponsibilities as one would have in most other research
rograms. We have made adaptations to our training
rogram to increase the clinical exposure beyond the rar-
fied environment in the NIH Clinical Center by opening
oth an imaging and surgery research program in a com-
unity hospital. This permits the clinical fellows to keep
ouch with the basic practice of clinical medicine as well as
uide some of our research projects to very practical issues in
community hospital and not only to what a major teaching
ospital experiences.
At the NHLBI Web site (http://www.nhlbi.nih.gov/
ndex.htm), the laboratories and branches of the NHLBI
re listed (Table 19). I would encourage you not just to
hink about the NHLBI, but look at the NIH intramural
rogram as a whole to look for research programs that might
e of particular interest to you on the NIH Web page
http://www.nih.gov).
uestion: I would like your advice on how to contribute to
eaningful research over a career in interventional cardiol-
gy? What might be reasonable expectations and objectives
o set? Then I would like to direct this question specifically
o Drs. Bonow and Fuster: what qualities define a true
eader?
r. Ferguson: From the standpoint of research in inter-
entional cardiology, you can certainly do more than just
erform a whole bunch of procedures. You should look at
oing whatever you can to advance the field in some way,
hape, or form. But the key is being able to distance yourself
rom the nuts and bolts of sitting around doing procedure
fter procedure.
You have to acquire some intellectual skills to be able to
ook at what you do. In getting back to some of the
uestions raised earlier about why you do what you do and
Are there ways to think outside the box and do things
etter?” the interventional laboratory provides you with an
pportunity to do a lot of things that we could not do
efore.
As technology advances, imaging modalities are nowoming back into the interventional laboratories. Realisti- kally, you are only limited in interventional research aspects
y your own imagination and how you want to do it.
r. Bonow: You have to be in a good teamwork environ-
ent. It is your responsibility to explore that: for example,
How good are the stem cell people? How good are the
hrombosis people?”
r. Ferguson: The number of procedures does not matter
s much as the scope of the work that is going on and the
reativity of the individuals doing the work as well as how
ggressively they are pushing the envelope. In terms of your
rofessional development, a lot of that comes back to the
ssue of mentoring. Look at the people who are there; look
t the people you are going to be working with. Are these
eople who basically come into the laboratory from seven in
he morning until eight at night just banging out proce-
ures? Or, are they thinking about and exploring things,
sing new techniques, and advancing the field? Are they
laying with the new toys or collaborating with other
olleagues to advance the field? The best advice I can give
ou as you look ahead and plan your career is look for quality
nstitutions and quality mentors.
r. Bonow: As to your second question: how does one
ursue a career that will eventually place you in a leadership
ole? We have all kinds of leaders here today. I doubt if any
f us actually started out assuming that we were going to
ave these roles. We all got into medicine for the same
easons you did. We wanted to take care of patients, but
long the way we developed interpersonal relationships
eeded to become leaders. A lot of this is how you work
ith teams, how you build teams, how you get self-respect,
nd how you develop the self-motivation to try to do more.
You must earn the respect of other people. Use your
nstincts. One of your key objectives, as we have mentioned
efore, is networking. Networking is absolutely critical, and
he mentors you develop now could be the mentors who
elp you move to the next level of your career and write
hose letters for you. All of us can probably identify four or
ve people who helped get us to the next step each step of
he way in our own careers. Therefore, getting involved early
n the ACC and AHA programs for young doctors allows
ou to start doing that and begin taking the steps upward.
alentin?
r. Fuster: There really is no such career path to becoming
leader. And if this is what you want to be from the
eginning, I would persuade you to change gears, because it
s not going to work. Ambition for ambition’s sake does not
ork. You should strive to do the work and enjoy whatever
esearch career you want to undertake.
If your question was more general, I would say there are
our characteristics to being a leader. The first quality of a
eader, to me, is to learn how to listen to and observe people.
nce you have that captured, the next step is not to be
fraid to make changes, because if you are frightened, you
ill never be a leader. You have to make changes if you want
o accomplish something. The third thing is you have to be
nowledgeable. Today, you cannot be a leader if you really
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October 4, 2005:5A–72Ao not understand the nuts and bolts of what you lead. And
he fourth is to have ethical standards, which are becoming
ore and more critical. The role models I always had were
eople who, to me, had the character and the characteristics
f ethics, which was critical to me.
II. CAREERS IN BASIC CARDIOVASCULAR RESEARCH
radford C. Berk, MD, PHD, FACC (Center for
Cardiovascular Research, University of Rochester
Medical Center, Rochester, New York)
career in basic science research is like getting a birthday
resent every day: there is always something new to learn as
wander through my lab and people show me their new
ata. They are showing me something that didn’t exist
efore, and for me, that joy of discovery keeps me excited
nd coming back into the laboratory every day. It is
hallenging and unique; there are fewer than 500 National
nstitutes of Health (NIH)-funded basic science cardiolo-
ists. That means there are good job opportunities; if you
ake it all the way through the process of becoming basic
cience investigators, you will very likely have a good job.
Basic research is very creative; it requires that you
ontinually think of new ways to address problems. It is also
echanistic, for those of you who have engineering back-
rounds or who would like to better understand how things
ork. The basic science researcher will do a lot teaching.
nd, if you want to be a basic science investigator, there are
ome lifestyle considerations: scientists in this field are fairly
ccentric and free thinkers. If that is you, it may give you an
pportunity to do something uniquely appropriate for your
ersonality.
ow to become a basic researcher. It starts with your
entor and, today, the more mentors you have the better. If
ou need mentors, you might as well start at the top. Do not
e shy; go talk to your chairperson. The Chief of Cardiology
nd the laboratory director are immediate choices. I urge
ndividuals at our organization who are interested in doing
esearch to form a “thesis committee” of two or three
eople. Touch base with these people every three to four
onths to go over your progress and get their advice.
In terms of choosing your immediate mentor, it is
mportant that you find someone you like and can talk to.
any of these people will become lifelong friends and
upporters. Finally, you should have what I call idols: Nobel
rize winners or other geniuses. These are the few people
ou look up to who you think are so brilliant you could never
e that good; that sets the standard you are trying to
chieve.
The second most important factor in becoming a basic
esearcher is the environment where you do your research.
urround yourself with the best. Find a lab that is exciting
nd challenging. Find a place that has trained a lot of
eople, because that takes a lot of expertise. Talk to the
urrent people in the lab. Surround yourself with people
ho are passionate and competitive, yet friendly and col-aborative, so that you can interact with them. You should
eel impressed you got into that club.
In terms of the training to do basic research, it will take
t least two years. There are many opportunities, such as the
ndividual NIH National Research Service Awards
NRSA), or perhaps your institution has an institutional
32 training grant. You also can get pharmaceutical and
oundation support to help pay for it. I say this sincerely: use
our time wisely, and avoid the clinic. It is very tempting to
elp out clinically, but this is really the only time that you
ave dedicated to research, and you should use it wisely. I
hink it is critical to get publications—at least two—and to
rite a grant. I urge many of our fellows to write individual
RSAs or pharmaceutical grants, because it is essential for
our future career to learn how to write a grant.
To accomplish all of this, you need a lot of support:
nancial, psychological, and scientific. In terms of financial
upport, you will need personal money as well as financial
upport for your research. Moonlighting is a reasonable way
o maintain clinical proficiency, especially because you can
ontrol the amount of time you sign up for when you are
oonlighting. For psychological support, talk to your
riends, family, and colleagues about what you are doing.
et them to buy in, and invite them to attend your
resentations. Scientific support comes from the confer-
nces you need to attend, where you meet the experts in
our field as well as your colleagues. I always tell people at
he American Heart Association (AHA) and American
ollege of Cardiology meetings to hang out at the poster
essions, because it gives you an opportunity to talk to
omeone one-on-one. I am very happy to talk to people who
o that; it really is the most fun you can have at a
onference. I am at the poster sessions to meet you.
If you want an example of how this support structure
orks in reality, I did moonlighting in cardiac care units and
he emergency room for five years. My wife was very
upportive of everything I did. She came to conferences,
istened to me explain experiments, and went into labor with
y son while I was doing an experiment. I had some really
ood friends back then who are still my friends today; I
orked with them in the labs, and they were my mentors
ho were very supportive of what I was doing. Also, I
able 20. How to Become a Basic Researcher: Career Paths
ellowships
● NIH: individual NRSA, institutional training grant
● AHA: national and state fellowships
● Pharmaceutical and foundation fellowships
unior faculty
● NIH: KO8 series
● AHA: scientist development and fellow-to-faculty
● Pharmaceutical and foundation fellowships
ext steps
● NIH: RO1
● AHA: Scientist Development Grant, Fellow-to-Faculty Award,
Established Investigator, Grant-in-Aid (local)
● Pharmaceutical and foundation support
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October 4, 2005:5A–72Aeceived a lot of support from the NIH and the AHA. Both
r. Fuster and I have, over the years, paid back that support
any times over by working for NIH and AHA, and this is
long tradition seen with many people assisted by these
rganizations.
The biggest mistake people make in choosing a basic
cience career is not taking enough time. No matter how
ood you are, research takes time. I always have MD and
hD students in the lab, and frequently, because they have
chieved so much already, they think they can just show up
or 6 h and turn out a good thesis. That never works. You
ave to work even harder to prove to everyone that you can
ucceed with both careers. There are no short cuts, only
ncomplete experiments. You need to schedule time. Do not
eel guilty about not spending as much clinical time as your
olleagues. A career exists over a very long time, but it
equires just two years to get the basic science training you
eed; you should put at least 90% effort into those two years
r you will not succeed later.
Make some decisions and set your priorities. For me, it
ame down to doing an angioplasty fellowship or not.
ltimately, I decided not to be an angioplasty fellow,
hoosing instead to get an NIH K08 award and do research
s a beginning faculty member rather than another year of
ellowship. At that time, that was one of the hardest choices
had to make, but looking back, I do not regret it.
We can’t consider the basic elements of becoming a basic
esearcher without addressing enthusiasm. If you do not
ove it, you will not make it. Many people are very
nthusiastic at the start, but they do not always end up
oving it. Therefore, it is critical that you self-evaluate on a
egular basis to see how much you are enjoying it. That also
s part of the reason for writing a grant, because a grant
eflects the fact that you have invested sufficient time in an
dea that you are willing to defend it, that you are enthusi-
stic enough about your idea to carry through over the next
everal years, and that when it does not work the first time
r even the ninth time, you still believe in the idea. I do
llow people to quit after the tenth time, because if it does
ot work after the 10 times, then for sure it is not going to
ork.
Another part of science and enthusiasm is to be able to
ithstand disappointment; you are going to be wrong most
f the time, because it is just impossible for all of your ideas
o be correct. If you are going to be frequently wrong, you
ust be comfortable with the fact that you may set out on
able 21. Opportunities in Cardiovascular Research
Diseases: hypertension, cardiomyopathy, transplant, atherosclerosis,
stroke, restenosis, hyperlipidemia, arrhythmias, congenital heart
disease, peripheral vascular disease
Organs: heart, blood vessels, brain
Disciplines: biochemistry, bioengineering, bioinformatics, cell biology,
developmental biology, electrophysiology, genetics, genomics,
integrative physiology, molecular biology, vascular biology
Techniques: gene therapy, receptor biology, signal transduction, ionatransport, stem cells, transgenic miceproject and find out that the project does not work, yet still
e positive about your goals. The goal is not always directly
bvious, and sometimes you have to circle around to get to
he goal. That is the essence of creative problem solving,
nding different ways to get to your goals. Consequently,
oday when I am writing a grant, it is always about
omething I really want to do. I have a lot of commitments,
nd the research time I have is one of the most valuable
ommodities in my career, so I make sure I am doing exactly
hat I want to do. I really enjoy being with people in the
ab, and I tell them they are doing a good job. Even if the
esults of their research are negative or unexpected, it does
ot mean they did not do a good job. It is important to
aintain that positive attitude and really sit down and talk
ith them. It is communication; it is dialog over results and
deas that make science exciting.
areer paths. We need more basic scientists, and there are
ifferent career paths to follow to become a basic researcher
Table 20). At the fellowship level, there are least six or
even places you can go to for funding, and organizations
ike the AHA have funneled most of their research dollars
nto training new investigators. They have very few grants
vailable for established and senior investigators. The AHA
lso has this new fellow-to-faculty transition, which is a very
ritical grant mechanism. There is a similar effort by the
IH; it is an entirely separate case series of awards, K08s,
23s, K24s, and KL1; they are all dedicated to junior
aculty.
Once you get through the junior faculty level, the next
teps include getting your first investigator-initiated indi-
idual grant or R01, which is the biggest NIH grant. The
HA, even for very junior transitioning faculty, is willing to
elp with additional scientist development grants, fellow-
o-faculty awards, established investigator awards, and local
rants-in-aid. Finally, the “next steps” include pharmaceu-
ical and foundation support.
It takes a lot of time to be successful in a cardiovascular
esearch career, but the possibilities out there for basic
esearch careers are enormous. Pretty much any disease you
an think of that has a cardiovascular component is fundable
rom the NIH (Table 21).
Of all the elements required to become a basic researcher,
ocus may be the hardest. Find what you are good at, what
ou find easy to do, and what you enjoy. There is no extra
redit for taking the hardest assignment. Let other people
o what you think is difficult; they probably think what you
nd easy is hard for them. Pick a big area to focus on, such
s hypertension, and then choose within this large subject
atter those areas you want to tackle. Here is a question for
ou: If you are going to give a plenary lecture in five years
ased on your research, what would the topic be? What
ould you say that you achieved over the past five years?
he key is to pick a good question—you do not have to
now the answers and probably should not know the
nswers in the beginning, but at least choose a good
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October 4, 2005:5A–72Auestion that can help you focus and define a good area of
esearch for you.
onclusions. When I started out, I was struggling to find
y focus. My mentors were enthusiastic about different
reas of research. Ultimately, blood vessels attracted my
ttention and I chose to work in vascular biology. Later,
hen I looked at the new techniques and the new areas of
esearch, I looked into signal transduction, which was a
till-evolving discipline when I was a fellow. When I started
onsidering the opportunities for basic research in cardiac,
ascular, and other areas of biology, I decided to work on
ignal transduction in the vasculature, and that is what I
ave done for the past 20 years.
Over the years, in my research, we have figured out a lot
f the biochemistry that makes cells different from each
ther, and we really have some exciting ideas about redox-
ependent events that seem to be different in normal flow,
nd this is fundamentally important because of nitric oxide
20,21). Nitric oxide goes to the smooth muscle cell and
auses contracted smooth muscle cells to relax; it is instru-
ental in regulating blood pressure. Well, when I started
ut in this field, it was in its infancy and, at the time, it was
ot a hot field for investigation. As many of you know, in
998 three gentlemen won the Nobel Prize for their
iscovery of nitric oxide: Ferid Murad, MD, PhD; Louis
gnarro, PhD; and Robert Furchgott, PhD. One might say,
You are in a field where there is already a bunch of Nobel
aureates; isn’t that a bad thing for someone looking to enter
field of basic research?” Well, that Nobel Prize became a
ery good thing. If you look at the amount of research in
itric oxide since 1990, it has gone up 10-fold as a
onsequence of the enormous interest in the work of these
hree individuals. This is really an important message: do
ot be frightened to go into a field that has really famous
eople in some very exciting areas, because the presence of
uch people makes the whole field much higher in both
rominence and priority.
III. CHARTING A COURSE IN
ASIC CARDIOVASCULAR RESEARCH
tephen F. Valner, MD (Cell Biology and Molecular
Medicine, New Jersey Medical School, Newark,
New Jersey)
hen I was going through internship and residency, my
entor at that time advised me to take a fellowship in basic
esearch, then return as chief resident and pursue a career as
clinical investigator; however, for a variety of reasons, I
ever returned to clinical medicine. One reason was cer-
ainly related to the fact that I was fortunate enough to have
een associated with several outstanding scientists, includ-
ng Nobel Prize winners who influenced my career at
edical school and during my fellowship training.
This is an example to point out that there are other career
aths for clinically trained MDs interested in research. The
harmaceutical industry is another option for clinical investi- Aators, and many of these doctors have been able to stay in “Big
harma” or go to biotech and invest in their own companies.
ne example is Roy Vagelos, who as anMD became chairman
f biochemistry at Washington University in St. Louis and
hen went on to head Merck; today, having left as president
nd chief executive officer of Merck, he still plays an active role
n biotech. Another example: when I was at medical school,
he chairman of medicine was Lewis Thomas, whose primary
ontributions were in research. After his medical training, he
oved through the professorial ranks . Eventually, he became
rofessor of pathology at New York University, then head of
hat department, and finally, chair of the department of
edicine. From there, he moved on to become dean and
ventually chancellor of Memorial Sloan-Kettering Cancer
enter. This was to a great extent based on major research
tudies that spanned several disciplines. Thus, if you want to
ook to the future, there are a lot of opportunities for clinical
nvestigators in leadership positions, not only in the pharma-
eutical industry but also in academia.
urrent career models. While my career path was that of
cardiologist who is exclusively a basic scientist, this model
s mainly obsolete. One reason is that it is a career path with
imited options. Obviously, on this career path you can
ecome a professor, either in a basic science department or
linical department, and then become an institute director
r a chair of a basic science department. It is less likely now
or a basic scientist to become a dean or a chancellor,
ecause understanding the economics of medicine is poten-
ially paramount in running large medical schools. It is still
ossible to become a leader in a “Big Pharma,” and many
asic scientists also direct biotech companies.
Today, it is important to maintain your options as a clinician
nd as a cardiologist even if you want a career in basic research.
his combination of skills is in great demand at academic
nstitutions. Very few cardiologists have sufficient training and
xpertise in basic research to compete for National Institutes of
ealth (NIH) funding, run a basic laboratory, and bring new
deas from the bench to the bedside that will make a major
ifference in changing health care delivery. Therefore, it is
mportant today for basic scientists to maintain their clinical
kills, primarily for reasons of salary and career options. With
his combination of all skill sets, a cardiologist can become
hief of cardiology or chief of medicine, and still have the
ption of conducting basic research.
There are both pros and cons to this kind of mixed career.
eginning investigators may be worried about getting grant
upport. Recently, receiving grant support became more com-
on with the doubling of the NIH budget. However, cur-
ently we are facing a serious dip in grant funding. Over my
areer, I have worked through vicissitudes of both relative ease
nd difficulty in receiving NIH funding. In addition to these
rawbacks of difficulty in obtaining research support, if you
pend full-time in research, your salary is likely to be less than
f you were an interventional cardiologist, but there are other
ays to increase your income and be competitive financially.
lso, you have to be concerned about the time you must invest
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October 4, 2005:5A–72An establishing your career, because basic research takes several
ears of fellowship training. Moreover, there is a need to
onsider the many hours you have to apply to research to be
uccessful, run your research laboratory, teach, as well as honor
our clinical commitment.
Having said that, there are several important features to
he career path I have outlined that favor this approach.
rimarily, there are benefits related to the diverse career
ptions: maintaining an interest in patient care, teaching
nd directing a department, or working in industry or
overnment. The intellectual challenge of this type of career
s particularly attractive. While it is important to maintain
our clinical contacts and see patients to gain the personal
eward involved in their healing, there is also some repeti-
iveness to patient care. In contrast, in a research career, you
ome to your laboratory and work on major different
rojects with different methodologies, which change over
he course of your career. For example, I started my research
areer using large animal models before moving into work
nvolving murine genetic models and more bench work; for
e, every year is a new learning experience. Thus, this
ombination of clinical work and basic research offers some
ajor advantages in terms of maintaining intellectual
uriosity.
Finally, a career path including research is very rewarding
nd fulfilling, not only in your personal and intellectual life,
ut also in terms of magnifying your contributions to health
are. Whereas the physician can make a very important
ontribution to health care in terms of individual patients
nd individual families, with a career in basic research, it is
ossible to discover a new gene, a new protein, a new
herapy that may improve the lives of countless patients.
uestion and Answer
r. Fuster: You feel quite optimistic about careers in basic
esearch, but you feel it has to be somewhat linked to the
linical scenario, which did not happen before. Can you
xpand on this?
r. Vatner: It gives the clinically trained investigator an
mportant background and advantage in basic science in
erms of knowing the end point of patient care while you are
orking with some gene, protein, or cell system. To be able
o understand, ultimately, where your efforts are going to
ead in terms of understanding the pathogenesis or therapy
f disease is important, and I think that is why there is so
uch emphasis at the NIH on clinical investigators and
nvestigators with MD backgrounds.
r. Fuster: Another change that has happened is the issue
f the team effort. Your opinion?
r. Vatner: I fully support that, and that has been the track
f my career. I started with a very small laboratory and built
t up with four R01 grants from the NIH. Then we got our
rst program project about 15 years ago. We got our second
rogram project five years ago, and now we are in the midst
f applying for a third. We’re recruiting very basic research- trs. We have people—from the clinical investigator all the
ay to people working on yeast genetics—all working
ogether, trying to find new pathways and novel therapies.
o I agree with the team concept 100%.
IV. CAREERS IN ELECTROPHYSIOLOGY RESEARCH
ouglas P. Zipes, MD, MACC (Division of Cardiology
and the Krannert Institute of Cardiology, Indiana
University School of Medicine, Indianapolis, Indiana)
f the fundamentals required for a successful research
areer, perhaps the most important are motivation, drive,
nd perseverance. You need to be able to work long hours
nd continue to work despite disappointments and setbacks.
ut if I were to pick one key factor that predicts success, it
ould be drive.
Temperament is another important general requirement,
nd the temperament of a cardiac electrophysiologist com-
ines the cognitive thinking of the cardiologist with the
ctive approach of a surgeon. The clinical cardiac electro-
hysiologist requires great cognitive skills, because he/she
ust interpret very complex electrocardiography and elec-
rophysiology (EP). Yet, our jobs are often surgical in
ature, given that we implant devices and can locate an
bnormal area of the heart and ablate it, thus curing the
atient of their problem. For some years, I have been
empted to put a sign up over the EP lab, “We fix
lectrocardiograms,” because we are virtually the only sub-
pecialists in cardiology who actually cure patients of their
roblems. Other specialities ameliorate the problem,
hether it is with a stent, thrombolytic therapy, or some
ther intervention, but often when you enter an EP lab with
olff-Parkinson-White Syndrome or some other life-
hreatening problem amenable to EP ablation, you leave
ured of that problem, which is really incredible.
The specific requirements for clinical cardiac EP are three
ears of internal medicine (IM) with American Board of
nternal Medicine (ABIM) certification, followed by three
ears of cardiology with ABIM certification, and then one
ear of clinical cardiac EP, again with ABIM certification,
lthough that year of clinical EP is definitely insufficient;
ractically, to be well trained in clinical cardiac EP takes two
ears. The complexities of the devices we use, combined
ith the various ablation approaches we must master, can’t
e learned in a year. The ABIM is probably not going to
hange that requirement, at least in the immediate future;
evertheless, the practical aspect is that two years of EP
raining are necessary. Once trained, you are required to
aintain ABIM certification over a 10-year period, and you
ust renew your certification in cardiology and electrophys-
ology, while IM boards are optional.
P research. Electrophysiology research requires training
t an institution with a strong research track record as well
s a recognized EP leader, good infrastructure support, and
xtramural National Institutes of Health (NIH) or other
ype of funding. Research is expensive and inefficient; it
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October 4, 2005:5A–72Aequires time, space, and money to produce work that may
r may not lead where you think it will. Indeed, one of the
efinitions of research has been “what you’re doing when
ou don’t know what you’re doing.” To a large degree, this
s true, and we are often wrong more than we are right.
When starting off on an EP career, do a literature search
f the publications produced by the mentors at the institu-
ion you are considering joining; find out what their track
ecord is, how many publications they have had, particularly
he individual with whom you would like to work, what
heir funding status is, and so on. Even earlier in your career
rack, while an IM resident, I strongly recommend you
iggyback on existing EP studies in your area of interest,
nd the earlier you start, the better. During IM training, and
articularly during your cardiology fellowship, seek out a
entor who is expert and willing to help young investiga-
ors. It is an important combination; it is not particularly
ffective to have a mentor who is an expert but who will not
pend time with you. Then select a focused, doable project.
his is critical, because too many young people want to
nvent the world, and that just does not work. The more
arrow, the more focused, the more doable the project, the
ore likely you will succeed in completing it. It is important
o demonstrate a successful track record, and by that I mean
o complete a project, submit the abstract, write the manu-
cript, and submit it for publication.
I see young people who are good at one or two of these
teps, but never take the project to completion, and that is
big mistake. These are obviously different skill sets; one
erson may be brave with new ideas, another, highly
uccessful at the actual technical completion of a project,
hile a third person may be particularly suited to writing up
he paper; however, to succeed as an independent investi-
ator, you really need all of those skills.
Once you become part of a research team that operates
ike a well-oiled machine, then it is appropriate to have
ndividuals who are specialized in a particular area. In one of
he presidential pages I wrote during my tenure as President
f the American College of Cardiology, I wrote about the
eed for the “interdependent investigator” as opposed to the
ndependent investigator (22). The interdependent investi-
ator is the researcher who excels at one task but not at
thers. This is the person who may not get ahead individ-
ally in academia, yet he/she can be a very important
ontributor. I chose that topic because so many of the
omplex research projects being done today require individ-
als with different sets of skills for their completion, but the
act remains that, to establish your credibility at the begin-
ing of your career, you really need to take a project to
ompletion, submit the abstract, and write the manuscript.
Also, you should plan ahead and write a fellowship
pplication for your third year of cardiology training. The
BIM designates that third year as a research year, and
uring your first year of cardiology fellowship, you probably
eed to write a fellowship application to obtain funding for
hat third year. It is helpful in three ways: first, you get bractice writing grants, and that helps focus your thinking
n a particular project and consider its various aspects, such
s the original concept, how the work will be done, how it
ill be completed, the pitfalls, and so on. Second, there is a
reat deal of prestige associated with obtaining a grant at
hat early level of training, and that becomes very important
n your curriculum vitae as you apply for applications after
our training. Third, by getting your own funding, you help
he particular division you work for to free up $50,000 of
unds if you get a fellowship grant. There are a number of
rant sources, and those are discussed elsewhere.
As you consider your training, you should think about
btaining a master’s degree in public health, science, clinical
esearch, or some similar degree. The purpose is to give you
dditional training beyond what you will get at your
articular medical center. Many places offer such programs,
nd you can learn a great deal during a master’s level degree
rogram that can be applied to clinical or basic research.
Research training is not complete without a thorough
nowledge base regarding the protection of human subjects
nd informed consent. At my institution, I recruited a
right young interventional cardiologist who was also a
asic scientist with an NIH R01 award. He was doing four
o five clinical projects and running a basic laboratory, but
e made some mistakes related to institutional review board
IRB) requirements for paperwork, such as keeping track of
ll the informed consent statements for his clinical projects.
he IRB came down on him hard. No patients were in
anger, but he did not follow the approved protocol. The
RB forbade him from doing any clinical studies for the next
ve years, and put him on probation for the succeeding five
ears. This extremely talented young investigator’s science
areer was ruined by not following through with all of the
ecessary things that human subject investigation requires.
o those wanting to do clinical research, I strongly empha-
ize being certain that you fully understand the knowledge
ase regarding protection of human subjects and assiduously
dhere to protocol requirements of the IRB.
As many others have said: do not be discouraged by
isappointments along the way. Rejected manuscripts,
rants that are not approved, and failed projects happen to
ll of us. Indeed, if you have never had a manuscript
ejected, you are not publishing enough. Even at our senior
evel, we still get manuscripts rejected from prestigious
ournals. You pick yourself up and resubmit the manuscript
omeplace else. Rejection is difficult from an emotional and
go standpoint. When you write something and submit it,
ou’re putting your ego on your sleeve, and when you receive
riticism, initially it is very difficult to press on, but you need
o pick yourself up and continue.
My 40-year research career has been spent with one foot
n the animal lab and one foot at the bedside. When I first
ransitioned from my cardiology training and had the
pportunity to spend a sabbatical doing basic science, one of
he things that struck me within the first few weeks of doing
asic science was that you can go a very long time without
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October 4, 2005:5A–72Any positive feedback. Think for a moment about your
linical experience. Virtually every day, some patient got
etter and thanked you for the care you gave. In the clinical
etting, you receive positive input daily, and we thrive on
hat; however, in a basic laboratory, you do not have that
ind of feedback. Indeed, if your experiments are not
orking, you can go weeks or months without any positive
eedback. After the first six to eight weeks, I was depressed
nd I could not figure out why; then I realized it was because
went from being a clinician to a basic scientist, and with
othing succeeding in the research I was doing, I had no
ositive feedback for quite sometime. You really need to be
ware of that going in and understand the nature of basic
cience work as opposed to clinical work, where positive
eedback is a daily occurrence.
However, I cannot adequately express the thrill you get
hen you conceive a hypothesis, go to the bedside or the
asic lab, and prove that what you conceived is correct. For
hat small moment in time, you may be the only person in
he world who possesses that knowledge, and there is
othing that I have found that exceeds that, intellectually.
or me, that is one of the driving forces that have made me
o excited about research for 40 years. The thrill of that
iscovery is what creates the fire in the belly.
asic cardiac EP. For basic cardiac EP, the ABIM offers
n investigator track. This shortens the IM program by a
ear. After two years of IM training, the ABIM investigator
rack requires three years of research, which can be molec-
lar biology work, patch clamping/mapping, or clinical
esearch. Then it is on to two years of clinical cardiology and
ne year of clinical EP, should you choose to become both
clinician and a basic scientist. Once again, careful selection
f the mentor and the project is very important; keep it
ocused and make certain that the project you have chosen
o focus on is something you can accomplish in the time you
ave allotted.
At the junior staff position, make sure you “get it in
riting” the recruitment promises. This includes a clearFigure 7. Traditional paradigm. Source: JAMA 2003;289:1278–7. Copnderstanding of your protected time. The amount of
rotected time you get will depend on what you want to do,
ut at a basic level, you need far more protected time for
asic science research than you would if were going to be a
linical investigator. You also should get in writing the
esearch support you will need for a minimum of two years,
ncluding technician, lab, expenses, and salary. Finally, have
n agreement giving you the opportunity to take classes in
tatistics or other pertinent areas. At this point in your
areer, focus, publish, and get grant support.
Can you be a clinician and an investigator? For clinical
nvestigation, certainly, it is no problem to be both, but the
ombination is much more challenging for basic investiga-
ors. When I started, it was relatively easy to be a basic
lectrophysiologist and a clinical electrophysiologist, so I
ust grew up that way. Early in my career, the chairman of
edicine related to me the story of a young farm boy who
as given a calf. Each day he lifted that calf and, despite the
act that the calf grew to be a big cow, since he started lifting
he animal when it was still small, he was able to continue
ifting the animal when it grew well beyond calf size. That
s how I managed to start at the basic science level, and even
s it grew more complex, I was still able to do it. Today, that
pproach would be much more difficult. It is not impossible;
t is doable if you work hard. Particularly helpful is choosing
project that addresses a clinical question (i.e., translational
esearch). In our labs, the thrill has been the bidirectionality
f the research we do. If we have a clinical question that
annot be answered readily at the bedside or in the EP lab,
e bring it to the animal laboratory and get an answer.
onversely, we can take a basic idea and translate it to the
linical area.
The “C” in implantable cardioverter-defibrillator, or
CD, was developed by taking a concept from the animal
ab (23) and bringing it to the clinical area (24); we do the
everse as well. We had a series of studies recently, using
ptical mapping in an animal model to explain the mecha-yright ©2005 American Medical Association. All rights reserved.
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October 4, 2005:5A–72Aisms of ventricular tachycardia and atrioventricular node
e-entry that we see clinically (25–27).
It is also important to pay attention to patentable ideas.
hen we implanted the first cardioverter (24), it drew
nterest from the news media, including having a news
onference. After the news conference, my dean threatened
o fire me if I ever did anything like that again, but today
ost schools want that kind of publicity. They want you to
atent ideas, because it raises money that helps support
ther kinds of research. So, intellectual property is very
mportant to both you and your university; clearly, one
hould take advantage of ideas that can be patented.
onclusions. The EP job market has never been better,
specially for those with a proven research track record
emonstrating the ability to take a project from concept
hrough protocol writing, IRB approval, data collection,
nalysis, presentation, and publication. Electrophysiologists
re in great demand; for instance, ICD implants are
rowing at a rate of more that 20% per year. We now have
iventricular pacing that we can combine with ICD tech-
ology; indeed, some 40% of that growth in ICD implan-
ation is in units that include biventricular pacing, so the
arket is increasing dramatically. Atrial fibrillation and
udden cardiac death remain major problems and will
ontinue to provide job security for the basic and clinical
lectrophysiologist well into the next century.
Considering the striking advances in both our under-
tanding and treatment of cardiac arrhythmias (28) and the
xplosive growth in EP, there it is certainly a wonderful job
arket for the individual who fits the picture I have
escribed of the EP researcher.
V. MAKING THE TRANSITION TO
RANSLATIONAL INVASIVE RESEARCH
avid R. Holmes, JR, MD, FACC (Mayo Clinic College
of Medicine, Rochester, Minnesota)
here are many different ways to define translational re-
earch. Translational research integrates science discoveries
nto clinical applications or, conversely, uses clinical obser-
ations to generate research foci for basic sciences. It is
esigning strategies to test basic pathobiologic or patho-
hysiologic concepts of disease in a human/clinical arena. It
s also identifying mechanisms of disease or healing in
ndividual patients that can then be tested in larger, vali-
ated population studies. Or it can identify patient popu-
ations with disease and then study the cellular mechanisms
f the disease or that particular population. These are all
xamples of translational research and how it relates to
nterventional cardiology.
In a recent article on the central challenges facing
ational clinical research, the authors described the first
oadblock as translating information from concept into
rst human studies, and the second roadblock is the
ranslation of information from clinical trials into clinical
ractice (Fig. 7) (29). Invasive interventional cardiologistsay find they have interest in both of those roadblocks and
nvolve themselves in trying to get that information from
cience to a specific patient or to the larger population.
istorical perspective. In a 1997 article in the Journal of
linical Investigation, Goldstein and Brown (30) tell the
tory that pinpoints the modern beginnings of translational
esearch. Philip Hench (1896 to 1965) (31), a rheumatolo-
ist at the Mayo Clinic, noted in 1929 that several of his
atients with painful rheumatoid arthritis experienced dra-
atic improvement if they were either pregnant or jaun-
iced. He hypothesized that these conditions produce an
nti-inflammatory hormone he called “anti-rheumatic sub-
tance X.”
The only common biochemical denominator he could
nd in pregnancy and jaundice was elevated cholesterol, so
e administered lipid extract from bovine adrenal glands,
ut no antirheumatic effect was seen.
Five years later, he began collaboration with Edward
endall, PhD (1886 to 1972), a chemist who had already
solated cortin, a crystalline substance composed of 28
ifferent steroids, from the adrenal cortex in dogs. Kendall
as able to isolate six steroids with activity using bioassays.
orking together, the men tried to identify and purify the
ix steroids showing activity. Separating closely related
teroids was an arduous process that required 10 years and
50 tons of adrenal glands. Their first study involved
ompound A, which was 11-deoxycorticosterone, but it
ailed. They moved on to the sixth steroid, which was
ortisone.
Finally, in 1948, after starting in 1929, Kendall and
ench, in collaboration with Merck and Co. Inc., devised a
7-step process for the synthesis of cortisone, the most
laborate biochemical method process created to date. They
roduced several grams of cortisone, enough to treat one
heumatoid arthritis patient with 100 mg intramuscularly
or nine days. In a video shown in 1949, a dramatic effect
as obvious in a 61-year-old patient with chronic, severe
heumatoid arthritis who couldn’t even walk before the
reatment. The Lazarus results in an immobilized patient is
n example of translational research and led, the next year,
o the two researchers sharing the Nobel Prize in physiology
r medicine.
This is translational research. It worked because it was
ased on clinical observation, clinical need, and collabora-
ion between a passionately committed clinician, a basic
cientist, and a pharmaceutical company. Success required
onfidence and resolution despite repeated failures. It re-
uired innovation and resources and is pretty much where
ranslational research emerged as a field, where those same
oncepts apply as much today as they did then.
aking the transition. Clinical observation, clinical col-
aboration, confidence, resolution, innovation, and resources
re all common themes in translational research. How, then,
o we make the transition to interventional translational
esearch careers?
If you are an interventional cardiologist and would like to
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October 4, 2005:5A–72Ae a translationalist, you will need formal scientific training
ith mentors, and it will require rigorous and focused
raining based on whether you decide to concentrate on
ellular, biochemical, or molecular research, or perhaps
ome combination. Because of the emphasis on basic sci-
nce, your formal scientific mentor is unlikely to be an
nterventional cardiologist, but the mentor should have had
dvanced clinical interventional practice who can identify
ssues and be aware of the technology. This will perhaps
equire a couple different mentors.
Once mentorship is in place, with both basic science and
nterventional experience, the next crucial ingredient is
ranslational research space and equipment, access to an
nimal laboratory, and relevant state-of-the-art equipment
o assist in studying those ideas brought along from your
asic science training and then carrying the findings into the
uman arena, which means some facility for patients.
There are other considerations, too, as the work
rogresses, including a mechanism for intellectual property
evelopment and protection, since you will bring along new
echnology and want to protect and develop it. A research
upport infrastructure is necessary for protocol design and
evelopment with Food and Drug Administration interac-
ion. Funding mechanisms will be necessary as well as
nternal or external facilities for prototype development. If
ou have a specific widget in mind, you have to have a
rototype of that widget to test in the animal laboratory.
areer issues. In translational invasive research, there a
umber of career issues. Who are your peers? It may be the
nterventionalist who does percutaneous coronary interven-
ion, or perhaps the basic scientist, or it may, in fact, be
eople somewhere in between with feet in both camps.
One key issue is figuring out what you are going to do
ith your interventional practice. Suppose in your interven-
ional training you did 500 interventions, but now you have
IH funding requiring 70% of your career be devoted to the
IH-funded project. You certainly will not be doing 500
nterventions or even 200 interventions. It may be possible
o do a handful of interventions, but what does that mean?
ow will you manage your clinical commitments? An
nterventional cardiologist must devote time to interven-
ions; otherwise, that skill goes away. These decisions will
ave to be made, and they are likely to be difficult.
When doing device or drug research, protocol design
ssues include whether you are going to use highly selected
r real-world patients. Does the situation call for a random-
zed trial, a registry, or a Humanitarian Device Exemption?
Finally, consider conflicts of interest: who will design the
rotocols and, if it is your device, who will use the device?
hould it be you? Who will report the data? Who benefits
rom financial gain? Hopefully, that concern will be an issue
ecause your device and career will be successful.
eal-world examples. With that background, consider
hese three different approaches to becoming an invasive
nterventionalist/translationalist cardiologist, all based on
eal people.The first example did his interventional cardiology train-
ng at the Mayo Clinic. At Mayo, he did 434 interventions
nd published nine papers in interventional cardiology. We
iscussed what he was going to do when he grew up, and he
ecided to take the road less traveled, eventually going into
ene therapy research. Today, he has three patents and does
ero interventions, is a star in the field of gene therapy. His
rip took him from interventional cardiology into basic
olecular mechanisms, where he decided to stay and design
reatment strategies for small discreet patient groups.
The second person is on more of a “mainline highway.”
fter internal medicine residency at Mayo, he stayed as a
ardiovascular fellow, which included two years as an NIH
esearch fellow within the fellowship. In 1997, he was the
irector of the Center for Coronary Physiology and Imag-
ng in the catheterization lab and a professor of medicine in
001. His major research interest is human endothelial dys-
unction, which has led to a randomized trial on L-arginine
nd endothelial dysfunction and a subsequent NIH R01
rant to study endothelin in early atherosclerosis.
Finally, the third example is a colleague originally from
reland, who started out as a PhD in vascular biology. He
ame to the Mayo Clinic as an interventional cardiologist,
here he did 370 interventions. He became a postdoctoral
ellow and is now an assistant professor of molecular
harmacology and experimental therapeutics. In 2004, he
id no interventions; instead, he has an Australian National
eart Foundation Research Scholarship, an AHA [Amer-
can Heart Association] beginning grant-in-aid, an NIH
PG and R01, and developed a wound care technology for
hich he received a $2.5 million grant from the Department
f Defense/Homeland Security. Additionally, he is the
rincipal investigator planning a phase I clinical trial of
enetically modified stents for chronic total occlusion.
onclusions. Obviously, you can get to translational inva-
ive research in different ways. If you arrive there as an
nterventional cardiologist, you will have to decide whether
ou want to stay as an interventional cardiologist who
ommunicates with the basic scientists for the cross-
ertilization that is necessary for success. This approach can
e extremely productive and make for great success, all
chieved from the platform of interventional cardiology.
he value is due, in part, to the fact that there is a large data
et of patients in an interventional practice, providing an
normous amount of information that can help advance the
are and treatment of these patients.
VI. PANEL DISCUSSION: MOVING
EYOND THE CLINICAL EXPERIENCE—
PECIALIZED RESEARCH OPPORTUNITIES: PART 2
obert O. Bonow, MD, FACC (Northwestern University
Feinberg School of Medicine, Division of Cardiology,
Northwestern Memorial Hospital, Chicago, Illinois)
VD
D
B
D
i
a
t
D
d
c
e
m
r
e
t
y
i
e
i
t
s
D
S
o
r
t
p
I
t
D
t
f
s
o
g
i
n
i
w
c
i
p
m
a
g
d
m
D
m
b
u
s
D
m
a
p
w
c
d
o
C
t
a
i
w
i
c
d
i
l
f
f
h
A
w
t
w
p
g
D
f
fi
h
D
c
m
s
a
s
w
t
a
w
i
b
s
c
48A Symposium Presentations JACC Vol. 46, No. 7 Suppl A
October 4, 2005:5A–72Aalentin Fuster, MD, PHD, FACC (Zena and Michael A.
Wiener Cardiovascular Insitute and the Marie-Josée
and Henry R. Kravis Center for Cardiovascular
Health, Mount Sinai Medical Center, New York, New
York)
ouglas P. Zipes, MD, MACC (Division of Cardiology
and the Krannert Institute of Cardiology, Indiana
University School of Medicine, Indianapolis, Indiana)
avid R. Holmes, JR, MD, FACC (Mayo Clinic College
of Medicine, Rochester, Minnesota)
radford C. Berk, MD, PHD, FACC (Center for
Cardiovascular Research, University of Rochester
Medical Center, Rochester, New York)
r. Fuster: We have heard a lot of discussion on the
mportance of the team in research. What is your gut feeling
bout working together on a team, regardless of the field
hat you are in?
r. Bonow: A multidisciplinary approach is critical in the
evelopment of research topics, and that is even true within
ardiology. I do not care whether you are going into
lectrophysiology, intervention, or whatever; my recom-
endation is the same: use multidisciplinary teams. We
eally see a trend for the future in being able to get good
ngineers, chemists, and molecular biologists to all team up
o solve a given problem. What I find to be utopian is when
ou can have people with a variety of interests, such as
ndividuals interested in atherosclerosis, others working on
lectrophysiology problems, and still others interested in
nterventional aspects, all working together and melding
hose diverse interests into some common questions and
olutions.
r. Fuster: The question is stimulation and incentive.
omebody raised the issue that today you can go to a private
r semi-private organization and have more money for
esearch and still accomplish many things. Please respond to
hat, because my concern is that while you may go to these
laces to do very specific work and the money may be there,
am not entirely sure you have the team, the stimulation, or
he excitement.
r. Bonow: I agree with you. Often in these environments,
he reason you get the money is because of the highly
ocused effort. Secondly, it is very difficult in those circum-
tances to develop the type of multidisciplinary team I just
utlined. There are exceptions to that rule, obviously, but in
eneral, it is very difficult to end up generating that type of
nterdisciplinary team when the funding structure is so
arrow with regards to the outcomes that have to occur.
There is a huge temptation to move in that direction, and
t is something younger cardiologists are going to be faced
ith more and more when making career decisions. It
omes down to basic research versus more applied research;
f you want to do basic research, these types of multidisci-
linary groups with the more classical academic environ-
ents are going to be required. If you lean more towards
pplied research, such as the phase III trials, the private troup or institute approach might be tenable. It really
epends where your talents and interests lie in terms of what
odel you follow.
r. Fuster: Let us say I am an electrophysiologist and I
ove into some kind of private setting. I still do research,
ut would not it be very important to keep in touch with the
niversity setting and with all the groups who are really
killful?
r. Zipes: There are two parts to this issue. One is your
ultidisciplinary team, your ability to garner the technology
nd disciplines necessary to really ask the question and
robe for an answer. As I said, imaging is a huge part of
hat we do as cardiologists, and being in a place where you
an look at what you are studying is critical. There are many
ifferent ways you need to look, all the way from good
ld-fashioned autopsy pathology to real-time imaging using
T and MR technologies. Those images give you some
angible mechanism to understand what you are studying,
nd it is incredibly important that in all these areas of
nvestigation you have that ability to look at what it is you
ant to study. That is, sort of, a technology side.
The other half of the equation, which is even more
mportant, is the intellectual environment you are in. You
an be hurt if you end up in a place that is so narrow that all
iscussions are limited to a single topic or a single body of
nvestigation. It is essential to be where people are asking a
ot of good questions, where there is a lot of intellectual
ervor about the whole field, because it is that cross-
ertilization that is so important. This is so important that I
ad one big complaint about the last American Heart
ssociation Scientific Sessions; the biggest problem we had
as we were so spread out throughout the convention center
hat it was very difficult for the basic scientists to mingle
ith the clinicians and the epidemiologists. I hope that the
rogram committee modifies this, because it is that min-
ling that is so essential for good ideas to emerge.
r. Fuster:David, you have been a good example of staying
ocused yet occasionally peeking here and there into other
elds within a multidisciplinary environment. Please explain
ow to do this.
r. Holmes: You can choose a highly specific area that is
ontinuing to evolve and grow, and through this growth,
ultiple disciplines may all come to bear on that very
pecific area: multiple people from different walks of life will
sk different questions, and all have different answers to the
ame questions. That is a very important point. Sometimes
e ask a question, thinking that we know the answer, but
hen somebody interprets the question entirely differently
nd gets a very different answer.
There is another issue that has not been addressed very
ell, at least, as we consider cross-fertilization and perhaps
maging. In many institutions, there are silos. These need to
e broken down; cross-fertilization is necessary between
ilos and outside the silos. As an example: I am learning
arotid stenting from a neurosurgeon in Buffalo, New York;
he reason why is because we each ask different questions
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October 4, 2005:5A–72Ahan each other, and together, this combination is very
owerful. So, in learning this, I may see things differently,
hich gives further strength to our collaboration.
As you begin to look at career opportunities, think about
he silos that are within whatever institution you are going
o work at. There are institutions where Radiology says,
You cannot do MRI [magnetic resonance imaging]. You
annot do CT [computed tomography].” Consequently, one
f the requirements for considering tremendous career
dvancement is that you go to a place where the mechanics
f cross-fertilization already are in place or there is a
illingness to break down silos.
r. Fuster: One of the critical issues we talked about was
enerosity, giving something to the other person and the
ther person giving to you. If you are stuck in your field and
re defensive, forget it; there are no silos that are going to be
roken. That is the reality of the world we live in today.
r. Holmes: This is the first time I had seen a slide that
isted altruism as being an element of a good scientist. One
ay you break down silos is by not necessarily having the
ested interest that keeps us from collaborating, and they
ay indeed require a bit of altruism as well. I applaud that
ttribute in successful scientists.
In terms of what you said about broad interactions, at our
nstitution, our research conferences are attended by basic
cientists and clinicians to provide cross-fertilization. And at
global level, the clinician is able to help the basic scientist
sk the questions that are important from a clinical stand-
oint, and the basic scientist is often able to critique the
linicians and make certain that they stay on line in terms of
heir focused research. So, that kind of interaction is
bsolutely essential.
uestion: I have some interest in genomics and their
elation to electrophysiology. As someone who would like to
o more translational research in terms of populations, I
ant to know whether a PhD is something [that] would be
equired for that kind of work.
r. Holmes: At our institution, we have a number of MDs
ho essentially function as PhDs. So, I do not know that
t is the title, per se, as much as what the knowledge
epresents, and to me, the latter is more important. I do not
hink you need to be holding a PhD necessarily, as long as
ou have had the two to three years in a basic lab acquiring
he skills to do the kind of genomic research that you would
ike to do.
uestion: I ask this question as someone admittedly
acking a little bit of focus, because of my interest in imaging
nd ethics in cardiology. It seems to me that, in the absence
f good National Institutes of Health (NIH) funding,
omeone is fairly dependent on industry when you are
nvolved in the use of new technologies. How do you
egotiate with industry when they seem so indispensable in
lot of research settings?
r. Berk: Some aspects of cardiovascular research have an
pplied industry focus. The good news is that if they want
ou, then you certainly can get them to agree to a contract ind to provide you with a funding and you can hold them to
hose contracts. It is true that the NIH is a much safer
ureaucracy than most industries, which experience con-
tant changes in their business plans and personnel. The
ational Heart, Lung, and Blood Institute as well as the
ther NIH institutes have been around for more than 50
ears and are very stable environments. I think all of us
ake our primary focus to obtain NIH funding, but that
aid, a very focused appeal to industry to do something that
s of mutual benefit usually ends up being quite successful.
r. Holmes: In terms of your relationship and negotiating
ith industry, one important point is to negotiate up front
ome of the rights to the data. I am going to give you a
oncrete example. I was the principal investigator for the
RESTO (Prevention of REStenosis with Tranilast and its
utcomes) trial. This was the largest trial of interventional
ardiology for restenosis, and several years ago we thought
he results were going to be incredibly positive. While the
tudy was being planned, we asked the sponsor to fund a
ublication center and 20 manuscripts, any 20 manuscripts
hat we wanted. We wanted them to commit those funds up
ront, and they agreed.
It turned out that the trial was negative. But we had in
lace the ability to continue working with this 10,500-
atient data set and to write what ended up being good
opulation studies. Subsequently, we have published 20
apers out of a negative study. Had we not negotiated that
p front, the drug company at the end of a negative trial
ometimes just disappears as does everybody associated with
hat trial.
r. Zipes: There is yet another aspect to working with
ndustry; you can have a great scientific idea, but if it can’t
nd its way into the market place because of regulatory
ssues, that can be a major stumbling block.
uestion: I have two questions about career planning.
irst, I would like to understand why someone would want
o be become a department head or chief of medicine or
ome comparable post, because it looks to me like it steals
art of your time. The second question pertains to the future
f interventional cardiology. We see so many advances, and
aybe one day we are going to have a drug that melts plaque
nd 80% of the interventionalists are going to be out of
usiness. How do you see the future of interventional
ardiology?
r. Fuster: Though it is true that everybody sitting on this
anel is the head of something, I do not think this is
ecessary for everyone. When you really work in research,
e have so many people who are not necessarily heads of
nything. Moreover, probably 75% of the ones who are
epartment heads are not really the mentors who are going
o make your research careers interesting. You should not
ake away the impression that you have to be the head of
nything.
r. Zipes: Becoming head of cardiology was not the most
mportant contribution to my own career; I never considered
t until shortly before I assumed the position. In fact, it was
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ot want someone else to be head of cardiology. I once
lotted the number of manuscripts per year in my career and
hey fell dramatically when I became head of cardiology. So
or those people who are seriously interested in a research
areer, my bias is to do the research and not get involved
ith administrative responsibilities, except for your own
urvival. You may need to have some sort of a power base to
e able to determine what it is you would like to do.
r. Holmes: That is true, although I would add that if your
areer is based upon developing strategies, or taking care of
roups of patients, or doing population research, then
ometimes you are in a very good position as an adminis-
rative head to hire the people necessary to make that
appen and to carry forward your vision.
r. Zipes: Besides payback for the successes of a career, an
dministrative post may help you put policies into place that
ou have developed and would now like to take control and
ove in that direction. Also, some of the best chiefs I have
ver interacted with are those who really have a love for the
nstitution and a love for the science and they want to see
oth propagate.
As for your other question, as to whether we are going to
ut any field of science out of business by curing cardiovas-
ular disease, I do not think there is a need to worry about
hat just yet.
uestion: My question pertains to Dr. Holmes’ talk on the
nvasive cardiovascular translational scientist. The examples
ou presented are very interesting, and we can aspire to be
ike the people you discussed. Obviously, it takes a lot of
ard work, dedication, and time. I have a PhD in cellular
olecular biology, went through internal medicine, chief
esidency, a cardiovascular fellowship, and am in my third
ear applying for interventional cardiology. Do you feel that
t is essential to have that one year of interventional
ardiology training? The people you spoke of probably had
hat interest and drive to do those procedures and go into
nterventional cardiology, but they are doing zero proce-
ures today. Was that year essential to get where they are
ow or to get the focused projects that they need?
r. Holmes: That is a great question, and I think the
nswer is yes, it is important to put in that year. It is
mportant to be immersed in the clinical arena for a certain
eriod of time, to know the problems that are faced by the
atients or in terms of the system itself, to know what it
eels like, then actually having been there is essential. All of
hose individuals would agree. They were interested in
aking those relationships, and that was part of that
rocess; being side-by-side, facing the same sweaty issues.
nce you have that relationship, you can move ahead and
uild on those relationships, and they have done that. All of
hem would say it was a tremendous year, not a wasted year.
hey picked up the currency of the field.
r. Zipes: Our interventional cardiologists are the most
ought-after collaborators within our program right now.
heir skills, their knowledge, their appreciation of the croblems as well as their ability to attack the problems in
nnovative fashion are very important elements in our
esearch team. I am glad they took the year to get interven-
ional training and I am glad that they are in our institution.
uestion:How much basic science research do you need to
now to become a clinical investigator, and if you do not
ave much basic science training, how do you go about
etting it? Also, if you are in an institution that does not
rovide a good infrastructure for clinical or basic research,
ow do you pursue a career as a clinical investigator or in
cademic cardiology?
r. Fuster: In regards to how much basic science you need
o become a translational researcher; all I can say is you
ertainly need it. I have a PhD and spent three years in
etting it, but if I had to start again, I probably should have
tudied basic science at least for one or two years. I got into
field that was evolving, and I have been able to carry
hrough successfully with NIH, but this is getting tougher.
In terms of your institution, if you are not in the right
nvironment, move out. Only you can decide what you
ant; if what you want is to succeed in an academic career,
ou will become a neurotic wreck staying in a place that
oesn’t provide what you know you need and want. It may
ake time to find the right place, but that is what I would do.
uestion: I am starting my interventional fellowship next
ear. How do I go about continuing my career in interven-
ional cardiology and then move on to the field I am
nterested in? Unfortunately, my institution does not have
uch in the way of research in this particular field.
r. Fuster: That is a rather complex question, and I say go
ith your gut feelings. You have to get down to earth and
sk, “What am I going to be contributing to, and where is
he best place to make that contribution?” Be very practical
nd allow yourself to guide you in one direction or the other.
r. Bonow: You have heard how important environment is
nd how important actions are. If you are not in the right
nvironment, then the advice from Dr. Fuster is correct.
hat gut instinct, as he called it, would be the indication
hat you have the fire in the belly to do research and you
ave great curiosity about problems you can solve. It might
e that you need to look at the institution.
r. Fuster:We are not suggesting making a hasty decision.
any times we become impatient because we want to
chieve everything rapidly. Give it time, be patient, and go
tep by step.
uestion: It is clear that you have to have the fire in the
elly and that in any academic career you must be commit-
ed and dedicated over the long term. But what about the
ther fires that we may have, such as the fires we may feel
or teaching or getting involved at the bedside?
r. Fuster: While we are discussing academic approaches
o life, we also are talking genetically. Whatever the fire is,
ust follow it and find out who you are.
r. Holmes: There are many different sorts of fires. You
an find incredible rewards in a lot of different areas in
ardiovascular disease. For instance, you might say my
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October 4, 2005:5A–72Ability to interact with scientists is really fun, but what I
eally want to do is to look at population approaches to
isease. Therefore, perhaps you get involved in something
hat is incredibly valuable to the practice of medical care,
uch as the American College of Cardiology Guidelines
pplied in Practice Program. If that is what you would like
o do, there is tremendous opportunity to do that, but only
ou can decide what it is that lights your fire.
r. Zipes: I want to speak to family issues, which are
ritical. Do not sacrifice your family for your career. If you
iss your 7-year-old son’s birthday, you can never make it
p and he never forgets it. Spend time with the family.
oach Little League. Do all the things that are important,
ecause when you get the gray hair that we have and have
one your research, one of the most important factors in
our life is your family; do not become estranged from your
ife and children. At times, you need to stay in the lab with
n experiment that is working and you may get home late
or dinner, but in the main, make the decisions that are
mportant for the family. Family comes first!
r. Berk: I totally agree. As I said in my presentation:
nvolve your family, take your kids to the labs, take your wife
o the meetings, let them know what it is you are doing so
hat they are part of that. If you are happy and you come
ome happy and excited, they are going to naturally want
ou to be that way, so the more they understand, the happier
hey will be. That said, there is always this ambivalence of,
Do I agree to write one more paper, chair one session, go
o one more meeting, show up Saturday morning in
ashington to talk to all of you?”
But some of these issues—I call it ambivalence—are
nresolvable. To be successful, you have to learn to live with
he fact that you are never going to resolve this, and it is
lways going to be an issue. If you recognize that fact, then
t least when you get up every morning, you are cognizant
hat “I am going to have to deal with it and do it
uccessfully.” Then most people figure out good mecha-
isms to do that.
r. Zipes: One approach that worked for me was I did all
f my writing at home. Obviously, you do the experiments
r whatever in the lab and at the hospital, but after dinner
nd the weekends, where it was just the writing of the paper,
did all of that at home. That way, my wife and children
lways saw me there and I could take a break and go out and
hrow a ball with the kids or whatever.
uestion: There is no doubt in my mind that most of us
ill have a career change. How do chairs of cardiology look
o junior faculty when they make a career change, and what
atal mistakes would you advise us to avoid if we are making
career change?
r. Berk:Do not make it in isolation. If you are feeling that
ome aspect of your career is not very satisfying right now,
ou need to communicate that to your chief. Part of a good
hief’s role is to mentor you, point out your talents, talk
bout what is not satisfying in your current career, and help
uide you towards a better career. As chiefs, we invest a lotf time in our fellows and in our junior faculty. You are the
urrency that we are judged on, and if I have invested a lot
f my time and energy in a junior faculty member, I want
hat person to succeed.
When people are making career changes, that frequently
s the time they need to acquire new skills. It is the chief’s
ob to help them choose where they are going to get the
kills and to know whether our institution is the place to do
hat.
VII. CARDIOVASCULAR GENETICS, GENOMICS, AND
ROTEOMICS: CAREER OPPORTUNITIES ABOUND
hristine E. Seidman, MD (Harvard Medical School and
the Cardiovascular Genetics Service, Brigham and
Women’s Hospital, Boston, Massachusetts)
he application of genetic, genomic, and proteomic ap-
roaches to discover cause, understand pathophysiology,
nd ultimately to treat cardiovascular diseases has garnered
onsiderable excitement among physician-scientists. The
pportunities to participate in these novel investigative
ethodologies are many, whether as a research leader or as
n academic practitioner. Molecular genetics and genomics
s particularly rewarding for physician-scientists, because
hese disciplines require clinical skills and insights as well as
asic research methodologies. For me, these fields of inves-
igation satisfy both a desire to participate in creative
iscovery and real opportunity to practice medicine. If the
onsiderable technical advances in genetic, genomic, and
roteomic platforms are going to realize their full potential
or creating powerful new tools in modern medicine,
linician-scientists must contribute to interdisciplinary
eams that will transform biomedical potentials into clinical
ealities. Some medical disciplines appear more proactive in
ssembling the interactive teams needed to harness these
ethodologies to solve human disease. For example, the
ich collaborations between oncologists and cancer research-
rs have promoted a remarkably rapid pace in the discovery
f the molecular causes of malignancies, in the definition of
arly serologic markers of disease, and in the identification
f signatures associated with aggresive cancer properties,
ork that has fueled the design of novel rationale therapeu-
ics. These same opportunities exist throughout cardiology
o foster a better understanding of the causes and cures of
eart disease.
In the context of my research laboratory, we use genetics,
enomics, and transcriptional proteomics to discover the
olecular causes of cardiovascular disease, and use this
nformation to build models appropriate for deciphering
isease mechanisms and for defining potential therapeutic
argets. This work integrates colleagues who are trained in a
ariety of different career paths including clinical cardiology,
opulation science, molecular and cell biology, and bioin-
ormatics. Therefore, the “lab” is a virtual place that includes
linical, computational, and wet-bench space.
Molecular genetic investigation of cardiovascular disease
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October 4, 2005:5A–72Aegan over 20 years ago with the study of single-gene
efects. My research in this arena was spurred by a long-
tanding clinical interest in cardiac remodeling; faced with
ny one of a myriad of different adverse stimuli, the
yocardium changed in one of two distinct patterns,
ecoming hypertrophied or dilated. Although the clinical
nd histopathologic manifestations of either remodeling
athways were well described, clues about the molecular and
ellular processes that triggered cardiac hypertrophy or
ilation were few. Human molecular genetic study of
amilial or inherited forms of cardiac remodeling provided a
owerful new approach to discover the pathogenetic mech-
nisms that caused cardiac remodeling. My laboratory
ndertook clinical evaluations of families with inherited
ardiac pathologies, assessed the mode of disease transmis-
ion, and used molecular genetic analyses to determine the
hromosome location of disease genes and ultimately de-
ned disease-causing mutations. This approach, sometimes
ermed reverse genetics, while initially focused on heritable
eart disease in families, is also the fundamental principle
n which the discovery of genes that contribute to heart
Table 22. “Solved” Monogenic Cardiovascular
Cardiomyopathies
Metabolic disorders
LDL
LDL
HDL
Lp (a)
Homcystinuria
Hemochromatosis
Amyloidosis
Vascular disorders
Marfan syndrome
Ehler-Danlos IV
Supravalvular aortic stenosis
Osler Weber Rendu (HTT)
Coronary disease
Cardiomyopathies
Hypertrophic
Glycogen
Dilated
Dilated/conduction system disease
Barth’s syndrome
Duchenne muscular dystrophy
Friedereich’s ataxiaisease in the general population is based. gThe power of genetics and genomics comes from the
nbiased approach in which the entire human genome is
nalyzed. With the development of extensive libraries of
ingle nucleotide polymorphism (SNPs) or non-functional
eoxyribonucleic acid (DNA) variants that are scattered
hroughout the human genome, genes that cause or con-
ribute to cardiovascular pathology can be precisely located
n a particular chromosome region. This genomic mapping
rovides information that directs subsequent analyses to
olecules encoded within the region with biologic relevance
o the disease. Furthermore, the incredible wealth of infor-
ation about gene expression and function in the hearts of
any model organisms as well as in humans provides
onsiderable information for interrogating the relevance of
otential candidate genes in cardiovascular pathology.
aken together, datasets that allow genomic mapping of
isease and annotated gene information have consider-
bly accelerated the pace of cardiovascular disease gene
iscovery.
onogenic cardiovascular disease. Human genomic re-
earch efforts has changed a once bland map of the human
ase: Metabolic/Vascular Disorders,
e Locus Gene Product
3 apolipoprotein B
13.2 LDL receptor
23 apolipoprotein A-1
6 Lp (a) lipoprotein
22.3 cystathionine b-synthase
1.3 HLA-H
11.2 Transthyretin
21 Fibrillin
4.3-q31 Type III collagen
1.2 Elastin
Endoglin
MEF2A
Cardiac troponin T
13-q13 Myosin binding protein-C
12 Cardiac b myosin
2 a tropomyosin
Cardiac actin
2 Regulatory light chains
4 Titin
PKAG2
LAMP2
14 Cardiac actin
12 Cardiac b myosin
2 Cardiac troponin T
4 Titin
2 Phospholamban
12 ABCC9
1 Lamin A/C
5 ?
Tazaffin
1 Dystrophin
FrataxinDise
Gen
2p2
19p
11q
6q2
21q
6p2
18q
15q
2q2
7q1
9q
15q
1q3
11p
14q
15q
15
3, 1
2q2
7
X
15q
14q
1q3
2q2
6q2
12p
1q2
3q2
X
Xp2enome into one that today is littered with annotation of
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October 4, 2005:5A–72Aisease genes for virtually every type of cardiovascular
athology (Table 22). Our appreciation of the role of genes
n lipid and cholesterol metabolism has been greatly ex-
anded and enriched since the early discoveries of mutations
n the gene encoding the lipoprotein receptor. Other sys-
emic disorders including hypertension and diabetes that
normously increase the risk for heart disease can also arise
rom single-gene mutations. Primary disorders of the heart,
ypertrophic and dilated cardiomyopathies, and cardiac
lectrophysiologic disorders can arise from inherited gene
uations. Discovery of the genetic contributions to struc-
ural malformations affecting the vasculature, including both
he great vessels and the microvasculature and congenital
eart malformations are increasingly identified.
In addition to providing new and fundamental biologic
nformation about specific diseases, knowledge of the mo-
ecular basis of these diseases has also changed the way in
hich we clinically evaluate and manage disease in patients.
or example, given a genetic substrate for cardiovascular
isease, the clinician must look beyond an individual patient
o all first-degree family members who are at risk for
eveloping the disease. While families are often aware of
ncreased risk because of familial relationships, health care
ystems have yet to incorporate appropriate mechanisms to
ounsel and evaluate family members. Similarly, the indi-
idual with genetic risk for cardiovascular disease but
ithout overt disease manifestation poses another new
hallenge for the new field of cardiovascular genetics. These
ndividuals define a new and preclinical phase of cardiovas-
ular pathology—when traditional signs and symptoms are
ubtle or absent. Detailed assessment of cardiovascular
orphology and hemodynamics that characterize this phase
ay uncover new clues about disease initiation and may
ndicate factors that stimulate conversion from genetic risk
Table 23. “Solved” Monogenic Cardiovascular
G
Arrhythmias
Prolonged QT syndrome 3p2
7q3
11p
Brugada’s syndrome 3p2
Lev’s disorder 3p2
Familial heart block 19q
Congenital sinus node dysfunction 4p
Atrial fibrillation 1
ARVD 1q3
17q
6p2
Exercise-induced VT 2
Congenital disorders
Velocardiofacial syndrome 22q
Holt-Oram syndrome 12q
ASD with AV block 5q3
ASD/atrial aneurysm 5p
ASD
Carney’s syndrome 17qf genetic disease. Insight into this earliest disease phase mrovides enormous opportunity for interventions that may
rolong disease-free duration or attenuate cardiovascular
isease expression. Clinical investigations that harness novel
maging modalities as well as transcriptional and proteomic
nalyses have great potential to teach us more about recog-
izing and some day treating pre-clinical disease (Table 23).
Another area that is ripe for discovery is the relationship
etween genetic cause and phenotype expression. Consider
ypertrophic cardiomyopathy, an autosomal dominant dis-
rder. There are 10 different genes that carry literally
undreds of independent mutations that produce signs and
ymptoms that appear to clinicians as a single pathologic
ntity. Yet some of these patients will have profound
eterioration in cardiac function and require cardiac trans-
lantation, some will experience sudden cardiac death, and
ome will develop few symptoms with mild disease mani-
estations and live long and functional lives. Can we harness
ur knowledge of the considerable molecular diversity of
auses of cardiomyopathy to define those patients who need
n implanted cardioverter-defibrillator and those who will
eed only medical treatment? Can we determine if clinical
esponse to pharmacologic therapies relates to underlying
enetic etiology? In short, can we use this wealth of genetic
iscovery to inform our clinical decisions for patient man-
gement? To answer these critical questions requires collab-
rative study by cardiovascular clinician-scientists and basic
esearchers.
The discovery of genetic basis for inherited cardiovas-
ular disorders has also allowed directed questions about
linically related heart disease of unknown cause. For
nstance, hypertrophic cardiomyopathy of the elderly is a
ell-described disorder with a related but usually distinct
ardiac morphology from familial hypertrophic heart
isease. Knowing the latter is caused by sarcomere gene
ase: Arrhythmias and Congenital Disorders
ocus Gene Product
SCN5A
HERG-K channel
KVLQT1
SCN5A
SCN5A
?
Plakophilin
Plakoglobin
Desmoplakin
Ryanodine receptor
-q11.2 TBX1
TBX5
Nkx2.5
GATA4
cAMP-dependent protein kinaseDise
ene L
1-24
5-36
15.5
1-24
1-24
13
1
21
4
11.21
2
5utations allowed studies to determine if elderly-onset
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October 4, 2005:5A–72Aisease was genetically related. It would be hard to
nswer this question using family studies since parents of
ndividuals with diseases that manifest late in life are
ften deceased. But we can begin to ask this question
nother way, by direct assessment of whether cohorts of
ndividuals with elderly-onset hypertrophy have gene
utations. These analyses were remarkable: 20% of
ndividuals with elderly-onset hypertrophic cardiomyop-
thy have a sarcomere protein gene mutation in the same
enes that cause familial autosomal dominant and early-
nset hypertrophic cardiomyopathy. Notably, the precise
esidues altered by late- and early-onset disease are not
he same, implying that there are important biologic and
erhaps biophysical differences in the consequences of
ifferent mutations in a given gene.
enetics of complex traits. How do we use genetics and
enomics to move from single-gene defects that cause
ardiovascular disease to more complex traits, an area of
ntense investigation and excitement? One of the most
roductive approaches used to examine the genetic contri-
ution to cardiovascular diseases that occur commonly in
eneral populations are molecular association studies.
enomic libraries of SNPs provide information about
equence variants that are closely linked to virtually any
ene. Study of whether particular SNPs are enriched in
ffected populations, therefore, can provide indirect analyses
f the relevance of that candidate gene in cardiovascular
athology. While the success of candidate association stud-
es in uncovering previously unknown molecules in heart
isease has been limited, whole-genome association analyses
old more promise for success. These techniques take an
nbiased survey of the genome for chromosome regions that
ontain molecules potentially involved in cardiovascular
isease. One significant problem with these whole-genome
ssociation studies is that the number of SNP analyses
erformed to cover the entire genome is large. For sufficient
tatistical power to compensate for multiple testing, sample
izes must be huge. Further, to be certain that any associ-
tion is valid, replication in an independent study cohort is
eeded. In part, these complexities will be solved with better
rchitectural information of the human genome. For exam-
le, construction of haplotype maps (genomic regions that
ontain SNPs that vary in a predictable pattern in popula-
ions) will allow fewer genetic hypotheses to be tested yet
till allow comprehensive interrogation of the human ge-
ome. Emergence of the human haplotype map (or hap-
ap) as well as the improved biostatistical algorithms and
ther statistical tools indicate that population genetics will
ontinue to grow and to be powerful for defining new genes
hat are critical in cardiovascular pathology.
In the not too distant future, analyses will move from
ssociation studies that examine sequence variation or SNPs
hat occur throughout the whole human genome, to direct
etermination of the entire sequence of the human genome
n patients. The speed at which whole-genome sequencing
s becoming feasible is staggering given that in the 1970s pNA sequencing methodologies could define only hun-
reds of nucleic acid base pairs in a day. Technical advances
n nucleic acid biochemistry and automation today allow the
etermination of 400 to 600 base pair routines in just hours.
hereas contemporary sequence approaches are based on
elective analyses of particular DNA fragments, application
f nanotechnologies and bioinformatics allows comprehen-
ive genome sequence strategies. For example, total genomic
NA can be sheered and attached to millions of nanobeads
n a microscope slide for individual amplification by poly-
erase chain reactions. Each individual nanobead serves as
platform for simultaneous fluorescence-based DNA se-
uencing of each DNA fragment. The millions of base pairs
etermined by DNA sequencing are then reassembled using
ioinformatics. With further development these emerging
latforms will soon allow researchers to examine a subset of
enes or the entire genome in one patient or a large cohort
f patients with heart disease. With the ability to have such
vast array of fundamental genetic data, cardiovascular
linician-scientists will have the opportunity to design
owerful questions to test whether genotype informs clinical
henotypes and the risk for cardiovascular disease.
More sequence data on more patients with cardiovascular
isease is unlikely to provide a simple solution to how and
hy heart pathologies occur. But this data will indicate
trategies to discover signals that trigger genetic predispo-
ition or risk into clinical disease. Development of animal
odels of human disease is likely to remain a critical
pproach to investigate pathophysiologic mechanisms.
hese models should serve as a test for novel therapeutics
nd will allow us to begin examining the modification of
nfluences of disease expression, including genetic, environ-
ental, or lifestyle factors.
uilding better animal models. Contemporary ap-
roaches for modeling human cardiovascular disease largely
ely on genetic engineering of mice. These models allow for
he study of the mammalian heart with physiology that in
arge measure approximates human heart structure and
unction. With the discovery of a genetic risk factor for
ardiovascular disease or possibly a human gene mutation,
ne can engineer the corresponding genotype into the
ouse genome and assess longitudinal changes in cardiac
orphology, cell biology, and transcriptional profiling.
hile this approach benefits from the extensive power of
ouse genetics, this remains a very expensive and laborious
ndeavor. With considerable advances in comparative
enomics, other organisms have emerged as excellent tools
or studying human disease. The translucent zebrafish has
een used by multiple investigators to examine genes im-
licated in structural diseases of the heart and vasculature as
ell as in pathologies such as hypertrophic and dilated
ardiomyopathy. Zebrafish can be genetically manipulated
hrough injection of morpholinos or oligonucleotides that
re designed to disrupt normal ribonucleic acid (RNA)
rocessing. The consequences of these manipulations can
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October 4, 2005:5A–72Accur within 72 h, allowing a rapid assessment of molecules
otentially implicated in a particular cardiovascular disease.
With such wonderful models, researchers can delineate
he cellular and molecular processes that occur early in the
nitiation of disease as well as later when compensatory
echanisms are also evident. A general approach to exam-
ning these processes is transcriptional and protein (pro-
eomic) profiling. Cardiac expression of RNAs is analyzed
y hybridization to gene sequences affixed to microarray
lides (or chips). While this approach provides data about
hether RNAs show increased or decreased expressed in the
ontext of disease, microarray analyses are most robust when
hanges are large.
An alternative approach is to directly examine the num-
er of RNAs that are present in the cell. This approach,
ermed Serial Analyses of Gene Expression (SAGE), cap-
talizes on the advances in high throughput determination
f nucleic acid sequences. For example, to investigate the
arliest changes produced by a human gene mutation that
auses hypertrophic cardiomyopathy, my laboratory has over
0,000 different RNAs by SAGE that are found early and
ate in the disease. This SAGE dataset is a robust collection
f molecules that has the potential to indicate the earliest
ignals triggered by a gene mutation that initiates changes,
hich ultimately herald overt disease. While today SAGE
nalyses are primarily used to study models of cardiovascular
isease, this same approach could also be harnessed to
rovide a transcriptional profile of human heart tissues.
roteomics. Transcriptional profiling will undoubtedly be
trengthened by incorporation of proteomic information.
ignaling pathways can be triggered or repressed by changes
n protein activity as well as by changes in protein levels. To
e able to identify the full impact on cell and molecular
athways that lead to cardiovascular disease, one needs to
onsider the activity of critical kinases and phosphatases,
olecules that affect the function of target proteins and
athways by reversible phosphorylation. Proteomics allows
he survey of protein levels and provides data on the
odification state of these proteins. Proteomic analyses can
e performed on selected subcellular fractions of cells, whole
ells or tissues, or body fluids (blood, serum, and urine).
roteomic surveys are already being harnessed to examine
eart disease. For example, proteomic analyses of blood
aken directly from the coronary sinus of patients undergo-
ng cardiac catheterization may provide novel insights into
ardiac metabolism in health and disease. Proteomic anal-
ses of serum in hypertrophic cardiomyopathy patients
ndergoing alcohol septal ablation for outflow tract obstruc-
ion may provide new information about the immediate
esponse to acute myocardial infarction.
onclusions. From genetics and genomics, from transcrip-
ion profiling and proteomics, and from bioinformatics to
ioengineering, there are incredible opportunities for car-
iovascular discoveries. While no one researcher is able to
aster all of these techniques, compilation of these strate-
ies through collaborative teams should provide powerful mew advances for heart disease research. Cardiovascular
nvestigators are well positioned to contribute in all arenas
f this research program—as the physician who evaluates
nd performs patient interventions, as the discoverer of
enetic risk and genetic disease, as the molecular modeler
ho elucidates disease mechanism, as the clinician who
ranslates molecular discovery into patient care. With the
ower of modern technology and the talent of cardiovascu-
ar trainees, the future for improving our patients’ lives has
ever been brighter.
uestion and Answer
r. Fuster: I would like to get a sense of how you see the
eld evolving. We see the new technology that you are
laborating on; will you be able to tell us much more rapidly
hat is really going on in terms of associations and
roteomics.
r. Seidman: Association studies that examine a single
ene and assess whether or not it is fundamentally involved
n disease pathogenesis have limited power and will likely
ive way to genome-wide association studies. I believe that
he tools of modern genomics will make genome-wide
ssociation studies feasible and important. A critical issue, in
hich cardiovascular physician-scientists should become
ctively engaged, is how to define the cohorts for study. In
ther words, what heart disease phenotypes should we
nterrogate by genome-wide association? The more specif-
cally we define a cohort of patients for study, the more
ikely they will share a genetic contribution to their disease.
ith the considerable advances in imaging and serologic
arkers of complex conditions such as coronary artery
isease, we should be able to group patients into similar or
issimilar phenotypes better. This is important work that
nly outstanding clinicians can do, yet it is essential for
roductive genomic science.
Another interesting question is going to be whether
ariants in genes that cause monogenic disorders also
ontribute to the risk of common disease. For example,
ould some variants that in genes cause long QT syndrome
lso contribute to arrhythmias that arise only under stress?
hese scenarios of gene-environment interactions that con-
ribute to disease are unlikely to be recognized as inherited
raits. With the ability to rapidly sequence known genes that
ause cardiovascular disease, researchers will be able to tease
ut more subtle associations.
We have also not addressed the ethical aspects of some
enetic information. If you want to know how to look at an
ndividual at risk for developing hypertrophic cardiomyop-
thy in the context of a family, right now, you can do
chocardiography and an electrocardiogram serially until
hey are 40 years of age or you can do a gene test. The same
pproach is taken with long QT syndrome—serial evalua-
ion or gene-based diagnosis. As clinicians we want to be
ertain of a diagnosis, but given gene-based diagnosis we
ay need to modify our management strategies. For exam-
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October 4, 2005:5A–72Ale, if a long QT disease gene is found in an individual who
as had sudden death in family members, will you elect to
mplant a cardioverter-defibrillator regardless of symptoms?
think there are enormous opportunities to address these
hallenging questions in clinical medicine.
uestion: For cardiac fellows who enter your lab, how
uch recent experience do you expect them to have prior to
ntering your lab?
r. Seidman: We have had fellows as well as very accom-
lished PhD scientists come to the laboratory who were
nitially unsure which side of a pipette goes into a test tube.
oth have been successful. As an MD, I am aware of my
linical strengths and my experimental weakness. Many in
he audience may know that I co-run the laboratory with my
usband, a brilliant PhD scientist. We believe that we
rovide a complementary matching of talents to the labo-
atory, which has been productive. He examines research
uestions from a technical perspective, I examine them from
biologic and pathologic perspective. Although much of the
roteomics, genomics, and bioinformatics language used in
he research laboratory is at first intimidating to physicians,
here is no need for this. It is like any new vocabulary. Once
ou have spent three weeks in the cardiac catheterization
ab, you acquire the language and protocol appropriate for
tudying patients; the same is true in the basic science
aboratory. There is no need to think that you have to have
PhD to do basic science.
r. Fuster: Say I am a first-year fellow at the University of
entucky and I just listened to you. And I realize this is my
eld; I really want to work with you, and I give you a call.
hat advice would you give me?
r. Seidman: If someone wants to do what I call discovery
esearch, where you are going to find out something that no
ne else knew before—to find a gene, for example—you are
oing to have to invest three to four years to do it. On the
ther hand, if you want to use the discovery information
hat someone else has already generated, you can begin to
sk clinical questions as soon as you are ready to sign on to
he lab. It is a matter of what you consider basic research. I
o not think basic research is that different from good
linical research anymore; genetics and genomics are enor-
ously interactive procedures. Go find the lab that is
lready doing this work and, if you do not have three to four
ears to discover a calcium-signaling program, ask another
uestion that capitalizes on the information someone else
as already generated.
uestion: You mentioned earlier that you found genetics
nd genomics after some dismay you felt when treating
eart failure patients. I am curious how clinical medicine
lays a role in your career now. In other words, in advising
uture fellows who have varying interests, how does it all pan
ut?
r. Seidman: I continue to see patients. I no longer attend
n the wards but I care for outpatients and for my
ospitalized patients. I have tailored my patient population
o be those individuals who have unexplained cardiovascular Sisorders. I see many patients with primary cardiomyopa-
hies, known genetic disorders such as Marfan syndrome,
nd very few people with coronary disease unless they have
typical manifestation—very early onset, a very malignant
henotype that appears disproportionate to their risk fac-
ors. There is a great need for taking care of patients in the
ontext of genetic disorders, and it is a great career track for
esearchers who want to continue to excel at clinical
edicine by focusing on a particular niche.
uestion: Senior investigators typically advise us to focus
ur attention on one theme. But as an early investigator, as
fellow, it is hard enough to find a project yet alone be
ocused in one specific area. Can you comment as to when
ou should know this is your area to work on and that it is
ime to focus?
r. Seidman: The rule is focus, focus, and focus, in the lab
r in clinical medicine. The more you invest in a particular
rena, the better you get at it, and the more you see breadth
f disease and the opportunity to address the burning
uestions about the disease. So, focus is the way for you to
ecome an expert and be the go-to person recognized by
our peers within your institution and eventually outside
our facility.
When beginning a career, however, it is wrong to focus
ntil you are committed to a program. I tried several very
ifferent research projects before I decided that genetics was
oing to drive my career. PhD scientists have that oppor-
unity to shop in their graduate programs. They go to
ifferent laboratories and pick up a couple different tech-
iques and get a sense for each experimental system. Those
f us with medical degrees do not do that so much, in part
suspect because of the long clinical training we have been
hrough prior to starting some research. Yet, it is enor-
ously important to be able to say when a research direction
able 24. Women and Academic Medicine
omen in medical school
Applicants to medical schools 46.6%
New entrants to medical school 45.8%
Graduates 43.2%
Women in residency programs 38%
omen in medical constituencies
Internal medicine residents 39%
Cardiology trainees 10%
ACC membership 6%
AHA Clinical Cardiology Council membership 9.8%
omen faculty
Tenured faculty who are women 15%
Percent of women who are tenured 16% (33% of men)
f the 27,051 women faculty in 2002
Professors 11% (31% of men)
Associate professors 19% (24% of men)
Assistant professors 50% (36% of men)
Instructors 18% (8% of men)
New faculty hires 36%
Faculty departures 30%
Department chairs 8%
Associate chair/vice-chair 19%ource: AAMC data, 2000 to 2001.
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October 4, 2005:5A–72Ar problem is not what you want to do and then shift to
omething else. It does not mean you do not want to do
esearch, but it is wrong to stay and focus on something if
ou are not interested.
uestion:How do you choose a good collaborator? A lot of
cientists do not like working with clinicians because they
elieve clinicians have some kind of inferior understanding
f science. The second part to this question is: how do you
efine the relationship of a collaborator? Who takes the
ead? Is it you or the PhD scientist who has the original
cience you are asking for?
r. Seidman: Isn’t this very much sort-of the same conflict
hat we see sometimes between the fellow and the senior
esident and between the nurse and the physician at the
edside? How do you work with people? How do you figure
ut who is in charge, who is going to do the grunt work, and
ho is going to get the credit?
I do not think you necessarily choose a collaborator. You
hould plan to collaborate in all aspects of research. That
eans there will be lots of give and take. While you cannot
emand that any researcher provide you the technology to
sk a particular question, you can almost always structure an
xperiment so that it is a win-win situation for both
ndividuals. That is how collaborations work best. I am less
nterested in who is going to be the senior author than
etting the answer to the question we are trying to ask; let
uthorship issues work themselves out and be generous.
ecause you should look for collaborations with individuals
ho do not have your skill set, there will be a need for
penness and trust. That way both collaborators learn from
ach other and advance the research agenda.
uestion: You were mentioning, before, the concept of
ollaborative work and a team effort. You also made refer-
nce to the need for a niche physician who takes care of
atients with these various genetic disorders. I was wonder-
ng what role those physicians play in collaborating with you
nd how they fit into the academic infrastructure, in the
ontext of the challenges we have talked about at this
eeting, in terms of promotion, and so on.
r. Seidman: Because of the way in which human genetics
esearch has evolved, my laboratory first focused on rela-
ively rare diseases. We found individuals with these dis-
ases because we read papers authored by talented, acade-
ician clinical investigators. (Although clinical reports have
omewhat fallen out of fashion, insightful detailed informa-
able 25. Gender Differences in Academic Careers:
aculty With Children
Women Men p Value
nstitutional support
Research funding 46% 57%  0.001
Secretarial support 0.68 FTE 0.83 FTE 0.003
ublications 18.3 29.3  0.001
elf-perceived career progress 2.6 3.1  0.001
areer satisfaction 5.9 6.6  0.001mTE  full-time employee.ion about any disease remains a very important way to
dvance medicine and science. These point out the nuances
f clinical disease that can initiate research questions that
oster discoveries.) We have collaborated with clinicians
rom around the world. My responsibility to those individ-
als is that they are an equal partner and have the full
uthorship rights as somebody who is making the gene
iscovery. The publications from my laboratory often tend
o have many authors listed; I think that is perfectly
ppropriate and indicates collaborative science.
You are also asking whether long-term collaborations
ffect promotions and academic advancement. This is an
mportant question, one that cannot be globally answered,
xcept to say that when each member of a team has
emonstrated expertise in a particular area, promotion is less
roblematic. So become an expert and the go-to person in
ny collaboration and I believe your accomplishments will
e recognized.
A related question is how to define a career track that
romotes an individual who does not want to be in the wet
ab but who can translate genetic discovery into clinical
edicine. For example, what are the earliest signs of
enotype/phenotype conversion? That is a good transla-
ional biology question that my laboratory cannot anwer. It
s a fine project for a clinician who is well versed in genetics
ut not working in a DNA laboratory. Given the experience
n clinical trials, the cardiac academic community knows the
alue of teamwork and that should help to solve collabora-
ive issues when promotions come around.
r. Fuster: It seems there is a paper every week on
olymorphisms and some specific disease or condition; then
hree weeks later something is published that refutes this
ompletely. Is there a lot being published in genetics by a
ery small number of people, and is there confusion in the
eld?
r. Seidman: For association studies to be worthy of
ublication in a reputable journal I believe they need to
rovide statistical analyses to account for potential con-
ounding issues such as multiple testing, and also demon-
trate independent validation of the result in a second
ohort. Until both are completed, the experiment is not
one. The standards for publication of association studies is
uite variable, and so yes, there is much confusion about
enetic contribution to common cardiovascular diseases. I
elieve that with the newer tools that we discussed, more
efinitive information will be obtained that will hopefully
educe confusion caused by poor science.
VIII. WOMEN AND ACADEMIC MEDICINE
lizabeth G. Nabel, MD (National Heart, Lung, and
Blood Institute, Bethesda, Maryland)
ccording to the Association of American Medical Col-
eges (AAMC), about one-half of medical school graduates
re women, but there is a fall-off as you look at tenured
edical school faculty (Table 24). Based on the percentages
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October 4, 2005:5A–72Af women at different points of their medical training,
omen make up about 40% of internal medicine (IM)
esidents, but only 10% of cardiology trainees.
Once through medical school and training, how many
omen are choosing research careers? In 2002, Leon
osenberg (32) of Princeton University co-authored a paper
xamining the gender gap in physician-scientists. His con-
ern was to stimulate the number of physician-scientists in
cademic medicine in this country. To this end, he analyzed
ata obtained from the AAMC, the National Institutes of
ealth (NIH), and the Howard Hughes Medical Institute
ertaining to the expressed research intentions or research
articipation of both male and female medical students in
he U.S. The report documented a statistically significant
ecline in the number of men and women who have overtly
xpressed an interest in academic research careers in the
ecade between 1987 and 1997. Not only was there a
ecline in both genders, but women were less likely than
en to be interested in a research career. Furthermore,
hile female medical student participation in the Medical
cientist Training Program and the Howard Hughes Med-
cal Institute/NIH-sponsored Cloisters Program has in-
reased, it lags far behind the growth in the female popu-
ation in medical schools.
The researchers noted three worrisome trends in the
esearch career intentions and participation of the nation’s
edical students: a decade-long decline for both men and
omen, a large and persistent gender gap, and a negative
ffect of the medical school experience for women. They
oncluded that these trends presage a further decline in the
hysician-scientist pipeline. As a country, we cannot afford
able 26. Institutional Support and Professional Outcomes
Variable
Adjusted Means
Women M
aculty with children, n 652 842
Receive research money from institution, % 46.5 57
Secretarial full-time equivalents 0.68 0
Research assistant full-time equivalents 0.93 0
Funded grants (1992 to 1994)
Any grants, % 41.2 43
Grants, n 2.6 2
Total career publications, n 18.3 29
Self-perceived career progress§ 2.6 3
Career satisfaction 5.9 6
aculty without children, n 297 160
Receive research money from institution, % 51.4 51
Secretarial full-time equivalents 0.87 0
Research assistant full-time equivalents 0.90 0
Funded grants (1992 to 1994)
Any grants, % 39.9 38
Grants, n 2.7 3
Total career publications, n 17.6 20
Self-perceived career progress§ 2.7 2
Career satisfaction 5.9 6
ith permission from Carr PL, et al. Ann Intern Med 1998;129:532–58. *Adjusted
ge, and marital status. †The value for women minus the value for men of the same p
On a live-point scale on which 5 indicates faster progress. On a 10-point scale ono lose, in total, the number of individuals, men or women, rho are interested in research careers, and it is critically
mportant to pay attention to the issues of why people do
ot go into research, particularly women.
Not surprisingly, similar trends are apparent at the faculty
evel. The AAMC did a study that included data from 1976
nd 1996. Among faculty who were first appointed in 1976,
2% of the men but only 10% of the women were eventually
romoted to full professor. Women took longer to advance
o full professor, sometimes twice as long. Based on AAMC
ata analyzing the 21,434 women faculty in 1996, 10% of
omen were full professors compared to 32% of men.
omen were more likely to be associate professors, but if
ou look at the data for assistant professors and instructors,
t this lower faculty level, women actually outnumber men
Table 25).
The AAMC also found that the disparities between men
nd women seem to grow even worse as you went on to
enior leadership positions within an academic medical
enter, a hospital, or a university.
arriers for women. On the surface, this may seem like
epressing information, but I would like to be very practical
nd provide some reasons why this is the situation and
ropose some strategies that we, in academic medicine, can
o to confront it.
Nancy Andrews, a faculty member at Children’s Hospital
n Boston, did a survey among her women MD/PhD
tudents (33). She asked, “Are you interested in going into
esearch? If not, why?” These are students who should be
nterested in research careers, because they are getting their
hD in addition to their MD. But the issues they typically
Adjusted Mean Difference
(95% CI)†
p Values for Effects
Gender Interaction‡
10.6 (16.4 to 4.8)  0.001 0.07
0.15 (0.25 to 0.05) 0.003 0.08
0.01 (0.31 to 0.32)  0.2  0.2
2.0 (6.7 to 2.8)  0.2  0.2
0.4 (0.8 to 0) 0.06  0.2
11.0 (15 to 7)  0.001 0.04
0.5 (0.6 to 0.4)  0.001 0.005
0.7 (0.8 to 0.5)  0.001 0.009
0.4 (11.4 to 12.2)  0.2
0.05 (0.13 to 0.23)  0.2
0.16 (0.15 to 0.48)  0.2
1.9 (6.5 to 10.3)  0.2
0.4 (1.4 to 0.6)  0.2
2.9 (7.9 to 2.1)  0.2
0.2 (0.4 to 0.1) 0.01
0.3 (0.6 to 0.1) 0.11
dical school, specialty, race (majority or minority), year of first faculty appointment,
l status. ‡Interaction of sex and parental status in a multivariate model for all faculty.
10 indicates higher satisfaction.*
en
.1
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October 4, 2005:5A–72Anfair treatment, lack of role models, and a perception that
esearch was not an attractive career pathway.
Furthermore, women in her survey perceived that it is
mpossible to combine a successful career with childbearing
nd a family life, an issue that should be important to both
omen and men, because the expectations of men entering
cademic medicine are more similar today than dissimilar to
hose of women. Most professionals will likely have a
wo-career family, and combining career time with family
ime is equally important for men as it is for women.
erhaps more women coming into the profession would
elp change the culture of the profession so that it will be
ore family-friendly, not just for women but for men as
ell.
Some of these barriers, however, are starting to break
own. When Bruce Fye was American College of Cardiol-
gy president, he addressed the issue of women in cardiol-
gy on his President’s Page in the Journal of the American
ollege of Cardiology (34). One of the salient features as to
hy there were so few women in cardiology was what he
escribed as a lack of critical mass: there were not enough
omen in the profession to really provide role models and
entors. He also felt that sometimes cardiology projected
oo much of a macho image, riding into town like John
ayne to “fix them and ride out.” He noted that cardiology
ad an image problem in terms of balancing career and
amily life. He advocated that the subspecialty really must
hange to address both women’s and men’s concerns.
areer and family. Phyllis Carr and colleagues (35) have
ointed out disparities in the way female and male faculty
embers are handled at universities. Prior to their survey,
ublished in 1998, there was evidence that women faculty
ublish less, have slower career progress, and generally have
more difficult time in academic careers than their male
ounterparts; however, the relation of family responsibilities
o gender in academic productivity was unclear, so she sent
ut a standardized 177-item questionnaire to full-time
cademic medical school faculty at 24 randomly selected
edical schools. Based on 1,979 respondents, more than
0% of time devoted to family responsibilities was spent on
hild care, which was the same for both men and women.
igure 8. Distribution of department climate ratings by gender, on a scale
f 1 to 5. With permission from the Report on the University ofn
ichigan-Dearborn 2002 Survey of Academic Climate and Activities (37).
ark bars  males, n  68; light bars  females, n  42.mong faculty with children, women had greater obstacles
o academic careers and less institutional support, including
esearch funding from their institutions (46% compared
ith 57%; p 0.001) and secretarial support (0.68 full-time
quivalents compared with 0.83 full-time equivalents; p 
.003), than men (Table 26).
Similarly, compared to men with children, women with
hildren had fewer publications, slower self-perceived career
rogress, and lower career satisfaction. The survey also
onfirmed previous observations of no significant differences
etween the sexes for faculty without children, suggesting
hat perhaps the playing fields are more level when children
re not a factor. The authors concluded that, compared with
emale faculty without children and compared with men,
emale faculty with children face major obstacles in aca-
emic careers. Some of these obstacles can be easily modi-
ed (for example, by eliminating after-hours meetings and
reating part-time career tracks). Medical schools should
ddress these obstacles and provide support for faculty with
hildren.
Not surprisingly, the family issue is not only one of
evoting time to childcare but also related to geographic
obility (36). Two-career families probably have experi-
nced this already, in terms of choices about where to go for
raining. This issue is heightened when there are choices
bout where to establish a research career or a clinical
ractice. In a study by social scientists at the University of
ichigan, women scientists were much more likely than
en scientists to be in a two-career marriage, and scientists
n two-career families were less likely to migrate than a
ne-career family. Also, the evidence suggested that while
amily constraints on women scientists’ careers generally
ppear to be weak, it becomes acute when they have
hildren. Specifically, women with children were less likely
o have the geographic mobility to pick up and move from
ne place to another; however, it is important to keep in
ind the big picture. Obviously careers are very important,
ut never underestimate the importance of family and the
atisfaction that it will give you if you choose to have a
amily as you go through your career.
Before considering strategies, let us address some of the
oncerns Nancy Andrews raised (33). Regarding financial
oncerns, the NIH Loan Repayment Program is a fantastic
rogram, and I encourage anyone concerned about repaying
ebt when you’re working towards a research career to apply
or the Loan Repayment Program. The acceptance rate is
ery high, and information can be found at the NIH web
ite (www.nih.gov). Another financial concern is that aca-
emic salaries must be competitive with practice salaries.
iven recent changes in many practice salaries, academic
alaries are becoming increasingly competitive.
ddressing family issues. What can be done to address
amily issues facing both men and women? First, we can
engthen the tenure clock if women or men need more time
ecause of family issues or whatever; the tenure clock should
ot be a problem. Also, leadership should be sensitive to
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October 4, 2005:5A–72Aarly morning and late afternoon meetings that affect the
bility to drop off or pick up a child from day care. The
nvolvement of your significant other is very important, as
hose with two-career families will learn very quickly that
hings have to be done in a compromising fashion for
verything to work. Addressing ongoing family issues is
omething neither spouse can do individually.
Will I be treated fairly? That’s a question that is asked
egularly by women. It is important to have some degree of
ransparency of salaries, resource allocation, and promotion;
nyone should know the criteria for appointment as a
ecturer, an instructor, or an assistant professor. What is the
tandard package that comes with that recruitment? What
re the expectations in terms of academic promotions? If
ou do not know the answer to these questions, ask. As you
egin your academic appointment, understand very early on
he criteria for promotion and develop a professional cur-
iculum vitae that contains objective documentation of your
cademic accomplishments.
I cannot emphasize enough that there has to be an
bsolute commitment to the promotion of women and
inorities throughout the academic ranks of senior leader-
hip within an institution. In a study conducted among
cientists and engineers at the University of Michigan, some
f the conclusions were that female assistant professors in
cience and engineering received less mentoring than other
roups; women had a higher service rate on formal com-
ittees than men, but did not chair the committees at a
igher rate; and women received fewer items in their
enegotiated contracts than their male counterparts (37).
he perception created by the data was that women were
ot being treated equally, and this was apparent in gender
ifferences ranking the “department climate.” Compared to
heir male counterparts, women rated their departments
ignificantly lower on gender egalitarian atmosphere (e.g.,
he environment promotes adequate collegial opportunities
or women, and women are appropriately represented in
enior positions) (Fig. 8). A number of similar studies have
merged at other universities. It takes senior leadership to
eriously address the issue.
For investigators just starting their research careers, what
s the future likely to bring? Perhaps the numbers are not
here they should be in terms of the number of women in
cademic medicine, but the numbers are improving all the
ime. There is now a critical mass of women in IM, just as
here has always been a critical mass of women in pediatrics
nd psychiatry. The number of women in cardiology is
ising. It is not where we need to be yet, but it is getting
etter.
areer strategies. Why do I think the climate for women is
mproving? To put it simply, we cannot afford to lose the next
eneration of physician scientists, men or women, and based
n widely reported findings in the last few years regarding
ormone replacement therapy and women with heart disease,
omen are now demanding to see women cardiologists. aAs you formulate the strategy for your scientific career,
here are several personal-level issues to address. For me, the
ost important issue is finding your passion. Just find what
ou love doing, then go out and give it your best. At the
ame time, it is very important as we go through our careers
o assess our strengths and our weaknesses. You have to be
illing to take a realistic look at yourself and say, “This is
hat I like to do, while this other area is more difficult for
e.” I always encourage people to lay out a game plan, not
ig details, but more of a sense about what you want and
here you want to go, including both short-term and
ong-term goals. Then focus, focus, focus. There is a
roductivity equation: productivity is equal to the amount of
ork you put into something divided by the amount of
istractions you have. Trying to be all things to all people by
oing a lot of different things will prevent you from being
ruly focused on the couple of things you want to do in your
areer. But be an active participant. That does not mean you
ave to serve on every committee or be all things to all
eople again. But consider what things you can do within
our division to demonstrate good citizenship, given your
nterests and time constraints.
onclusions. As women, we have an extraordinary oppor-
unity to be gainfully engaged in our profession. It may
eem, at some times, that it will take us awhile to get there,
ut I assure you that the rewards and satisfactions are
remendous. I enjoy reading biographies about women and
heir lives and the issues they faced and had to address. I
ecommend the story of Jill Ker Conway in The Road from
oorain (38). Jill Conway went from the despair of a very
rutal, physical life during the Depression on a sheep ranch
n Australia to eventually becoming the first woman presi-
ent of Smith College. There is another wonderful story
bout Anne Martindell, who was told, at age 20, by her
ather, “Anne, you have got to drop out of school. You are
oo smart. You’ll never get married. No man will ever want
o marry you” (39). She did. She went on and raised a family
nd, in later years, went back to school, earning her
ndergraduate degree from Smith College at age 87. That’s
igure 9. Matriculants, ACC fellows-in-training, and ACC fellows.
ource: ACC and Association of American Medical Colleges Data
arehouse, 2003. Open bars  men; solid bars  women.testament to the importance of education and persistence.
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October 4, 2005:5A–72AAcademic medicine is a richly awarding career. We all
ave a number of choices within medicine, but we shouldn’t
ose sight of how fortunate we are, as evidenced by the
enuine goodwill that exists now among leadership in
cademic institutions who are looking to make the playing
eld equal for women in academic medicine and help us all
ucceed.
IX. PANEL DISCUSSION: GREATER REPRESENTATION
OR MINORITIES AND WOMEN IN CARDIOLOGY
obert O. Bonow, MD, FACC (Northwestern University
Feinberg School of Medicine, Division of Cardiology,
Northwestern Memorial Hospital, Chicago, Illinois)
alentin Fuster, MD, PHD, FACC (Zena and Michael A.
Wiener Cardiovascular Institute and the Marie-Josée
and Henry R. Kravis Center for Cardiovascular
Health, Mount Sinai Medical Center, New York,
New York)
ugustus O. Grant, MB, CHB, PHD, FACC (Department
of Medicine, Division of Cardiology, Duke University
Medical Center, Durham, North Carolina)
arlan M. Krumholz, MD, SM, FACC (Department of
Medicine [Section of Cardiovascular Medicine, and the
Robert Wood Johnson Clinical Scholars Program], and
Epidemiology and Public Health, Yale University School
of Medicine, and the Yale-New Haven Hospital Center
for Outcomes Research and Evaluation, New Haven,
Connecticut)
lizabeth G. Nabel, MD (National Heart, Lung, and
Blood Institute, Bethesda, Maryland)
r. Fuster: We all know of the good work done by the
obert Wood Johnson Foundation. Why are there not five
oundations like that? Should we develop advocacy to see
ore of these foundations developed?
Certainly, there are very successful people in this country
ho should be approached to see whether we can engage
hem in something like this. It requires passion. We need to
arget certain individuals to ascertain their interest in
eveloping a foundation like that where we can attract more
inorities. It has been done; we just need to do more of it.
r. Bonow: The issues are really complex. This is where we
eed to be focusing some of our attention, including getting
o young people very early, in high schools, identifying
inority students, and getting them turned on to science.
erhaps foundations can help us do that, although there are
overnmental issues here, too. But we must find ways of
etting high school students interested and help them get
heir education on the right trajectory towards a career in
esearch. If we focus most of our attention on just trying to
et medical students or residents interested in careers in
esearch, it is too late at that point.
r. Nabel: The National Heart, Lung, and Blood Institute
NHLBI) has a program called BRTPUG, Biomedical
esearch Training Program for Underrepresented Groups. ae bring kids in at the high school level, and then we
ssentially take care of them throughout the remainder of
heir career. It has been very successful.
r. Bonow: I knew NHLBI was doing something on a
maller scale, but maybe we could think of larger scales.
uestion: I have two questions. Number one: Are there any
pportunities specifically for people interested in women’s
tudies, such as the study of cardiovascular disease in
omen? And number two: Are there research funding
pportunities for women in cardiology?
r. Nabel: I am happy to say that the NHLBI is the
dministrative home for the Women’s Health Initiative
WHI) (http://www.nhlbi.nih.gov/whi/), which is a very
road-based research program on women’s health issues.
e sponsored recent studies on hormone replacement
herapy. I think it is the intent of the Institute to continue
o support and sponsor the WHI. So, that provides a great
pportunity to conduct research on a variety of issues related
o women. At National Institutes of Health (NIH), there is
lso the Office of Research on Women’s Health, directed by
r. Vivian Pinn (http://www4.od.nih.gov/orwh/). They are
nvolved very broadly in a number of research and educa-
ional programs.
Your question about whether there are funding programs
pecifically for women investigators is a good one. I do not
now the answer to that, but I do not think so.
r. Bonow: I do not believe there are any funding mechanisms,
ut I would strongly encourage you to look at both the American
ollege of Cardiology (ACC) (http://www.acc.org/) and
he American Heart Association (AHA) (http://www.
mericanheart.org/presenter.jhtml?identifier1200000)
ebsites, because there are committees for women in
ardiovascular disease and they can be helpful if you are
ooking for a career in research. Certainly this is a big
ssue. If 50% of medical students are women, we do not find
hat 50% of the cardiology fellowship applicants are women
Fig. 9). We have a major workforce crisis right now in
erms of providing enough doctors to provide cardiovascular
are, and it’s going to get worse with the baby boomers
rowing up.
Both the AHA and ACC have major efforts underway to
dentify some of the issues Betsy was talking about and
etermine how we overcome those. At the AHA, it’s more
eared toward the investigators and researchers. There is a
omen’s luncheon every Tuesday of the annual AHA
eeting, and there is travel support available for eligible
omen fellows to go to the meeting for free and attend that
uncheon.
r. Nabel:Many of the AHA councils now have a women’s
ommittee. The Clinical Cardiology does, as does the
ouncil on Arteriosclerosis, Thrombosis and Vascular Bi-
logy (ATVB). The Clinical Cardiology Women’s Com-
ittee is very active and offers travel awards. The ATVB
lso has a luncheon at the annual meeting and gives out a
umber of research and travel awards. Networking through
n AHA council is a good way to access that information.
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October 4, 2005:5A–72Ar. Fuster: Harlan, let us say I am a fellow who wants to
ursue a career in epidemiology. It seems to me that what
appens, at least in dealing with fellows, is that they reach
he stage in getting a degree where they can understand
pidemiology, statistics, and so forth. They work on some
tudies, but they are mostly anonymous because these trials
ay involve thousands of people. Are those of you who
ade it into the field of epidemiology unique? What kind of
n approach would you advise?
r. Krumholz: It is challenging to develop a research career
here you are trying to establish yourself, obtain funding,
nd address important questions. The rewards are substan-
ial, but in the beginning, especially in large collaborative
tudies, it can be difficult to distinguish yourself and develop
n early body of work that is known as your own. Some of
he best research now is conducted in the context of these
arge teams, but they work best when there are ample
pportunities for people, particularly young investigators, to
lay prominent roles in substudies that address worthy
esearch questions. These opportunities rarely just land in
our lap. It is important for young investigators to develop
research plan, and seek opportunities and mentorship. You
an avail yourself of people locally or around the country;
eople who you think are doing interesting work. You will
e surprised how receptive individuals will be in talking to
ou. You need to find senior people who can guide you with
dvice and opportunities, and help you see how you can best
e successful. You need to bring energy, ideas, and a
illingness to work hard.
Perhaps the most important issue is for you to decide
hat you, as a young investigator, are most passionate about
nvestigating. If you become immersed in a large research
roject, there is a possibility that you can become somewhat
nonymous. At Yale, while we are helping young investi-
ators get experience doing research, we are asking them: if
ou were going to write a paragraph characterizing yourself,
hat would it say? What are you really about? What is it
hat you are trying to accomplish in your career? I have done
his with fellows and with faculty, people who are still trying
o formulate their interests and direction. For the young
nvestigator, there are many questions. You have got to have
sense of what the field is. Who has come before you?
hat are people in the field currently doing? What are the
hemes of research underway, and what kinds of skills and
pportunities exist for you? What do you want to do? Then
ithin that general framework, you have to find a niche for
ourself, and that niche may evolve over the course of your
areer. But if you can define who you are and what you are
rying to accomplish, you can be very successful. But you
ave to be resourceful and tap into those people who can
elp direct you and give you advice.
These large projects can be great opportunities, but
entors need to help young investigators ensure that they
re not just employees, but are having the chance to develop
heir career. Of course, goals will vary by individual and it is
mportant to determine if you are interested in eventually yeing an independent investigator or whether the goal is to
ontinue to be a contributor to research, but not in a
eadership role. And this gets back to being able to describe
ho you are and what you want to achieve with your career.
r. Bonow: That is a great response to what people need to
o with their careers no matter what they are going to do;
owever, if they want to get into outcomes and health policy
esearch, you mentioned they need specialized training. Can
ou define that training? If they are already in a fellowship
rogram, they may or may not be in a program that has a
30 or other means of providing this. What is necessary for
hese people to get the tools they need?
r. Krumholz: I have always thought of this not in terms
f degrees but in terms of skills and competencies. To be
uccessful in the long run, you need to have a very deep
nderstanding of clinical research design and biostatistics.
ou have to be able to invest yourself in understanding the
edical literature and to understand the strengths and
eaknesses of what is published, and you have to be an
utstanding clinician who knows the challenges of clinical
are and the needs of patients. Sometimes interns come to
e saying they want to do research. I tell them to spend the
ext two years becoming the best clinicians they can because
hat is going to be the fundamental next step to becoming
he very best clinical investigators they can be.
My general advice: start the clinical cardiology fellowship;
ecome an outstanding clinician; then start building the
ext steps in terms of those specific skills I laid out; and
ecide what you want to do. You may go more in one
irection, and you will need deeper skills in that particular
rea. But the point is that there is a range of institutions
round the country with the capability to train you and
rovide mentorship as you develop this. If you are not at one
f those places, you need to move, or else your chances of
uccess will be greatly compromised.
r. Nabel: Do you recommend people get a masters degree
n public health (MPH)?
r. Krumholz: The degree is not as important as the
nowledge and skills that are gained. An MPH or master’s
egree in another subject can be a good way to gain these
undamental skills, but I have also seen people who obtained
egrees but seemed to have missed the opportunity to
cquire skills and insight. The drive to learn is what is
mportant, and a degree can often be helpful because of the
tructure and content of an established curriculum and an
ccess to teachers, but it is not the only way. In my career,
y opportunity to pursue coursework at a school of public
ealth was critical to my development as an investigator. I
id obtain a master’s degree, but the goal per se was not the
egree but the experience that led to the degree.
r. Fuster: It is interesting because all of you give much
ore importance to the goal you want to achieve than the
nstruments of the process. And that is reality: first you need
he passion, the drive, and then you find a process that gets
ou where you want to go.
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October 4, 2005:5A–72Ar. Krumholz: You have ultimately got to put yourself in a
osition where you will not be denied. There are so many
hallenges along the way; you must have that internal sense
hat this is really what you want to do with your life, and
hen find people who can help you do it.
uestion: My question pertains to what you have been
ouching on right now, which is the methodological train-
ng. Clearly, and especially for those of us who are more
dvanced in our training, it has been eight or nine years
ince we have done epidemiology. Unfortunately, I do not
hink there is anything more than a rudimentary introduc-
ion to epidemiology in most fellowship programs. So,
) does your institution provide anything different? And, 2)
hort of getting a public health degree, is there anything that
clinical fellow can do in terms of finding a program where
hey can be sponsored for three months and get some basic
kills like those you described?
r. Krumholz: That is a really good point, but it is first
mportant to realize that you never stop learning. It is not a
atter of getting a certain set of skills that are going to stand
ou in good stead the rest of your life. I am doing research
ow using methods I did not know when I was a fellow. I
ontinue to learn from the people around me. Another
mportant point: unlike people who did research 30 years
go who could sequester themselves and tinker with what-
ver they were doing and still produce insights, the very best
esearch today is being done within teams in which there is
ultidisciplinary collaboration. The best situation puts you
n a position where you are working with people who are
pecialists in particular areas and yet can work together for
ommon goals.
By the way, getting teams to work well is a very important
esearch skill. How do you make sure people on your team
eel appreciated, engaged, involved? How do you foster the
ecessary communication? How do you work together for
ommon goals? Those are important organizational skills
hat will lead to great success within research.
Part of acquiring the skills you need is your attitude. Are
ou developing your own critical thinking skills? Are you in
classroom environment where people are willing to go
eyond superficial knowledge to a place that demands you
eally dig deep and understand? What is the basic philoso-
hy? You are not going to be completely knowledgeable
bout everything, but you must have a certain attitude
owards obtaining the knowledge and skills that will be
equired to successfully pursue your projects. There are
arious places around the country that encourage this kind
f attitude—these places push you, and engage you intel-
ectually. It is the context and environment you put yourself
n that will help you raise the level of your game. You should
e trying to acquire those skills in a way that is not just, “I
m looking for the degree,” or “I am finishing this course,”
ut you are really asking questions of yourself and others. It
s putting yourself in a position to be a tough critical thinker
nd giving yourself an attitude about knowledge acquisition. er. Fuster: So, in summary, you ask Harlan for a job and
o to work with him.
r. Bonow: That is a good option, actually. But if you
annot get a job with Harlan or you are not in one of those
rograms, but you are really serious about it, there is a
0-day course every summer on epidemiology, sponsored by
he AHA’s Council on Epidemiology and Prevention. The
aculty is there with you for the entire 10 days. It is a crash
ourse, but it’s very thorough in how to do clinical trials;
hat epidemiology is all about, and methods involved in
ata analysis—all taught by the experts in epidemiology.
uestion:My question is about fellows such as myself who are
ot in an investigator track but are interested in doing
ranslational research, such as gene therapy or stem cell biology
n our second and third years of fellowship. At this point in our
areers, is it more important to get experience in the basic
cience side or in the clinical research side, or is it possible to
et experience in both at this stage of our fellowship?
r. Nabel: You need to think about what you want to do
ong term: Do you want to practice medicine or be engaged
rimarily in research? As Harlan said, I really view this as
eing a part of a research team. If you see yourself practicing
edicine, then you are going to want to partner with a basic
cientist to help bring those ideas forward and do phase I or
I studies. That means you will want to get training in
linical trial design and clinical data analysis.
On the other hand, if you want to spend your time
rimarily doing research, eventually bringing things forward
o the clinic, but you would rather hand it off to a clinician
t that point, then you will want to spend time in a
aboratory and learn molecular and cellular biology. That is
oing to give you the basic tools to learn how to handle cells,
anipulate them, prepare them for clinical production,
ork with or develop animal models, do studies, and so on.
r. Fuster: It is the issue of whether you want a more
linically oriented approach or a more basic research-oriented
areer, and your future very much depends on the clinical skills
ou obtain along the way.
uestion: It seems like a lot of us are already H05, H06,
07, H08s, and many of you were talking about basic
cience and outcomes research that might require two or
hree additional years. Can you address the issue of the
ength of fellowship and how to deal with that?
r. Krumholz: In part, it is a matter of customizing your
ducation to your own needs. For example, people who make
ecisions and differentiate earlier can do things like short track
hrough internal medicine.Many people working withme now
re doing four-year fellowships—two years clinical, two years
esearch—where they continue gaining some clinical exposure
uring part of that research time. Everyone has their own
eeds, and it really depends on your own niche, what oppor-
unities you can find, and how you can put it together for
ourself. People also have different financial pressures and so
orth, but it is a matter of long-term perspective. Some people
pt out early, because they do not want to spend that time on
ducation and training, but then they are bored 10 years later
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October 4, 2005:5A–72Aith what they are doing and they are not finding the same
ulfillment they might have had if only they had invested the
ime and gone in another direction. Ultimately, opting out
arly ends up being a short-term gain, but it could sacrifice
ong-term satisfaction.
Think about what you are really aiming for. The big win
ere is to find something that thrills you for the rest of your life,
here it does not feel like a job and you are never bored. You
et that big win when you find yourself in a position where
very day you feel that you are making a contribution; every day
here is something exciting and stimulating going on. Then,
hatever you are talking about in terms of an extra year or two
t the front end falls away because of what you ultimately want
o achieve. Some people are going to thrive in clinical medi-
ine, and they should do it. Think about what fits your
ersonality type and what gets you excited, because it would be
nfortunate to make that decision early on and find yourself
eeding to retire early in order to find other things that will
timulate you. These careers that the people here have found:
hese are careers where there will be no retirement. That is
hat you want to find.
r. Bonow: It is a real issue. My question is this: if it is OK
o short-track and get two years of medicine if you are in a
esearch track, why does any cardiologist then need three
ears of internal medicine if that person knows right from
he get-go he wants to be a cardiologist? Dr. Fuster,
robably more than anybody else, has been trying to work
n streamlining training programs so that it is only maybe
wo years of internal medicine.
uestion:What is the relative weight of fame in the academic
ursuit? How does that compromise the original search for
ruth, which is our original passion? And in talking about fame,
ow big is the limitation that is imposed on people who are not
oming from famous universities in terms of getting a faculty
osition at a decent place. Are there limitations when you
pply for a grant because you are applying from a less famous
nstitution versus a famous institution?
r. Nabel: There are a lot of different levels to your questions.
et me start with the last part first. As an institute, we are
xtraordinarily sensitive to the fact that if we want science and
igure 10. Percentage growth of international medical graduate practicing
ardiologists. Reprinted, with permission, from Zoghbi et al. (41). Source:
merican Medical Association. Physician Characteristics and Distribution
n the U.S. 2002–2003 Edition, Chicago, IL: American Medical Associ-
tion 2002.edicine to go forward, we cannot concentrate resources in the
Eands of a few. Resources must be distributed equally across
he population in this country. We work very hard to try to
chieve that goal. Grant mechanisms are set up recognizing
hat grant applications may come from individuals or institu-
ions that do not have the same level of resources that others
ave. We go out of our way to try to help provide those
esources. So, at an NIH funding level, people are extraordi-
arily sensitive to those issues.
Am I going to get a job if I come from a university that
ay be less known than another? For many of us who have
ad the privilege of being able to hire people, you are never
ade by the name of an institution; you are made by who
ou are. You are made by your character, your passion, your
rive, what you’ve accomplished in your life. People who
ire understand that and are absolutely going to look at the
ndividual, not a set of credentials. That is my perspective.
r. Fuster: His first question is a very important one: the
uestion of compromising a genuine creative approach
owards discovery that you have at a young age versus being
ore engaged in who you are and what the world thinks of
ou. That is a great question for young people.
r. Krumholz: Ultimately, it all depends on you. There are
eople who become enamored of certain peripheral ele-
ents, and there are other people who are able to stay true
igure 11. International medical graduate (IMG) registrations for the
nited States Medical Licensing Examination (USMLE) step 1 and step
examinations. Reprinted, with permission, from Zoghbi et al. (41).
vailable at: http://www.acponline.org/journals/news/sep01/imgs.htm,
aguire P. ACP-ASIM Online, 2001.
able 27. IMG Cardiology Residency Trends
Year
IMG (% of All Trainees)
General
Cardiology
Trainees (%)
Clinical Cardiac
Electrophysiology
(%)
Interventional
Cardiology
(%)
996 36.6% 18.5% NA
997 40.0% 33.7% NA
998 42.0% 44.6% NA
999 41.2% 48.4% 39.7%
000 38.6% 37.2% 55.8%
001 36.7% 43.0% 49.1%
002 32.9% 41.7% 42.1%
eprinted, with permission, from Zoghbi et al. (41). Source: JAMA Annual Medical
ducation Issue. JAMA, 1997 to 2003.
IMG  international medical graduate.
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October 4, 2005:5A–72Ao their beliefs and core values. I will say this: if you are
oing to be successful in academics, you have to get used to
ailure. It is an incredibly humbling profession, because you
re seeking truth all the time and you are frustrated at many
ifferent turns. Whether it is a grant application or a paper
ou want to have published, whether it’s seeing the impact
f your work truly translated to the benefit of individual
atients or it all gets lost or ignored, you have got to be able
o withstand. In fact, in the end, it is not that you feel so
mpowered, but that you are constantly struggling to make
difference.
The people who are doing it best are constantly striving to
enerate the knowledge that is going to make a difference.
he people you end up respecting the most around you: it
s not so much about them; it is about ideas. It is about
rying to let the ideas fight for themselves. One of the most
onderful things about this, in terms of what you are saying
bout universities, is that somebody could be working
nywhere in the U.S. who could come up with some very
nsightful ideas that will see the light of day and maybe turn
whole field on its ear. With persistence and good ideas,
ou can make a difference wherever you are and wherever
ou are from.
r. Bonow: You all addressed the ego question quite well.
f your ego’s too big, then you are not going to be able to
ithstand failure. Ego is necessary, but also you have all
een around long enough to see people with various-sized
gos and how they respond. Go back to Harlan’s initial
omments about the people you want to be like and the way
ou want to lead your life. You need enough confidence and
go to go forward, but keep it all in perspective.
r. Fuster: Also, fame is not a job, fame alone cannot
ustain you. You go through failures, and your colleagues,
ho helped you succeed or not, know exactly who you are
nd what you do. It is not a free system in the U.S: you are
eviewed constantly and in a way that answers the very
uestions you presented.c
igure 12. Job opportunities for senior fellows. Training directors, n
137.X. OPPORTUNITIES IN TRAINING AND
AREERS FOR INTERNATIONAL MEDICAL GRADUATES
illiam A. Zoghbi, MD, FACC (Echocardiography
Research, Baylor College of Medicine and the
Echocardiography Laboratory, The Methodist DeBakey
Heart Center, Houston, Texas)
ince the 1960s, international medical graduates (IMGs)
ave constituted an important part of the health care
orkforce, currently filling about one-third of cardiology
raining positions and about one-fourth of clinical practices
n the U.S. International medical graduates are physicians in
ostgraduate training or in practice (who completed their
edical school training outside the U.S., Puerto Rico, or
anada). They are either foreign nationals on special visa
tatus (e.g., J-1, H-1, or F-1) or U.S. citizens or permanent
esidents who graduated from foreign medical schools. The
isconception is that all IMGs are foreign nationals; in fact,
3% are U.S. citizens or permanent residents in the U.S.
Some impressive statistics illustrate the importance of
MGs. Their influx during the last 40 years has been due
argely to unmet needs in rural areas. Besides being an
mportant source of manpower for underserved areas, IMGs
lso fill unmet needs in both teaching and research. Con-
equently, IMGs now comprise nearly 25% of all cardiolo-
ists in the U.S. and make up about one-third of all
igure 13. Mean ratings on the demand for various cardiovascular prac-
ices. 5  very high, 1  very low. Recruiting firms (n  113). Source:
CC Cardiology Workforce Study 2002 and Cardiology (43).ardiology training positions. The ethnic and cultural diver-
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October 4, 2005:5A–72Aity they provide is very important. Interestingly, they
roportionally contribute more women, especially women
ho are foreign nationals, to the physician workforce than
o U.S. medical graduates.
From 1980 to 2000, the number of U.S. cardiologists
ho were IMGs increased by 175% to a total of 6,178 out
f a total workforce of about 26,000 cardiologists (Fig. 10)
40). The number of IMGs is even higher in other disci-
lines, particularly internal medicine. Overall, the total
umber of active IMG physicians in the U.S. stands at
bout 196,000, which is a doubling of IMGs over the past
0 years. Two countries with high representation of IMGs
re India (18% of active IMG physicians) and the Philip-
ines (9%); IMGs from Spanish-speaking countries are
nderrepresented, with only 5% of IMGs from Mexico.
his is an interesting fact, given that the Hispanic popula-
ion is the fastest growing minority in the U.S.
One of the many challenges that IMGs face, either
uring training or in their careers, is whether they can stay
n the U.S. and practice in this country.
I chaired the American College of Cardiology (ACC)
ask Force on International Medical Graduates at the 35th
ethesda Conference (41). I want to share some of the
nformation that emerged from this task force, because
hysicians in training, in practice, or in academic settings
ay not be familiar with some of the issues facing IMGs.
lso, it may be helpful to understand the complex issues
eing addressed regularly by faculty and program chiefs in
erms of immigration-related problems and efforts to retain
MGs, especially those in academic careers.
urrent challenges. The first major challenge is certifica-
ion, which requires passing steps 1 and 2 of the United
tates Medical Licensing Examination (USMLE) (http://
ww.usmle.org/), a new English proficiency test, and the
linical skills examination (CSE) of USMLE, which was
mplemented in 2004 to replace the clinical skills assessment
est of the Educational Commission for Foreign Medical
Table 28. Visa Options and Other Requireme
Research
No Patient Care GME Trai
Visa Options* Visa Options*
● J-1 “Research Scholar” ● J-1 “ECFMG”
● H-1B—employer ● H-1B—employer
● NAFTA ● U.S. medical scho
F-1/H-1B● B-1 if a scientist sent
from abroad
Other Requirements Other Require
No U.S. medical exams USMLE 1 & 2
No state medical license USMLE 1, 2, & 3
ECFMG certificate
State limited or trai
*Unless indicated—all visa options are for non-U.S. permanen
Advisor, Baylor College of Medicine; intended for general inf
of information for decisions regarding legal status or rights.raduates. As part of the USMLE Steps examination, the aSE is now offered in five U.S. cities: Atlanta, Chicago,
ouston, Los Angeles, and Philadelphia.
There are restrictions, limitations, and perhaps financial
mplications for IMGs to consider, such as a more pro-
onged and difficult process for obtaining a visa to the U.S.
y 2000, the number of foreign medical school graduates
ntering the educational pipeline had sharply declined,
ased on the number of IMG registrations for the certifi-
ation examinations (Fig. 11) (42); however, the pool of
pplicants is still quite high, with IMGs making up between
7% and 42% of residents coming into cardiology in recent
ears, and the trends are similar for subspecialties (Table 27).
There is some duplication of medical training and costs
or physicians who have had postgraduate medical education
e.g., internal medicine, cardiology) in international training
rograms. In terms of the performance of residents going
nto fellowships, the cohort of IMGs overall has done well,
nd probably slightly better than U.S. medical graduates.
his is likely because there are a number of selection
rocesses IMGs must pass through before coming to the
.S. as well as the repeat training these individuals are likely
o experience.
Following clinical training, if an IMG aspires to have a
areer in the U.S., employment will depend upon whether
n individual has a J-1 visa. The J-1 visas are harder to get
ecause immigration laws have changed over the past few
ears, based on more stringent restrictions in place since the
ttacks of September 11, 2001. Consequently, the greatest
isk many IMGs face as trainees is not being able to join the
orkforce, which pertains largely to the 27% of IMGs in the
-1 exchange visa program. This program requires visa
olders to return to the country of origin that has sponsored
heir coming to the U.S. for two years; J-1 visa holders are
t increasing risk of not finding waivers.
ask force recommendations. Recommendations from
he ACC Workforce task force included maintaining the
urrent IMG workforce distribution, particularly if quality
r International Medical Graduates
Academic Clinical Practice
Visa Options*
● H-1B—Intl. Renown
● H-1B—limited
aduates: ● H-1B—unrestricted
● NAFTA—limited
● O-1 unrestricted, hard to obtain
ts Other Requirements
Academic license or USMLE 1 & 2
USMLE 1, 2, & 3
ECFMG certificate
license Full state medical license
ents. Prepared by Michele Stelljes, MA, Senior Immigration
ional purposes only and should not be used as the sole sourcents fo
ning
ol gr
men
ning
t residnd performance remain high. Another recommendation is
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October 4, 2005:5A–72Ao provide more accessibility to the USMLE examinations,
hich might include expanding further the number of cities
here testing is done, and perhaps offering some scholar-
hips. Short-tracking of individuals may be attempted in a
ilot project that would decrease the total amount of
raining required of IMGs, particularly if they had internal
edicine and cardiology training abroad. A final recom-
endation is to involve the ACC, the American Medical
ssociation, and other organizations into looking at influ-
ncing IMG immigration laws, particularly to find a balance
etween IMG training and the ability to remain in the U.S.
The task force also wants to facilitate international
xchange programs of physicians; IMGs staying in the U.S.
ould give back to their countries. For example, IMGs in
he U.S. might be required to return for short and extended
eriods to contribute to health care in their country of
rigin—for instance, in the form of sabbaticals, teaching
pportunities, or performing unavailable procedures. Part of
his might be an exchange process that would recruit U.S.
raduate colleagues to serve in a similar capacity, thus
erving to enrich the experience of U.S. physicians and their
olleagues in other countries.
areer opportunities. During the summer of 2002, the
CC sent surveys to senior cardiology trainees, cardiology
raining program directors, recruiting firms, and a sample of
omestic ACC members (43). According to responses from
37 U.S. training directors, there are outstanding job
pportunities in academic medicine or clinical practice for
enior fellows, and this is expected to continue for at least
he next couple years (Fig. 12). As to the ease or difficulty in
ecruiting qualified cardiologists, 113 recruiting firms re-
ponded, and 76% were finding it “very difficult,” and
nother 21% said it was “somewhat difficult” to fill cardiol-
gy positions. About one-quarter of senior fellows say they
re interested in academic medicine, while about one-half
ay they are interested in single-specialty practice. Looking
t the demand for various cardiovascular practices, the
ecruiters say the greatest demand is for general clinical
ork, then specialists. Academic positions (any blend of
ractice and research) are least in demand (Fig. 13).
For foreign-born IMGs to stay in the U.S., visa status is
rucial for establishing a cardiovascular career. To help
avigate U.S. visa and license options, IMGs need profes-
ional help to figure out the best ways to remain in the U.S.
Note: Medical schools and training programs may offer visa
ssistance or have an attorney on retainer.) For IMGs
pplying to come to or stay in the U.S., it is important to
now the application process and get help from academic
nstitutions that have advisors who can be important re-
ources for IMGs.
In terms of career opportunities, most IMGs prefer
areers in academic clinical medicine. Initially, IMGs might
onsider coming to the U.S. to do only research. Careers in
iomedical research are widely available for physician sci-
ntists from abroad. Moreover, research experience may be
n advantage when eventually interviewing for admission fnto a U.S. residency program. Also, universities, medical
chools, and research institutions may offer visa assistance
or research activities. Often these research opportunities
ead to careers involving patient care. As another pathway
nto U.S. training, IMGs have entered into U.S. graduate
chools to obtain U.S. specialty certification. (See Table 28,
or an overview of visa options and requirements for each
athway.)
Under the research pathway that involves no patient care,
ne visa option is the H-1 that is sponsored by the
mployer. The North American Free Trade Agreement
NAFTA) also provides some benefits for trainees coming
nto the U.S. from other North American countries. Inter-
ational medical graduates coming to the U.S. to do
esearch do not need other medical examinations or licenses,
ut they also cannot practice in the U.S.
For those coming through the training pathway, individ-
als attending U.S. medical schools are not considered
MGs. The J-1 visa has a two-year return requirement after
raining while the H-1 does not demand a return to the
ountry of origin.
For academic clinical practice, an O-1 visa is available for
ndividuals with stature or unusual achievements. In the
ast, this visa was relatively easy to obtain, but since
eptember 11, 2001, it has been much more difficult to get.
Options after J-1 training include returning to the coun-
ry of 212(e) obligation (i.e., the country that originally
ssued the Ministry of Health letter) for two years or leave
he U.S. and return on another nonimmigrant visa, such as
NAFTA visa for Canadian or Mexican academic phy-
icians or the O-1 Alien of Extraordinary Ability worker
isa. Another option is to obtain a waiver of the 212(e)
ome rule by serving in an underserved area. The
roblem with obtaining such a waiver is few underserved
reas have academic medical centers. The only real option
s a career opening at a Veterans Affairs (VA) medical
enter; however, those positions are getting progressively
carcer.
Despite these limiting factors, Congress passed a bill in
ctober 2004 renewing all J-1 visas. The bill allows
hysicians with these visas to stay in the U.S. if they agree
o practice in an underserved community for three years.
ach state will be allowed to grant 30 waivers per year,
ncluding 5 waivers for physicians practicing in areas not
pecifically deemed “underserved” by the Department of
ealth and Human Services. This option allows J-1
olders to stay in the U.S.; however, if these individuals
re aiming for an academic career, having a J-1 waiver in
n underserved area would delay this process for three
ears.
There are obviously many issues that IMGs have to
vercome to get not only staff positions but also research
rants. Most NIH grants are restricted to U.S. citizens or
esident aliens, but there are some exceptions; RO1s are
vailable for IMGs with either a faculty position or who are
ourth-year level trainees. There is an NIH visiting pro-
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October 4, 2005:5A–72Aram, wherein some foreign nationals come to the NIH as
visiting faculty or under a visiting fellowship. Such
ndividuals can stay at the NIH for a number of years
ithout having visa or working issues to contend with. For
ost other grants, such as those from the American Heart
ssociation, ACC, and others, there are no citizenship
estrictions.
onclusions. The IMGs wishing to stay and practice in
he U.S., particularly in an academic center, need early
rofessional immigration advice. Large medical centers
sually have advisors who will help IMGs navigate through
he system. There are workshops to educate foreign medical
tudents, physicians-in-training, and faculty in finding
raining and career opportunities. There is indeed a shortage
n the health care workforce in the U.S., particularly in
ardiology and other medical specialties. Consequently, this
s a topic of great importance not only for IMGs but for all
ardiologists in the U.S. Therefore, we should be aware and
upportive of legislation that will help IMGs to have access to
nformation, training, and career opportunities in the U.S.
XI. PANEL DISCUSSION: JUNIOR
ND SENIOR INVESTIGATORS EXCHANGE
alentin Fuster, MD, PHD, FACC (Zena and Michael A.
Wiener Cardiovascular Institute and the Marie-Josée
and Henry R. Kravis Center for Cardiovascular
Health, Mount Sinai Medical Center, New York,
New York)
obert O. Bonow, MD, FACC (Northwestern University
Feinberg School of Medicine, Division of Cardiology,
Northwestern Memorial Hospital, Chicago, Illinois)
hristine E. Seidman, MD (Harvard Medical School and
the Cardiovascular Genetics Service, Brigham and
Women’s Hospital, Boston, Massachusetts)
r. Fuster: We have invited young investigators to join us
n this panel discussion and we will let them introduce
hemselves.
ellow: I am from the University of Minnesota. I was born
nd raised in England, attended medical school in Egypt,
nd came to the U.S. in 1998. I did my chief residency at
eisinger Medical Center, Penn State, and have been at the
niversity of Minnesota for more than two years now. I am
oing work in stem cell biology and received a National
esearch Service Award (NRSA) grant based on that work.
lrich Luft: I am Ulrich Luft from Oregon Health Sci-
nces University (OHSU). I went to medical school at
HSU, did my residency at Stanford University, and then
ast-tracked into cardiology back at OHSU. I’m in my
econd year of fellowship and am doing my first year of
esearch. I received an American Heart Association post-
octoral fellowship grant award last year and have been
oing research for the last six months on some vascular
iology projects.
r. Fuster: Bob, tell us a little about your training. mr. Bonow: I started my career at the National Institutes of
ealth (NIH), going from residency to the Clinical Asso-
iate Program. That was back in 1976; it is no longer quite
he same. The way to do that today might be for someone
ho has already had clinical training with or without
esearch training to identify a possible mentor on the
ntramural side of the NIH. My mentor was Steve Epstein
nitially, and when I started telling people about what
entors can and should be, I always think of Steve. Along
y career, and I think this is true for everybody of my
intage, you gain new mentors over time and at any one
oment you may have more than one mentor.
r. Fuster: When you look forward, what do you plan to
o in the next three years?
ellow: I am committed to becoming an academic cardiol-
gist. I am planning to take the results that I have from the
RSA grant and apply it to an NIH K08 or K23 award.
he question for me is whether I am going to go with
olecular biology or translational research, because stem
ell biology is moving into translational science, at least here
n the U.S. We are hoping that the work we are doing will
ove into the clinical trial setting within the next two to
hree years, so I see a very good opportunity for translational
esearch in that area.
I will be applying for a junior faculty position within the
ext year and a half, and hopefully within the next year, I
ill be taking the data that I have and apply for a K23, and
hen take it to wherever I get my faculty position. One of
he things I have learned is it’s very hard to compete with
hD scientists in the laboratory, especially when you have
ig labs and especially when your mentor is a PhD, whose
nowledge is much more extensive than yours. Right now,
think translational research involves just trying to find the
ight area that has the greatest potential to grow and then
pply it to your own personal career.
r. Bonow: This may mean that your current mentor is
ery good for the basic research components, but as you
ove more to the translational side, to reiterate the point I
as making a second ago, you may need to have more than
ne mentor.
ellow: Absolutely, and I was very lucky that within the
niversity of Minnesota, we started doing clinical work in
he stem cell arena. So I have already doubled-up with
nother mentor who has started to do the clinical work.
One issue I want to raise here is that bench research has
well-defined training track. You go into the lab for two or
hree years, learn these techniques, and come out trained
ersus translational and clinical research, where the training
rack is, presently, less well defined. That is my current
truggle, and that’s what I want to discuss.
r. Fuster: If I were your mentor, I would do a little bit of
sychoanalysis on you. I would say that you are probably
ore interested in the application of basic research, rather
han basic research itself. Basic research is your tool, your
ethodology.
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October 4, 2005:5A–72Ar. Bonow: There is an issue concerning the structural
omponents of training in a clinical training program where
here is some research involved. We are very good at
eaching fellows how to push catheters, do echocardio-
rams, and hopefully, how to take care of patients. Beyond
hat, we are supposed to teach them clinical research, but
oo often we are asking them to learn that somehow through
smosis without any kind of didactic material. That’s not
one unnoticed, and there are, indeed, programs now that
ave put a curriculum in place for clinical research training.
he K12 and K30 awards do put structure in place for
eople who have interests in clinical trials, clinical trial
esign, bioethics, biostatistics, population studies, or out-
omes research, and these awards go a long way toward
elping you transition your current basic research into
ranslational research.
ellow: I agree with Dr. Fuster, who is saying that
hroughout your life as a junior investigator you learn several
ools and then you try to apply these tools where your
assion takes you. I knew my passion was translational
esearch, but the tools that were available to learn at that
ime were more related to bench science research. I think we
re starting to explore other avenues in other programs, in
oth translational and clinical, which is good. I am just
aising a point that was brought up in several discussions
hat the training track for clinical and translational research
s much less defined. There are institutions in the U.S.
rying to take some initiative and train their people, but it’s
ery institutional-dependent.
r. Fuster: Yes, but let us look at an example. I can have a rat
eart that I think contains stem cells, and I want to know that
here are several types of stem cells: some in the atrium, some
n the ventricle, and so on. I want to take these different cells,
ransplant them to make them grow, and then transplant them
nto the rat again. What I am doing is somewhat translational,
ut it is all in the basic research area. It really seems that you are
nxious to move the research to humans. But both, in a way,
re translational. Dr. Luft, what about you?
r. Luft: Academic cardiology is my career track. I have a
rant, and we are working on a very interesting project using
ascular biology and cellular electrophysiology. That is
here I have experience and did patch clamping for a few
ears before going to medical school. If our project is
uccessful, I will hopefully get some decent papers out of it
nd then continue doing research and academic cardiology.
y plan would be to apply for an NIH K08 award and hope
o move from there to an R01. I think my expertise and
assion lean more towards basic bench science as opposed to
linical investigation.
r. Bonow: We know that the K awards have been quite
uccessful. But are they going to continue at the same level?
ecause the NIH budget is not increasing at the same level.
lot of the doubling of the NIH budget turned out to be
ostly infrastructure. There are going to be fewer of the K
wards and, historically, there have been a lower percentage
f awards at the next level, the R01 awards. Do you see a colution here to maintain the investigator workforce at a
igh level of enthusiasm?
r. Fuster: Things have changed. If you had asked this
uestion about 10 years ago, the answer probably would
ave been different. But, at this time, it is so important to be
rained in a team environment; I think the K23 and the K18
re very important grants, because they really give you the
otor engine of how to function in the future.
r. Bonow: The R01 has been the metric in the past for
areer advancement, but now we are talking more about
eam-based approaches to research. Right now, in most
cademic medical centers, academic advancement is still
ased on how many R01s you have. Consequently, many
niversities now are grappling with developing different
romotion pathways based upon your contributions to
esearch, which may not be measured by R01s.
r. Fuster: Program projects and grants are evolving to give
pportunities to less senior people who want to contribute. I
now a number of people for whom these programs and
rants have been the entry to a successful career. There are
ore and more of these program projects and support for
ontinuous Research Excellence grants that are, relatively
peaking, better funded now. Christine, can you comment
n that?
r. Seidman: I tell people, “It is never too late to go into
asic science or applied science or clinical science.” That
s something more of us as physicians must do because,
therwise, medicine will not advance. Whether it is a
tem cell question or electrophysiology or how to make a
etter cath, it is profoundly important that you be
nvested in it. You certainly can change your career path
t any time. It takes a bit of guts, and it often takes a hit
o your income, but it is profoundly important and, I
hink, very rewarding.
With regard to R01s, I would unequivocally sanction the
dea that team science and investigation is what’s out there
ight now; there are no more single scientists. It’s incredibly
un to be able to work with your PhD colleagues, using all
our medical expertise, meaning that you’re going to see
hings in a different perspective. For example, you may see
uestions more from a pathophysiologic perspective as
ompared to, perhaps, a mathematical modeling perspec-
ive. But when those two backgrounds intersect, what can
appen is really an explosion of new knowledge. So, I would
ncourage you not to be worried about whether you fit,
hether you understand all the terminology or whatnot—if
here is a contribution you can make, do not be afraid to say
t, and do not be afraid to contribute it; ask questions, learn,
nd be part of a team. Right now, science is moving at such
n accelerated pace, there is nobody who knows everything.
r. Luft: I have a question that pertains to what we have
een discussing. When I think about my career and how it
ight develop, I have to admit that when I originally started
edicine, I figured I would go into academic medicine and
ecome a research or clinical investigator. But as I do
linical cardiology, I find that it is really fun, and the more
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October 4, 2005:5A–72Alinical cardiology I do, the more I enjoy it. Most of us here
robably enjoy pushing catheters and titrating drips. When
look at some of the descriptions given here of the physician
cientist or the clinical investigator—80% of your time
eing spent in the lab, and so on—it seems a little
isappointing. In fact, I had an attending who would put in
edside pacemakers and then go off to lab and do his bench
cience—he split his clinical and research time about
0/50—and was successful. Is there still a role for such a
hysician-scientist today, or do you basically have to decide:
ne or the other?
r. Fuster: It is not unusual to be research-oriented, which
eans that you are looking at the cause and effects and the
rocess; it does not matter if you are dealing with a
olecule, a cell, tissue, or a human being. I enjoy patho-
hysiology tremendously, but now I also enjoy what is
appening with stem cells and trying to understand them,
ecause the way I think is very similar to what you have
escribed. I have seen basic investigators who are superb
linicians based on their thinking process. Therefore, I do
ot think what you are talking about is unusual, because it
s pretty much the same principles.
Another thought relates to “What are you able to do at
he same time?” If you spend 40% of your time in research,
t will be difficult to be competitive with those who spend
0% of their time doing research. You might be able to do
oth in much the same way as many in my generation were
ble to do it. I was able to do it, too, for that matter; but
oday I look at what it is I did and realize it was very
uperficial. Because of the competitive nature of the world
oday, it is getting more and more difficult to really do
esearch that is fundable when you spend just a small
ortion of time on it.
r. Bonow: Yes, cardiology is fun and saving lives is
abit-forming; there is nothing wrong with choosing a
areer as a clinician. That is fine. Our role in the academic
edical center is also to train the next generation of
linicians and clinician educators. Along the way though,
ome of those clinicians can also participate in clinical trials.
ut Dr. Fuster is absolutely right: you are going to be
ompeting with other people who may be as bright as you
re and they are spending 100% of their time in research. If
ou need to compete with them for the money to support
he research you want to do, then you cannot dabble in it. It
eally does require focus and dedication. Perhaps at a later
tage in your career you can broaden what you are doing.
ellow: I want to make a comment about that. As much fun
s cardiology is, it also is demanding in terms of technical-
ties. I was discussing this with Dr. Balke, and he said 35
ears ago all he had to learn was catheterization and the
ngiogram; that was it. Today, there is a whole lot more to
earn. I asked if he thought an interventional cardiologist in
his modern age could be a clinician scientist. His honest
pinion was “probably not,” because of the number of
rocedures that an interventionalist has to do to retain not Sust certification but competency in order to be on the same
evel as his colleagues.
Also, I want to talk about the concept of the team. You
ave got the PhD scientists and clinicians working together.
he funding is in the name of the PhD scientist. This raises
nother problem, in that it appears a lot of universities tend
o promote those individuals doing basic research before
hose who are doing research and clinical work. I think this
ndangers this concept of a team, because if team members
re not credited with their work and earn the promotions,
hen people are going to just lose interest.
I think the technical demands are too much right now for
s to keep up. I do not have a solution for that. You have to
ompromise and you have to prioritize, personally, to get to
here you want. But institutions and chiefs of cardiology
ave to think about this whole concept of promotion, what
t is based on, whether it is a team approach or individual,
nd whether the money you get for research is what you are
oing to be judged on.
r. Fuster: I can only tell you things are changing, because
nstitutions are finding that great clinicians and teachers are
eaving because they are not being promoted. Therefore,
here is a lot of pressure to change the guidelines of
romotion. There is a new line, which is the teacher
linician, and their numbers are growing because of the
ressure created for institutions to really maintain people
ho are very necessary for survival of the institutions. So,
his is indeed changing in a very positive way.
r. Seidman: I agree with that. The promotions criteria are
nder active review in virtually every institution that has not
et executed the changes, and you shouldn’t make a career
ecision based on those potential problems. Anybody who
as been through any training program for a medical degree
nows that the rules are always changing as you go along.
hat is the nature of the game.
With regard to whether you can be part clinician/part
esearcher—for example, do invasive cardiology and research—
nd the answer is, unequivocally, yes. That is what defines an
cademician as compared to a private practitioner, but it
oesn’t mean that you are doing the same science as a
hD-trained individual who spends 100% of his time in a
et lab.
There is no better time to do clinical research. You can do
asic fundamental genetic molecular biology, transcriptional
iology, and so on, on people. It is simply a matter of what
ormat you are going to structure that in. Can it be done in
he cath lab? Absolutely—it is right now. If you want to
evote 50% of your time doing clinical care of patients, call
t private practice, you are not going to be as successful in
he funding arena. It is not that you’re not doing anything.
t just means that you are going to have a different
echanism by which you accomplish all that you want to do.
r. Fuster: That is an important point. The sense of
uccess is fulfillment, and although you may not necessarily
e publishing in Cell or Journal of Clinical Investigation or
cience, you may be able to do work that gets published in
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October 4, 2005:5A–72Aery good journals and be very instrumental in changing
edicine. You might not be as fundable as some other
nvestigator, but you still can enjoy and contribute to
cience.
r. Bonow: I agree. If you pick up Circulation and Journal
f the American College of Cardiology, most of the papers
ritten there do change practice and have immediate
pplication to what you are going to do tomorrow with your
atients. They are not written necessarily by tenure-track
aculty with R01s, but if they are putting paper after paper
n Circulation and Journal of the American College of Cardi-
logy, they are going to get promoted. So, I disagree that the
linician scientist has a different likelihood of promotion
han the basic scientist. It really depends on productivity,
nd there are other kinds of faculty, too, who are more
linician educators who rarely publish. Their job is to see
atients and teach, and they are on a totally different career
rajectory, and their grounds for promotion differ.
ellow: There is a trend that you are all aware of: the
rivate, not-for-profit institutions that are funding mainly
linical and maybe some translational research. It is well
nown that these nonprofit organizations offer better sala-
ies than traditional university settings, and a lot of people
o there, and many of them mentor people like us. If these
laces have the funds and the infrastructure for clinical
esearch, what do you think about this option?
r. Bonow: I do not think that there are that many
nstitutes like what you describe; most people go into
ractice. Yes, you will get paid more in practice, but it is
ery busy and it’s not easy because reimbursement is
ropping. There is a lot of competition, which means you
ave to do more to keep your head above water. Most
eople that go into practice do not already have a hugely
uccessful academic career before going there; conse-
uently, going in at the entry level into a practice like that
akes it unlikely you’ll achieve that level of stardom.
hen things get tough and reimbursement continues to
all, that’s probably the first thing that’s going to be cut
ff the agenda.
r. Seidman: Do not you want to be in a place where
iscoveries can be translated? Do not you want to hear that
ome mathematician has a new model that allows you to
ook at geometry of the ventricle and what better place to try
t out than in the echo lab? To me, the team approach is
uperior. And when I say team, I do not just mean the
eople you work with specifically, because communications
ave made us all closer around the world and you can
ollaborate with anyone. There is nothing like bumping into
he person next door and coming up with a great experi-
ent, because he or she is going in one trajectory and you
ave intersected in a different way. That’s the advantage of
n academic community, and I would say that a university
ystem is second to none in that environment.
r. Fuster: There are exceptions, though, when it comes to
ome private institutes. For example, the Cancer and Heart
nstitute started very private, and they have an incredibleesearch group in diabetes now. But, it’s not the same
cademic environment and the excitement that we are
alking about. There are significant differences.
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